var title_f41_20_42304="Short arm cast 2";
var content_f41_20_42304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Completed short arm fiberglass cast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 255px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Titus, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_20_42304=[""].join("\n");
var outline_f41_20_42304=null;
var title_f41_20_42305="Adherence of Helicobacter pylori";
var content_f41_20_42305=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adherence of Helicobacter pylori",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 190px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph shows the attachment of",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    to gastric epithelial cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the American Gastroenterological Association&copy;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc. at 1-800-432-8433.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_20_42305=[""].join("\n");
var outline_f41_20_42305=null;
var title_f41_20_42306="Pulm AVM PA gram IV";
var content_f41_20_42306=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple non-communicating arteriovenous malformations detected on a routine chest radiograph in asymptomatic patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzj4tePbz4ga+J3jNro9oCllaAY2L/AHmx/Ef06Vy2lwq0hRsgN/FjpXo2teDbSz1GWMlguNyuUPX+7QPCZtoIbq1iCxgAsrnls9xQBimxAiUpH5iYDNIBxkelT29rsTei7ggyOOldhDYxCFXteknGT0z3qpfaPKUQxmMZJBIbn2oAw7d2O4T7TsCnao71yPjJPtWqDavCDb0r1UaO0Ns8kuwggEEc5NchfWPnXLyFcnnGRQB5+LDcpLDB7ccVYg0ltrZjwvXNdmNGfcvBx17c1u6V4LvL1PNdTb2+OWccn6CgDz6y0Oa8uY4LWPfK3QKOg9a9h8H/AA6u4bcLt+z5wzSv95j6D2r034e+BbfRrKNorUNdSgF5ZFBIHYV3U9laadbS3eoSJHDGu55HYBQB15oAyvClxP4e0sR6pdT3UYHylhyPp61uT+JdKeJcXkIdv+We8bh9R2r5c+LHxrW/1Oax8NNJ9jhYqJum/wCntXjU/iXVGuDPBcyQSk7t6tlifc0AfZ/ibX72R3j0+JdhBKyu2Ap9a8v1E6rfttvb63Zm6I0qtn/CvGbLxvd3aiHWbqeVQuFfeeDVrUL+L+zrd0fLlyfMB/Q0Ad03giC9cefC0T8kSRfMM1iJ8OJLnUWTzUDgMU/hI44zXMad4k1Kzule0vZYwOCA5wfwrstH+IN5HldSEd2DxuIwxB7UAVrXwJ4htWKtb+bAG6seh+tdh4atLiCWW1u4nkiKYAbgxMemfauv8G39rrsBezkUqhBaKQ/Mhx6f1q9rNjBLAksCmO4JGXHUj1oAzvC6rpt5d2E6AgqG6jaT6irGr2ryAmMLGkeS3QYP071reE7Wy1ib7Deyr9pT/VykYJA7E1u678OnvY5Ab4eUw+YnII9+KAPCrmd7NxJHJCxX592Qdwz0/wDrVj+Ldc8Py3LX1xfSJcTooMKxklCBjk9O1b3iz4ealpMjJBGbu2LZ3p1A9MV4/wCL7KS2ufImieIrxhhg0ASX1xYSw7IJHmDtuyO5rNs7VZJ1AB61lRJgjYxHsK6HQFne6jjjIYnjkUAem+FtDUwWZGA2Rx1JNejWOkT5SR7hNqnJBGTgVzfgqK7M0P2yNRGhBjO3DV2utO6RBIImBCNs45JPrQBxeq3FxcSXEqMUhXdHGM4BOeteX3iQxPKxLXL7iSFHH0zXqMumzPaNbX8qWzFSwiZuX9M+lc5feG7i3tztjDR9cIOB+NAHBy3d2qhkjjiB9uRWdNqEzttkueTxxxiug1XQ9YvA0cFqVKckL/Wq1n8PLqSLzb66SEd1HJoAoWOp3kDfu7gOOm1znNdf4eW08QzJbz2cv2x/lHlqSPxp+heBtGRlN3LcSOvUHAA969k8H6fFa2sY0swbeykAH86AOOt/gJq91+9upoLOA/NuPzMR9BW/p/we8PaNGt/bQNfX0Q/eGXlc+oFew6LdXUcax3yM8TcA9cVrT2cNpG0pZFQ8kt6elAHhaaVNdShWYrtGUCLgL/hxXOeM/HEPg2yks9NuS+oODmUHLKfb/GtT41+MG04eT4ZRFt5MrNOvRG9K+ddQSW8nea5dpZ25Lsc0AY2t319q97Ld38zyyMc5ZiazNh7A1rzRFCVIO0+tSaTArX0KsBgnv60Abeh6BHback92oN1NyikZ2r/9etEeGhexXLuoRI4ixbbgA9hWovz3ClxwFA+laGr38z6a9pEwjhZRuwOTQB4xNA0croykbTUYUk4xzXWXtkHk5AIx3rMuNOMaiQD5c80AY5Q/41btbXzAh27iTgD1qTyB3J/Cun8O6dmy8x8g5wMjNAGe+kIqKEHy9+OaK7CLTm3qgwWJ60UAfSPjHw19oi89VIKDcCf4j6Yrk9MXMcv2oARAFcMeBxnNe/3mmRXtkwVRgqeP6V5BrOjrZ3DR7mVZGOUxuwaAOcsdFngjluOXikOVC8gk9/Y1estOuIZfNuIHIzuAYcf/AF62xYu80YhVlC/dUng8davXd4mn2qLcfNLj5EPOaAOO1+GJbt4YY/LMibiR2BrI0vQpby7SKGPzXYkAA5AHvXWafpd5r2qmONcyyHkkZCDHWvT9C8N22kwiC1Aa4P8ArJcdT/hQBx2h+BbexxNcoLi5PYj5QfYV11r4fjjZZ9QaOKIEYDkAfSk8T+JNN8JWjPMyz3p+6h6A14D4g+I2oa14gieWci1DEKoPAoA9x8T/ABAs9MUxaXGs0obZ5jfdBrwn4n+JNU1+CSCe4lljQ/MqthfpgVTvNV3RkvONocuU/vHtiuV1fV0h8wRuDI2Dk0AecahZvazMsqgMTnFUWOOgziuj1eKbUMzCMsxycgcViG0lCZYBeccmgDPcszAdjxV2yvvJX7PJloSe/Y+tWLbTHlR38xF2j160jaUERPMfg80AWYxhyfuqORjmrlu43EMcEdPeobSFHtvJjkbzAcgnpVyxtJ2cJ5Rds8Y5oA6fwB4jl8P+IbW9ZnNuzbJBnhlPUGvc/EPiI6V5UkGya0m24U8naen5V833ETqSskbIF5AUV0+ja7KdOt4bomdoH6MckDtQB9J+F00vUbG+DgW10ighgeCD3+tdPos0Wm6fL5t+Z42XAjds4PrXinw91Ufa7tpGLExgZ3ZOM+leht9neIlcuAAcluOPUUAQ6tIXndYpZIm6oynI+uK8D8cXt9JrVyt5FDIqNjLRD5h65r6RisYL+0NyYQrKCPm6px2rxLxD4YvH1EtB8wZ9+0t2/wA9qAPN5ZbDzP8Ajxh24zxwRXoPwzsbGbUDI2mRSJGuQ3XnHeqeteFJmuYTJbpFLIqlfLAIbHXNekeB/D1zaaZdyXMLQ8AK46MPwoA9G0SHSLfRFupdPRyGwqKu7BqDXryGa1b+zLGNJmwN23JGfSrPgZboWbxSpG0QUkAj73PatTVdRisLJRDAqSOSu4KOBQB5/wCH/A0Mt9cX+sFppC2cHnHsfWt7UNLsM7hZFgowFIG3H9Km0/XhJbsieUlv5h3uTzgV5p8UfF01z9pt7GXybRMKI1OMjuSeuaAL+t6pommQywSX1rBIxwUjG5vpxXLtrPhiGykHnvLPnPKfrXmGq3XlRhyVVjzjOc1gNfTtuGcrtPGaAPTDrWgNc7o57naQAcxferoPDmq6dFJ5sWsRJEpxtmXZg+xrwGOdwGkZ2CL3zgVm3+t3Fwnl7iIR0HrQB9dn4xWmkk21l5d+4GPMjYFV+prpvDevp4utjBf/AHJRuXyzgA18J211JCx8mRk78HGa774afEjVvC/iC1lybq23ASRE/eHf8aAPpTxH4CjeK6jCi4guBtI/iB7MK+cfEmgXGiarPY3UbIyH5SQRuHYivsbQfEWjeL9Mhu9JuFWVgC0DHDqfpXL/ABX8KQajZwXNxbb5EGwv/EM0AfINxa5zlTmoILIxOkoHRuK9S13wVNblzaHzowPmXGGWuTexZXIKgY7HjFAFsElVL4VCvLGi42zwiKJc9yxrZ0C2iuoEEwDuv8J6AVZvNKTKujKpHGM9RQBw81o7SBN24n+PGKo6paSRxCNx82c+n412zWMa3bxldzbfl5zVmx0ATzD7YBM0i4VeQc9sUAeaadpkl3c+WsZbH3sV2+k6c8R8mQGPuox3r1zw14TtrbSS/wBljFwTncRg9PWlvdAjneQWqKJMYEh4oA4ewskieMMnD8kkckUV6O3h0SWEc8u1CijOD6UUAe42N4hzE5CsCcfSquu6PbXqNKY180fxEfrVO2uPMkRgo7c46fWugRw4xjK460Acqmn29tbymRfmGQGFccfDMt/qh2Mx81vlU87R616Lq0Y2O0ZyGblfermkWiwQCRkAmcZY+g9KAKuhaHBotoILUDzGwZJSOT7fSsfx94ot/CekOVZftLjIyefr9fSuxrx74l/Z9S1SRY4hLOuFV35VfwoA8O1/VtR8R37Okckpb7vUAVjXGm3WmSq19tR+G2rzxXa69HPpsErBlQDoemfwrz7VdayxE5DyAcHPQelAG5IdPMYMkUrH/abH44rNmmg2si2kJJHyOexHrWLL4iWWMoq7ZF+6c9aoX+qSyzLIQEUgcJ0HFAGw04z5MpSRDwCowV/Gs7WrGGBwgxhhu3EgZrIe5O08nJPrzUM8r3EB3E70GRnuKALl2lvFbxos6Yb5iAajt2ifKl1Ixxzjms+OEzThcE8YovLVrdm3oVfFAGrBhJdrJlV6la7DSYY0MbwBtxK498mvNbZjy6uQ3TAPWug0rVrywUTRylNp4BoA9n1zwbJJdTXEewiQAxxqwJGRzmuOn8M3+nwm4kjSOEH5mzj86ueF/iLDeavbpr0nlQFgu4dFzXWXuktqdxf2UT/u1Jk3b9ylexAoAreGdLZ5IZfDswnlcATRk/OB6j1Fek3+n6lBEzwRyIhixjZznFcn8O9EurSW4uNPOJFVY/MUbiOeeK9w0i7u7rQ5f7QjCSo4CMRjd/8AXoA8yOtXum6ExlQybyFAIO5vpXEalfSXqOztNb6grMCQSAydse+a9v8AFGl6dd2SC58y2kY7iV4Ga8/1DwGLqXzrDWYEHT95kEfj3oA5GO/FrbaejXbTXiBjIygnbk5A5r1Lw1qYi0NgJWct/wAsyOvrWJonw8khBa51CCQuQxYZzxXplro1hbadFZxR+dI2AZNvT3oAteG7iCYExAZ2jGB2rF+JFxHbafG6kI7PtBPTkda6rTdOt7CPZbrj1rh/Hds2rny4mBRSVCqTQB5u108VkYbUl0kc7mPY9AK8++IGoC3jZLiIrOwBKg/er2W30qCwtUMkZ+Qctng+uK8m8UWcNzrO6NxMpck5OVU+lAHkc90W+aTdnuCelSi3VYEuZ5Nkcowijqa6a40+aeRhFaROC+zISsfXplln8qVI0Fuvlrjj8aAOR1WZZZnihI8lD3ON1ZjgEfeH51oz2iGVyGPfkc1V+wOw+Qjn1oArKpY/Kd3PQV1vhmGOBN0yhyexHNc/HatA2SDkd607G5+bB7c+9AHpmkam9jNHJYzPbzoN4IPUjtXsvhj4s297ob2nijJ24H2gDn8RXzbbXQJTCknGOtTzX7C1uA5GOmBxzQB9ZPplpe2iXunss9s4yksZyDXEeJfBUF+xaMLb3QHytjhvYivL/hd4/wBR8LXLLDMJrBh+8tpOVI749DX03o8mn+LtJTU9HbKsvzwt9+NqAPni1sn0rWTDfr5B+6Seh9CPatu40GSVhIxBRhwR1Neq+IfBUGvWhikQRXKj93Njv6GuQ8NaTqmk6jLp+ohWgU5wwOfwoA58aZbwPE8iHeuNu4YAHvXSeGPD7tevczZJY/u8gce9dJ/wjInuUITfGvI9K7jQ9EXYkjpsVRhfegDn102RbdW2YwcFc9famW2jPLcP5q7YwMsxGK7dtLhd9pOAOcU3XStpokxQAsFwo6bm7CgDxT4ga61m4s7MkSEYPoB6UVS1/RbmWN7m9ERuXGWAblR6UUAd9a+Ikt3+zyuUnJCoM8fXNdbpWotd2LiZj5q5kwP4gK8Wmg826eVZTuBOJGB49q9T8CWd1NDDfagCi/di5+/n1oA6aGIXpE2W8lv4T1yK06RVCjCgADoBWN4p1+00Gy828kCl+FGetAE2s6nHZRkFsHGTzyBXgfjLxZa2GqTAEKGbIZjxz6mqHjTxprGrW81xpgMdvHIyuC2Tgd/yrxnxNeS6gdzSEkmgDb8d6/cXWpkGeGWIDKvA25D+NcNcSKx3sQSf51XjlkDiF8qCeQelLu8jekgywOP/AK9AEboobfjPpnpTTcFWyB179qZNJlgAAB25pinnvnGOlAExfcDnG496bEwEuSGBqIIxIAyOxzU0MJeQBvlbsfWgBDIBdbg23PWtDUFfULUSiQmRRjmsyaFvNO7AI647VpWLJFa/vWPzH7woAwolZZAB8uCQat3MwkIQZwP1q/FFabuWZgxIrLltWSR8kjnIoAAzHpwBXpPh7xBN/Y0LtJILhQEzux8o6CuB0+wmuG+TBJ7ZxW/Y2VzBArgEqDgp1IoA9x+Gfiiax8TwNGyfZ7tDHLEfusccfjmvZ7TVW1CSO3kSRNx3KAOnNfP3wwsjNPHdSRnk/LvHf1r37w0qPdSMWCFAFUscZNAF3xTbr5MZYFlC9GNc/Y2qfYtyQPhWyPQnPNa3iaVmmALnHRcdBiqaS3K2BYhMyMDkdhQBPpyQyyHKsrk8DsPc+5rqkb7POu1VaPodvasDQA/2tRwCMkkjmukliR59+SqkclaALUrrFE8nbGfrXImays5mVJC9yR0A4XPWt3xC7LYqEDFSwzt9K80uNQjhu5psltpJGT09BQBT+LPiWw8NeG5JrkEXd6m23hT7wHdj6CvmeXxpe/anmKRt5nB3Dt9a6j4yahNqt+0s7FmQgD0Aryy9mRIVU/ePXFAHXWnja5t72S7sjtnaMpMM4DKa4251Q3U0juGDMTx1FQWD/wClYyuGUqd1VZQUZl75oAtwSgsDuHP4VZiRAkmQ24D5aylLcHtn9auQuX2EORzgj2oA1YY/OCxKmS386H0wKx+ba47g/rUKagsJ8tFKqDy/8RNXdNukuZVimk3LnJz1AoARrK4jjQqSx7dBkUTxyrEq7WXPJ3CtmO6VbqUwyL5DDG1hnj60y4JbdIPmjGMqeeDQBR0qMoSXJOBnivUPh14xu/D+oRyQO4hz8yZ6j6VxGiWlpcrK9w72sS5DOgyD6AD1qeBLmBi9sVnjB445x9KAPtLQNWtPE2mx3li6rLjLp6Gp9R0uLUolV123UY+WTufY183/AAx8YTaVqSJLK0asQCDxivqOwmS7torpVwZFB60AZOm2gjlFuwCkcsB3rWnuAi7YcFug9qZqauIGlgwJF5PHUVg2908l7s4GcKCrdTQBq2U0nnqZjnPFZnjWcG3ijDDCnea0FLxAecGVwTxn9a5TxZdBopmfPTHHXFAHKX9zBKGzlsDHz8YOaKyb5lTaF3EnLEHvj2ooA3/h5pL63etc3QxZQjdISPvt6V61bhXClQEgjHC9hxWZomkx6PpNppVsD8igyPj7x7k1yPxl8Xf8I5owsrJgLiUYPPIFAGh4y8XKdLvIdCu1S5jBPmjnp1AryO28St4g05tM1KR5ZcFklkPJx/WuG0jxJdrf8EySM+8IOcnvxUHiTTtR0/ULa6lk8m0lJlhJbOMnkfhQBPYX8en6xcw3hLxMD8h6MR0/GuK1y2zIzW+TGzH5QOldRJqNg00TJDvul+87HOah1uKV7YyLtEW7JVP4aAOIGmygFpQoU8ZY9Kbd6f5kCTPKSudvA61dnZVYgNlCOQ3NTrLBJprxkbSpyB1/GgDCa0RFGYywxkHPWkiBLlFAUkZNXPPUxFXkyMcVQLhJQWGM0ACIOSzEDrnFS2UYLsWG4D86gcsH2jlSccVIhmjRlRgOxyKAJJbdp7llhwSafcW/lwBQwAAwcmq8REbgs5x/Wo7plZSycZPJzQA6zgxINuWkIyRjoKleOXzWK4IXGdwqpC5jzIGGexqrdXk8nWUhfY0AdfoTMbyKKSIEOw3ZXHGa9X/sdLFGMEEYbG5gfmxxwa8I0vW5o54mkctt4JzzXs6+Knl021NtsdZYgGP8WV9aAPR/BE2nLFbxrJLkKWljCgD8P8K9W0SwhNvHc2iOYpBjacAivF/hysmpT/aLZVJihJdR1J7mvevDFrJa6WBIrqXbeEY8gUAed+Jr822r7S6oiyDejHBYDtitP7ZHI5dwIQcck/d49K0/ENtbXl5J9utoZSCNhyNwpk9tpsUT504yHHAL5wcUAQaBqhlu3+zbfJX7r+v1rqrRrtp5Y3wyf3zWdo0NpZ6ezW1qkTO3cc/hW7bp5dsXPDN8xJ5oAxfEJuPsssFuryOqAjHQVxEunD7MTMsizEZG1MBm9K7DV5riXUTHHKyoSFKhsD8auCELavuiM2Pu7j0P1oA+QvjVZvp97bxqw8ydPNZQeQM+leRSQYJlmDHuAa9X+OmrRXvjK4ZTDGkA8nCndyOuT9a8tN2EtWBkBYt3oAlt4rQzRl4nj3cAhuDVO9g/fuiPjBwNwq5ZXkcrqk/lhcgDHY1qx+GdQ1Sa5n05Flt7dQ8khbAX60AcqYmjQI49yadBwmVyBngirV7BJBcFZChYjOBVvT7Q39pK+zAjIyVFAFS5zJJiIAjAHFISLUrtbLsvJ9K27eHS0sJIEnkF5nKntWJdWkolIIJ5zkd6AF/tJ1bapO3uMZrb0PVre4mW1vZjDDIQC4HSuaZSDwMN71Zs9Oe4nQjIwfyoA7bUNQs/OFrp0jJBCflZur+5HrUOnzkuzGRg3r7VxN+8sN5J8wbaeoPWtTQL15LxIlUsT1oA9q8DaedYuoA8YlRSMnGGH419T+FTDFo0MUUvmhOCfQ+lfN3hHVdPtLOOx0y5Q39wo830UdwD2r2fwTJ5ILtIRBCoBHZmoA7+RgoIJGMcgmvPNejNjqEqrIVjb50K9c16CNtxCGB6jPFcN4zsz9qh81m5G3I7/jQAmjXVzM8O522k43Mc1Br6EiXeu8swXdmqtjfG3h2xfMsZ5GevtTrxvtKmQybUYAn0FAHC67CyNJ5jLkYClTk4680Vd1RUEcxbaS5IwOmKKAPdI9sMck0jYXG4nrgV8qfEWW+8Q+Ir2/uZPs9mJWRC/dQcDA/CvqPWbuOztQXQNk8Dt+NfLnxAVv7fuluvljLF1B5yDyMCgDhmmSwlB01ZPNH/AC2Jwc+v0rq9HvIfEulPpetOHuiN1pMTjy3Hb6GuL1HVVtWxKwWM9hgnH9Kw5tduSc2sgSPPBH3uO1AG3qESaXevBfDZOhwwHJqhc64yW9xFEB5bLjmor/UbXVfKuJ0ka4UBZDnk471k3kKNFLcW7M0SjGD2oAry3Qkh+TnGevWi1upHUoCA5GDWcrbj05q1bYQ7y2QfQcigCNGbHOSc4INSqVJyenv2pWXMnqp746U2NcsIwuf8KANLTYkjkWWR0KqclSO1VbufzZSEAERJNSrbztFmONsjjHtTY7Cdm+bCr/KgCofvYBzio7nJT0GePerqWyi42PJyDyFFW2toPmARjgfLuOM0AYKcIQzYGapyAsc9BW3BbJI8igbTjgdqoT2RUlc/N3FAFGIc5BHHvXQaXeXFvtVHYA9VB4rMsbB3JOBtzWnHaE3Kqu7sKAPcvgRcyPrTPDK6yRxsNoPUHHFfSOlapKLeR7ku2BgBjg5rwn4IaNFYiG6jAmMy5kIPII7V7bqjW9tYSytLtfP3evAoAjnhjnufNGVHcetVdUtBkIOuQBhuDUulSGSJsMPlG4Ae9QTvK88hGE4C/N/SgDfgiEVnEiMCWXOK24BiCMZzhQM1Q09BsgyONnfua0qAOdv7jfqxHyrDHjJ7n1zXK+ItZndTBZIUs1yWdifmP4Vu+JUihkmmBJZgcqO9ce/+kL5JOE2nAUnk0AfJnxItZo/Ed/5sYUvIXAHoea4idcHYB71798a/Cl3DBFq8NlMVU7JnIzx2PFeEXqyHcSrA/TrQBDkJgNkkeneur0LUf+JBqcfmTDcgARD9761xe055HNbGhXDWRmlKhgU2gH1NAEUVrdySqIQxVu7dq2bXUZLBWtfL+VxtkdDxWX9qdFmPmtubkY6CqH2mdW4kP40Aa6WZguIyMiHOVduRitfR7Zrm6aQSr5P/AE071laRqsm9Y5yGAG0BhkVo3V1d2ViyLsMBySQADQBvahfeF1TZc27JeYAzCMg4rjL2di5a0JCk8A8Vnrc5bovzHqa0rXyyyqG4bkrQARai0cHk3Nmsyk8tjn866fR9OsprZpdILpOUPmRuckjvisyEBJQhUKrDgdqu6Z5UVwMPJb3D/KNvagB+mTSW2obLCORGLDjv+de0+H/iIljDb2F021FAy4/iPcmvI5FltbWR9oec8O6nt6fWsuBzNIuJMMeiscD86APt/wACeJ7XU4mCSgpgEHsPxrodWtob1TFcrlGGAQOR9K+JfDPjLUdCvI4rOctbK+ZI25DYPQGvrr4ceLrHxjoKPDJtuYgA8bH5loA5vXdMk0e5WLO6E/8ALXoSKr6dcxudg3bRkHngivR9U0+PV9Pls5ztmGSjf3TXlYt3tbyWCT5ZYW2sp/i9SaAKesOrM3lgBQCCMfzoqW+h8wTBvlOMYPcUUAeq64v2qKRzzFGOAfX1r5W+NPiO2+3FNMCm5i+SSXOc/SvRvjH8QvOW40nw8S0YOyW4jPU+gr5t1SN1lka7YsScn1JoA5u7vHuXZ5GySeT61EZjtQNgKvp2NWLhIG2eVG+5icrnOBSrYSbQcgMeiHrQBZsYizeczbYXOM9637i309tNZLF55JSPn9DWZp9vIskO4MfUPworsLuOC20OWS2wJCyqFHGT3IoA4qPSJnA2Abfc4rRXTbZNLI2k3O8YK+neqzTTxOShIJPIx0qEXsquQshOeRkUAbGh2EVxfRWRiy0x2KWbABP9KuXem2+m3htWUErwjr0Nc0l3KXWUP86/MGzjBqxeatLO0ckkzSygY55AoA6KcRNtgtkbbjDFurY6ms26tfJwd6qCM8tj86yI7+UjDSENnHHGRVgujL82TkY5NACTsEO5Hi3H8ame4ZgizyR8D5exFZW0QSbz8yBuVHJFdM+q6JPpccDWuy6TIMmOuelAGPtW2k85nAQnIGc5qpfIEk3k8SHIHtTL2SBmLRckcD3rNN1LFwx3Adj2oA6bw7ZS3t1axspVJHCjAzXt8ngDTLeJ4mk8rdED5oXcc+teE+D9SuodatpA/wAg6Ln+VfSTaxBdaZbyojK7xgcjJyKAOw+GGhWmjRq9jIssS4Qkr1B6muw16yMs/kJGsqyoSpx0rE+FltLPpVy7ArE7DG4d/auw1bdbrG8JwyrgE80AcEzXWmTNDJCGDIVxyPpQdT8mB3mRsg7QM55NaviC4Eyr5sQcPxuDYP1rNjsdMSPDpcK5O05JIJ9TQB0vhvUHu7i3UAnCZbHAHFdRGWO4sMDPFY+hQrBa7bZET+eK2CcSqO2D/SgDlNYsLm/vXEaZt1Y7gWxzV3RNFjiiDS7Tx8owOKgurhINVuRIwK88Zq5bSvNDFHDkyMM5HRB6mgDO8V2djfWF1YzRB45EIYMOK+LfiL4dfStTmhjVSikkbTnivu2LSYetwWlc9cnA/SuF8c/Bzw/4ohdo3uNPveqTRNuAPup6j8RQB8ESwmOVsKSRT0nULGsg2jOTivSvi18L/EXgOUS3dolzpLNhb+2BKD2cdVP149DXmoeBJh5ysUxkjuTQB6BJoekX/hhdShvoYGGF8gsN7HufWuPi0yzupTbm6MMidGdchqj02+QXu6SHMH8Kg9KvaisTzxzwtsLE7gw7UAZ02j3lpIDs3gchlPBroZPtM+iJC9tvjYcnbyDj1qul+JbeURna2D174rpvhzqpYTW00mUOSQRnNAHmLRpHx8xZW2nFRmRkY4krpfGelJZa3OqY2k5UqcjmubmjZm3bRtHYUAbWmalmGczBfMjUFCfXNaVnNHNco8jfPkEfN1rmIdhsps5xkc4oM8sUsOwlVUfKT6UAdFJqEsd2zZZEJIxntVq4nF3ZoAqxBTjI6v8A/Wrn7CYyTATAeVnl27e9b89tBLOVsLqOa3jUcg4ye+KAIIbd4DknIHcHINenfCfxNLomuWtxFIV52vzwRXAWK+WhXeMd1ccN9K3bGx2gT2JJwcmPv+FAH3FaXKX9lb39uch1BOK5nxnpirdR6jCAomGyQD17Gq3wS1R9Q8CW/nnMsTshHfArrdatkm0iaNxwg3r9RQB5RqkWyLdxlRySfzoq7qKLJFICWx/DnsaKAPl6XVTc7sMWx8231NV9Q09vLSW4by0fna33jUEQTTrgmIiR84Oe30FdHpNt/aoV7qMsGOFLUAc3DaKcm3hwCeCOc1Pa2O2YyTfIyjOTyTXR61PDoMLwqId27GIxn8c1w2o6nPdOdvygnselAHQfbYLZ2aaJZo2TaAf4fesW61RXYASMcHO0dBWe1wotnidz5jDvWeUYHHegDWurhGkDwliDzmqzEBQSBk9KihkCAbgCB1pzSbpNwbaT2xigAxke+PWowNxBJ78YGKkDc09QzD5VOPagCuw5GSQPrU0L84J4HenPBIzYKkexpwtx5R3yBHXtQBFK7jhWByc1XeXYx44rR+wupG9iuRkECqVxAqSYBY/XFADBKch8AnqRVO6ffIWOBk9AKvfZiqqxHykcZ6VF9mYc7M56UATaLZiWePbIcg54r3v4eWztDKt9dFmjUPECMkD0rx3QbOaFBcNA+z+EAZJro9IvL+31uGdHePJGSc4xnp9KAPpr4e6rJpqTPNKXEzhVRvQdxXYPeNetLKXPk56Dt7Vh+FIYLq0triFIXLL94cj8a6mKzWOLefkVznHHFAGLq8m4RGVflI2rxxis/Urg7olKDheRnoPWte/iMZ3KfMCNubHPH0rnb+7UNJkvkDIGMkCgDqtFvFMfzSbvlA4FdLby+ama4jSGEcAVCSWXlulbemXc8SNCMMRnAbOfwoA5LX7h5vEslvCdzSsqjrxnvXounWaWVqkMY6D5m/vH1rj7fR5W8X217LlI1AO3P3jz1ruaACiiigCK6t4bu3kt7qKOaCRSrxyKGVgeoIPUV8m/HH9n25sLiXWvAdu1xYud02mry8Hq0f8AeX26j37fW9FAH5vW/hC8MUplkaG5j+bymUipdf0+40fSo47wxtLcx712tnA/pX3xqfgrRNRunuJ7RBMxyWUAc+tfOnx6+HclrPeahPdwxWm0Lbr8qDAHTHrQB82aVNEk5+0u6xldvyDJzWp4b1E2GoSDcw68juKzUszB+8bEik4GOmfWtjQ/Deq6vOzWNhc3A+6SkZwPqaAJ/E10tz9naI7jtO/8+MVzrS/e3DHvWpreh6rpV48N3bGMrwc87axDIC24/P8AhQBuabpclzp1zL5DvDGBuZRnae2agtNLubx2iiXz2TBAXqvtWhol+VgltoJWHmphkz1q7o4l0zS7u5Vtk+cBl6qPr60AcrepNFK8EyNF5ZI2MMfnSWV9JZyp5D7VByfc06bNyzSTszMeSzNzmqklu8IV2GVJ4oA7XS9SsrtsTrtfr16111lDMphntSzpkBNoryCIgHczBMcivRfhn4oGnatbPfKZLPcAVJ4HvQB9f/DaFbfTLVIgEl2/vUxjJPJNdtM+be5RwVwh6j2riPCzqPIvrKVXsZ/mVxyCa7fVBiwnljBJ2Hgd6APL9YUpbSFfmCjII4NFWtXVZLJweCVxn3+tFAHzd/wjYtN9xqubdFOC0h5P0Fcvqnix7dpbbSTtgJ2kHnPvTfGfi/UfErLLdMBHENioOiiuQX72TyM9OlAGut7Nd8zMHA5JYd6rzSMCY14T1HFVDIcYXGwdBV6CE3MfGF7kE0AQgEgPj2p4jZmBQbgfTrV1YYkiG45PoO1PuFbamxNiEZ//AF0AUjAQpJOMULFhQCWLE81MxwAu4Y7e9PiKEbHPX+KgCsVAGNuKdvYH0FX7iz2oshkXYR65Jqi6p0D5bsP60AWrWTz02kbpAe5p2xGYuVLbeTVKPC8lmBHAxWhCkMt2sYdgBy5J4oA7rw14Iv8AWtNt750VLeXhTuGSfSuM8UaNdabqBSe28rBICkg9K6LSNdawtLjT4LjhPmAz+g96yNYn+224mn4kLcuxyTQBQ05QMebD5hxwhFaca/Okgt0JA5AXgVT06KOKRHlJfn7o71tXlndLcSPbuRC33QrdPagC1p12rvao2EfO1sdCD7Vv6tYWkkYeO9iZlA8yIKQV+lYfhi1kW+i+0RGVNw+fGNvNey2/h/Tpnjkuo7eNg3JPcEUAdR8LJ10+whikkdreU7QzemBjFejjYHdHIypOA3OR2rO8OaTZw6dZPBbL8uRwP6V0LwRuxZlBJ70AUlgtZlBGF7ED1rMvNIhSRZEIbkg7h2rbkghWPAUr7CoXtI8KpLOTzjPSgDPt7NY33BV2p0GOta0RRCu/aJH54HSq7RhDtTGOtDJmROoOOtABNEBepKOQMYxWlWUGZJgD09CavwSluD1oAmooooAKKKKACvm79sC2uRp2nXTl1sBldwXIEh6A/gK+ka4b4v8Aw/j+I3hqLSZr+SyWOcXAZF3BmAIAPtyaAPh/wV4avvEbJbWBSdkbzGQnbgda+1Phpo0el+H4Fkto4f3YMkaLlAcdj3rk/hp8E/8AhENV86W5EsCuRgY/eL713XiCLxBpszjQII5bNVDESPjjuooA5/x14FsdXge/t4Y5HmUgggfn7V8pa58OtYu/EU+maHps1xdpk+XGPvAd819NWnjO48Xa0umWkf2SW2JWSJBuBb/e712lh4Pltka5tro2+ovGyebtBK5oA+C10S/0jUlt71Da3zZRonHzLWlr0dz4Wjit7uJZlnw/lueo96+m7j4AibUbO8TUkVoX3Osqli/PrXiH7R/hPUNE8WKbmSOcSIHj8v8AhTp0/CgDz+Saxu0aW1227EfMp5wfas9JQG8uLJc/edxzVKzsbq7vIrWziea4lOFRBkmux/sM6RIln4ntJLa4lUNEARkj1NAHOJYiXMikI393PBq9p0Rik/eKcdl7/WteHTUivI1VkK54U9/aui07Qm1GTzCvkk8LIRx16UAes/BDxeunrb6TqI3afL0bP+qb1+lfSihFtgrEMhGMjuDXxNbXDadfrAwEZiONzcZHr+NfUPwo8Sp4i8OtCHLT2ZC5J5YY4/woAb4rsjYrOqr+7bDRnH6UV0fiW3OoaG5iUNMgyB3460UAfnKWO3GM5PFPWI4DyDH+zjk1cjijtWKxJvk7sex9qnjX+KRPnIznFAFFYxvACgKe/cVahi2ON3yDOeTzipmmjgBy4ZyOeOlZ8twJDwcH09aANS4khR1yBx0xzTLq5TMeVG3A4PPbpWdyOCeP73pUivGluRgs27A+nrQA4ZJJOPwp8bIp+cH2qAkrgKec9RRvxuJOPxoAknuGbIJYKOfpVVueWJyewHNOZsj1Hcd6ahCk560AMaVl4547VPPKWlDo4DcE9v0qB0yy44z39qhYEyEkHPagDY8yBGE24sxHT0qNruScZU7uccjoKveHNCm1VT/CScBieK6rRPA97cSpHHCXUHJIHAoAxrKF/ILkc4A+70rcdwdEkLEiUMNoA5YV0d54dEMQgeXyyTjGzH1/CsXxDbwWNqvls7bGHU4BoAo6Lc6m7gRvJvRvu5/pXt3wx0K81Zxd6qZgqkHyiODjv7V5d8Mku9Z1xoLWNPJQZkfaOB9fWvorQNbttPhjhLqi42EEYORQB6Hp8Igs44wMACrNZK61atbLL5yHJx9KspqEBgDmRORzg0ATTKrnJPT3qBwRLzkkDt6VBLqtrj95IoGe560xtUsVOfNU8d6ALUxJOOmRihpMKAuMjv8A4VRfVbTGfNBHpUcepRSyxqqsWJ9ODQBYYs0oPOQOvqKuQuiAcDd9azdQvzbBUSL5jxk9BWe95dm3LlRsIyuByfagDqllUnGfan5rgo9SuftEU7s8cZYAoTmu4gbdHnJz70ATUUmMkcnilFABSPgAk4455pa8q/aF1PXNF8K21/oWofZ1E4hmhCAmUN0we2MGgD02W9torcTyTxiEnG/PGfrXhnxI+MENpqUtlYMnkxgqZQ3J9xXk2o+MvFF14KOjrMImgmMxdTh2z6/jXhmpzXbXUqXckhfcSwY96APp7T/jR4O06JZjBLHeA5doFBLt3JI7n1rs/DH7R3h/VIrg3VhfQLEQEfAO/wDwr4hrp/D0j21l5xZtjOQR7UAfoT4O8ZaN4ttHl0e9hmkT78Qb50HbI6ivH/jJoq+KfE1qUu4oy/8Ao+ShKg5/lXzn4O8a3Xh3xTLqFhM0RC7MA4DD0NewweLE8UaW2oSmOC8hbfA6k+WZf8+tAGB4r/sn4S+KBFpkRv8AUtgQ3LICkRI6A+9eT+Ktd1DxTrs1zqLeZcfdQIMBAOwr3iDSLDxha/ar4TRXkaEXKkZBZR1/+vXj95pVvYS3Fuk8cdwXOHYfeH17UAHhzULXTngi1kCaPIIQHBX8a7OTUblyPsTRSadITgR/wL3FeSXjTRSv55yAOp7/AONLp3iO7tCIY5WFuTlh0oA9WvNZtdUsTYLb5mVvkuj1QDt716V+z3qMml+KW0y53KJ4+CejeleQaLIl1ZedCwktiRucdY2PrXqXggr9vs9jg3duwaN/UemfSgD6XKATyR8hZFOD6Gih3LRRy5wdqsRRQB+fOoacLB3mnlKxnO3jkmsG5vWf5YmZU9+pq9rd9LqczT3bnB+6oPArGKICQpyvrQA52yOufelXtjvTUQs2AcgmpFRskBefX0oAUttXAJB7+9Pj2upViQw7jpT1jBQE53Zz0pw4XCIBj2oAlNlI1kLsEMqyBCo6j3qsEaQsOmTz7V2fhA218Xtb3ESSLscqByP8ax1s7eO+liu/ltkJ+f8AiIHbHqaAKuj6RLqk4jjJ2DqRyfwFdPqnhC0s1iVrlAzLn3X6n1rkbe+exuHexYxq3Tcece9Q32qXF05+0zM5OeB0oAuRSLpl4GXy7pk6cZXFdTpfhBvEtgt/bpiYvjYh6n6elchocT3c8VtHGPmbkk4/WvS/CuvajoN+v2OGBreBdzgJkEe5oA6rRfBl9H4bZJkigns2BKdGbn1Fdj4EC2V1cxXUscdvGDuUsPvdTzXNat4n1nVfBN5faWGjupwdm1R8gB5z6Vwuu6zqSeD7bbcI92zES/u8Ecdc9zQBufFvxPo+m6vJHpU32mVhuYg5RCfQ9683TUrrVla3Vd7uwJJ52iuNuLqee9JkZXJYDgcV6T4GL28InfHmMdoBTPJoA9m+Evhj7FaARt+8ePzCynbnjpVu/wBJnhuA7Qs0jSjcecfWtTwX4kjhngjvkhQlNomiUgH2PpWleI9xqGxZf3QBO3PBOaAOi0e0ij06BJZCxdsop4PStSFrdrTdv2MGII20lnbhZ7OOUZ8tVVffjPFaH2OCQSrkj5s88YoAwry2sWUFrtlzwTjis6W3slCj7ZEeCTkdQK2LjSEDSKAzJjg5zWTJocUhciElSMdcCgCOFoJJwEmRkXkhB1NbMTmIxTYAiBzj1qOz0a1soisRIZufWrN3b4mQclNoA7YoAnu/30oG3I4yccGqF8UVHVHbAGQuevrWkZAm0N/CM4Irn9W1e2DhUO5342IMnigCaxljeJRcqfIHIJ6//WrqtOO6IM7fIBgFj1rlPDunu1k9/rCvb20TFwkjZO0dzVa28bad4g19dKsJSsMZ+bHG49qAO5e6XzFIb92OvvVsEEAg5BrFuYI/s7Jsc5Xg1iaZ4ssre2kju52WOGQxbyO/pQB2pOOtcP8AF3SZNX8LeVHGshhlE21mxnaDxn86k8S6bH4x0UHStUNu6HcsikjkeuK8ymufEKO2l63cG6MI2qkcxy656+9AHmGrWd7HJe3MemtCZYgseTncx6Y9eBXkGsWct9K8kkZivBwyEY3V9Zanpv277E0MTJHAhDlkKhT2Gema5fxF4Oji0y41PUYkeNMtEQocux/hBHpQB8r+UI2IuNykfwgc13Ph2ysrvwPqU4ExvoP9UARtHPIIpPG/hcRkajaBhE4ywUZUf4Vh6DqN5ojHYhktJjhgB1oAxERvKlLbhg4PHOfetzQdcltZEgDsI14UZ4/GjxFEBE90oKPK+HQ/oa5wEjpxQB9PfCXxstxrzWc6xhHgYBlX5Rgd/rXMfECz02fVb+a1ZDeKSDGeFb/drl/hdqaw6PrXkADWBGPs0h6jHXHvXMRa7NaX7+fEXViS3mf3vWgCHUre5ecG9iZUIwG24ArMaycSL8v7snhgetemeH/GMc9rLa6vbxXVoyhVYpzHzT9Z8P2lxZ+dpk1vLbMP9WBgoT70Ach4d1CTSZQQwa3JxLED94f417Z4VZpZ7S408rJay7WQngrz90+4rwfVbBtNn8iU7T15/wAa9I+BniP7F4mi03UWzpdyRlm58qT+Fs+nY0AfbSHzNPhdQGIRcgfSio9CO2xSI/fTqfX3ooA/OC6VXX5GOM8gnmq4iycMSB3rYlsxDhshyRztOcVA0akjdzkYBoArW5WM5UZ7fjVkybhuBznpkVD5YQMpx14JoYgdBwec0AWUxwduT1I6YqORlHzYAOMcVV8xgQSeQPWjf8pGQe4oAtLcSI+6Btrd6lW/JKrMMv8A3h/WqattHHBHXmiUKFPTPU570AWbuCOVGZCpcnNZxjbcVc4arttNHHIFkOI6uR28FxN8jDrnk80Adh8JNLsp9RuDeyKrrCfKA7tXaWugz6zqsmiaVPHargG5mVeSSeFNcf4CFtY6i/mFnkfhQBkL717J4S1TSbGC4lkgVLmRxJLODhpDjigC146tLPwR8PxaNcxNPKvlLCGG9geCfpzmvmTW7/UDL9mWdmiJwFJ4/Cus+Jmrx3fie4m+1tdBuY9xyqD+6K89iWfUNXhig3uxbO1elAD9M064eYIVDXG77xPAr0HQbe4t08m4jdTkMHPAI+tc1/Y9+HaWIARL9/5sY967rw89zd2UMBeKeNP4X4JI96APQfCWoW0zxWlzFNDOhx8yZQ+hPpXZpbvBfAvMwcpltoyW/wDrVjeDtL077BELqSSJBkFgNzj0APpXS6BarJeTr5rzSo2EzxhfSgDt7S6jFlbEKfNROHI4/CktrjzGPmDac+tU44vIiSPJB9DUluQXAxlc9fSgB81zhcL90ZyP8azjcNJNlicHoAavXKqEYNknOSQap7VSQOMHdyKALLts+Y5I7ZqxPOiwhGDF8ZBHbNUWOAV5xjJIqURtKUEfzA8AUAUNTuWkgKKT5rjGFGT+FGg+HrfToV1LXGVCvKox4z6n39q1xBa6JB9svD5lwBhF/wAK4DXrq41y/SXUpGjijbMcCMcfiO9AFjxH4kOuXMdtDcvb2yybTGvSRT3J9K5bWfBF3aaiE0Zvs0xIkhnVjv8A/r1la1pV8l+tvDamRW+dDEDhifX6e9dnqdpLptvp+t3d/IbmyhA2luP9oEUAepaNby/2bAL07p9i7yBgE4ryDxYk3h7x1cIo8+wvkJC7chWx+VeveHNWTWdMiuoxgMoJ5yOlY/i3QzfbrgDJTDIAeh9TQBxngXW9P1OSaytZfJuoiVktnP6qfSup1TRNOuQl3d2fnXEPEUq8H6fSvFdb02+0jVrjUrHbb3IPEqngeo+tdrpXxQn0lLaLX7RpYmjBZ4hzn196APSp47fWtDl0+8jEUU48pYwfmHoRXD+NvAY0/wANTSade3Jht4Dvhb5gw6lvrTrv4i+HTdW17CZvLWVVGBhQSR+VehT3NxqGlT/2fDGzSxMI2kb5MkcZoA+VtQ02GPwTM88iyQTENCyHbvYfXrXhmp2t1b3I2kmGQ8Y4CmvoP4y+EtQ8L6FoK3Km7KGQvcQArGHZs7cfyrw/VtTY/aUa3SNSOo5NAF7xNb6fD4WtYEv1vb8gNKVH+r74zXnzgAnkmtSzmSKOe3ueVkGUbvn3NUjauH2npnGc0AS6XqVxpmoQXUBw8RBA7EeldX4k0+DVNLTV9MLvGy7pUI5ifuPpXHSMpbBHA4Fdj4dhurjQo4rKB2KFjKF7g+tAHJW08tpKJIHyO4H9RXb+FtUia4Ese6RDjzou/viuHureS2vZopWEbKefcVa0zVH0iZLixI88chmHA/CgD1fxVp1i+pR/bA1xpl3FuEkQ/eRMemR6D0rnbfRzo1+tq8hlVsMsoyA4rc8Cand63q9vdwolxNjEsbDIB9cV30mgwaubixlhEF4ctbsf4WHVc+hoA94+FGtDWPCVsXP+lWqiGQ5+8AOCfworhfgJcy22oXVjcr5b7SjITxx0/HrRQB8iwSSABCW2OenpU80sUIAXMhxwe1Vr65gKiO0z5QHLHqxqmj9ODg0AWW3TfO5wSOB60wR87d3OKWMb5MtjaPWpf9WVbGXI780AQcAg5P8AjSHIywI6/nTiGkbpgnv0p8cW5u1AEO9iORgj3o2lui5NWTCM/dP/ANamBgCSpLD/AD0oAhMZCYbg1NZbRMgcnsePrTCpccg/T0NT2EGbpDlQvU5oA9E8HXFna63bxXDShJVwxIwB7V2OvGzhnWz02BsO6+c0hJ3elebRakzTxu92gWHHKpk/SuyPjGG4tEeWWR7qH5twiA3emfWgDB+JWjQ6drFuhaHdNGGVY+AK5zRrb7HcvLJGRIT8o9fek8Ra4mqaiJ77zZHycOw6D0Arqb23gk0C1udPhkeSCNd7sc8+lAHT+ALay1ISW91EMSA7RnJz/hXb6f4Mgg8ry0UB5Cd69cehFeXfD3W7SPUg97I8WwHAx0Ne+eD9Tsb+7VraQNGV3ngkCgC7pui/Y4cSggPwG2bR0/Ko7KfZcyOdqSqwjJByB713apb3sW1nV0QH7vb8K5jU9IEM5a3LFHOWUrgD3oA14H8xFaQ5wM+1OSaETgeeg9BzTdMdkCWhVfKK4Y9waiOmkzoyTICvBB7UAT3PkB8NeKPm7Ak1DKtttT/Slbj+6RRPYiQkCZC305FFtoryTEtMgQDk0ASQKJ5QsTB+OpXtWiJI7JAsX7yXp9Kgl2wRGGz2jjGQaYFIEYz/AA5LEdTQBmXzm6uA9zvcYx8vFUmsgzs9go3oBzKOV55+tX5BlwMleAc024tWuZIUtZygIOT0GKAIbmzuJtHMiII5EYeWVXmQZ61z+v2f2rTltruWN5VU7lI7f411VyjWm64urlhAANgVsBveqDXNhqGYyiNnvkZ9+lAEXga2bSdNW0jd2gnQkEtwD6Cur0csI0iudxfDAjqCKge1torW3aDakEY5G7ofSp7bWtNMbCCaN7hQSUH3sigDnvFfhFdYn8+ydSqnMsJGBJjt9a818aeHprnTYp7Hzg1uWjaFhk4z0zXsltrU10ssiwmFMrsyuS3rWRKlvdQ3lsHMe6QSZxna39BQB80RQypqqxxctNIqLE475r678NPAmj2kEO1WjjAZM857n8683k8MeXqVtfT2yTokyneT6dSK7DxZ4XTVtJeLT7uewvD88UsR/iHIz7UASfEsaXL4QvrbWpIEhnXZH5v9/wDhx75r4v8AFnhNLOSSUTGSJwQpReD+Nei+P9K8TkzW2stPci2bd5iyFwuehx+dYXguaTV9Yi0PWJX2rzECMZPpQB4VqcZFwdowq8ADsKhE7EfQc19R+I/hYt1qMdvolrAVuyTyQoQ98n0zXh3xK8E3vgrUzBfQ+WX429vwNAHJwSqQSApkAwA1dL4bv7q0tmkt5XXOQdvHB9a42tjStTaKMQSDKcgEDpQBFfp50sjMxIySrf0qgyENzkIeRWk0XAYZ2knnPFSxCNohEyZ3Hj60AaHgfXbnQ9ds76BiqI2GTOAy+le+2N1FqCQXthMVV2Lw4bJDdWjNfOsFo9rKxkC7I1LqSeD7V6H8J/FUGn6sbfU2/wBCueCP7kn8LD05oA9y0mfyfGml3un8EuFvUBxtJHBxRXPfDO5uLfxpJZamP3ksnzEnOeeMUUAfMMa/Kdp+XGcjr709Adwz0oSNkOCADnBzVpG2lsfqKAEjQugwNpB59/wq/ZmIOUYbsDr71TRgXUYwB+tWDbOp3FdqkZFABKjeYxHI9PShIiG3HPXOKBPsbGQcdSaQ3PIww5oAdP8A6srtGc1ULgEdz9amO+b7pBbv6n6UJZyYHy4YcnNAELBihIbG41NZskTZ2gkDlj6mpYoPOt2RFLPuzle9S2ViPNCzuiyD7qE0APMhmxGoAXIy1bP2mz0+BEOWZgWZ88Vz+WZ51jYfK20571Fq4VbdMOGJ4YD1oAl1rUVuLyER28SRwoMbf4j/AHj71veH9RvPN2q5MTDDKeme1cUYwZxlztIx9a6PSJJLe7g2NhchXBPQHrQB0jLFLcKQpUvnMijAJr2P4SX76aslvcsjLKAw/wB3sPavMUt0khCQWvQ5Sbd8pU+orrdBmaHUrNUO3A2Sbekg/wD10AfR+kou8sjAAjjHP51reWhclx8pGCcZrzfwZqGpabdmG+PnWrEsgPVR6V6HDeQ3FvHIrqy4+YBuf0oAsm1ijIYLtC88VkOirOeBwecHrWg8hyApJHUd8UgtooWE9w3TOFxQBAmnRmTz5/ljx931qG9lMreWhCRY42nr9abqdy1wSA5Vf4R61TiYMdxZjgY6dKALASMKDxjuKsqC7IRjA6Y5xVJgWB3McjoParFuxYquRnqfpQBRu0bez9QMdKzbiK6vQ5tgHCL86k4K/StKdl+0SI3LHue1YuqXECeZHE8qTEZZ4zjnFAFHUr+WGa1S4RjGx2MD8y1t/wBiWujact4U4fJdl5256CsAzrceTFIHlctjCIcY9TWmZ5Ghu1sykluCECSvgA9+tAHM2/iIRatNFdsUhRtqx8k4Pf3q94j01NN1KPxBpzbrd0/eRKMmRsDH0FUvElgdUniurFYrbVFKxsxIKntgfhXTW3hPWLfwvLZ31xEx2HiHLEfmKAN3wrrkOtQW8nlLC8YAaND90kdxWPeRT6PPeyzT/aobl8woF5UZOeaz/hXpV/MmoahqAms1LGHY67N+3+L6e9ddDHaapARezw4VyAhYdf60AY2pajFHYq5jkUHoqHNVfDfi9LWeSK+kd4Gbhjz5Y6c+1XL34eWF2jvFqN2jhmZdsuVUkcjHpXnkuiXOiXTJPfO8k77UnwNp5+7QB6x4j0Cz8T6PJHFLtaRd0dxGec/WvGpNCn0HxCBqenvcxRKWW9ij5wOucciugfxDrXhmJhZCC5tYyM25PzN7rit/wz8VvDmr3gtrtZdPvAcFJxlffB9KAMLR7nUNRjt7/Q4HjaI4H21dqyqT0zV740/C/wD4TrwjI0ty/wDatnEZrdVUAFwv3Px6V12reLtAa3e0iuY7qVgVWKLnnHH0rxVvjb4jsNWm0fU9Pskt2JhSUhhJGOgJ5wfyoA+S7i1nhciWMqwJBB9aktIm2OzZC9PxrrPHvhqbSdekjNw1xFcfvUlP8WefzrkVmkhcK652nBBoAnBkgdd4YwtziteMRiH7RHsdR0x1qKN4tSt/KjcI/wDcb+lZcguNPdo2J2N1HY0Ab5uTfRkzRhVIwOOPwrGbz7e62upiIPHfiqskjyEOhwvbB5FWUkNxH++UtIv3aAPo/wCGVzPrdxoepxOrGBltbjueOhornf2W7x28V3ViQTBJEXx2Dg8UUAeXvZLJAJyHGCQSOcmqSQMrDbz7itC4mltrdFL7EY7toHUVnm8ZwwKBR6etACJIELEfM3Y0s9zNcNmR8gfkPYVEHGQU64ppBHTOOuaAHMxI68Y6etOiiaQ99vrTQRnODz05qZpGiUBRhcUATKghU7m+Y9DipIWkdWxKNuOhbGaob5HHJHTp60RAghnb5T0oAupcyQiRYyIcjG4/0qCKdXn3zfO46N05q3JbxyWJMUgMuQSD1HtWS3yNh1I29jxQB0L/AOk3CxQRlnCj7g6nvVHWdNuFWIlGUEE5PGa1fB1152pRW0Sj7ZnETkdPrXSfFOwe1litAxLRqCeOMkc4oA8wXPngKQHyAD1rqLLRbl185juXoWPGT7CsW3tpoJVkC7igyNo5JrvPDtreOlvcXCyxRTudjshwT7fSgD1H4TeF2v8ATY4btGkAP3s8KPpXay/D5rS9WRZjsVtoXABA9c96Ph7D9jjt5lcuqLg4bAZuxNelzRRanZs8zeYTg5j/AITQBx0hS0D2s1xsbaUViRk+3tT9GAieGK2kdnkOdnUn1pZ/D2qXWobLm3gvLNiP3n3XArrYtL0nw9uvIodkrDaoLZOfQUAakSJawq85Hmnjr39qy7qWS8lIDKQOAoNV3n/tJ33OROg3CMdMYrNEFwtywVJASxPegDXltpDj5AOODmo/ssifwA7uuW/lVdoLjyRtWT5uCOeKrrDd5HyPjnHByKAL5RsrvTHG0896t20eJAXx07dqxzvV0DBzjqD6VsWyBAmTliuQAKAM/UyouJAoA4ABzWDOAk7t5e4AYzjvitTVnD6kV6FfmUkcVGsW5VldcooJIJoAzsyRbZG+WXIZcDaBUWt2cQ0ly0hjtmO4BRlia0Q7AhlAf+IqRk4HTiqXiK7+2KFaNoYlAGcYWgDk7azGu6rbxW7GMwEENkfMRyOlepw+JJ21aPTnsZDI8Zbzl+7ketedaFaPFrtq5mjSEHaxRslvw9a9BuLq0sPEVs/lt5kkbIpzgdqAOc8beL7jS/EcGmyov2ZwgY+pY/yql4n8M6tBdSXuhlZ7ORhL5DMFMb98Z7Gp/GPkahcvPcxK8qSBfLK5IUY5rqLr95oK3CZYoARg4GD2oAyfBk13/aE6X9s1sJovmIb5WOMDj1qpqXhtp/CWoW8uVSNy0Zd84OepPaq0sX9owIIZ5raVZNxTJzx6H0rQvJ9Qs5ZLcRQ3+n3cQBGTn9aAPMNW0fVEjTNpPJIgCq0LBgwI7EH9a5+QqL0C/wBOlUowIZRhgOhLHvXqdw2i2NpFaM0mmMckKAQo7dawJ9Pkso7u3sr6K/OQzrLgttNAHH2Gp3OjaxNqNtsvdMjYsJEPf0I6g1ia7qFh4uJvEgWHUVJJj6h/TH0rZ1mGwQ3sFlDdWEhj/exP8ySP7c8V5LqExtbsrGSrZzkNgA0Aa/jIXGr+G7bOUubBmZFYY/D615pc3Qu1QTqBMvytgYNdXc+KZjb+VdIkka5G4Dk/X1rl9SkW+kM0CBWXgleM0AU0aWzlDqMc5BpHuHmLeYWcnseaSOQklHBYnjGKmNnNAqyshCP0B4OKAK8EmxtpPyn9KuwSFZMnqO1ZprQ0yMTMDgkx9R6igD2D4JXE+g+NNIuICSLt9r46KD60VofCO2lvbtYmCoFxJEQOdwPSigDxaSVpHyzbj0x7UpJwcnJ96giKqBjjHtzUu5cdOMflQBIpG4g5GfSp7hDHsBzluwHSoYUZ5FVASTzxV+9mNxKobaqxr260AVAvy5YHHc471LKhWBJShVG6H1+lW5rwtpVvbGJFSJmIbHLZ9aQ6gzWNtBJErQws21SOMH1oAzmOcHkmiGOSVwsYyx6U83BVyYwqkdDUP2p928Eg+o70AaEqpZoVEu9zwwA4qvJdpMFXywzr3x2qkzE5z1680vn7SGjULgYzQB0Ohau2naqs1sFilPBlVRlR/StPW9U1LVreZnuDPMRgDjOB3rjku5U+4VO7g8Zz/wDXourllVyjuCe+aAIpru4LMBLKJOBnP6V3OheIL37FbwS3cwSI/uwX4XPXivN42IkG3lia6eyQRWoLcBjgj3oA+jfDXiC7fQorW5Ox3G6K4IwreikjvSR+KNetbiVo7q4SZRk7T8jY7gd68z8J3zalYjT2lciD5kG7OPavTvAVnDr2uQaK0dwrOu6SQt91VOSMelAHsXwwv9Vv9AfUddaMI7ZiYLtyvcn8a5/UdVl1zxHFNveO3ikaJYiOgB+9+PpWl411mGLUtO8OaXPFG0TK08IPzbMfKo/nWVDJ5euQxqvzb8yKD69z7UAdjpThrhtpJwDk45NSTxzMwKSHIPHzcVDeXEdtIUgi2h2ySWySanhmBBwuD9etADI5pWiIklbeD6nmq5eSNmIlfd6FjV5V4GU+XGQcc81Qu9wucooCnuR1oAmg3k7mLHsc9ua0I1PmqTjgDAqgGU88KT61o2kgkdSRhh39aAMvUQUu5GUKVzjBXNVJ75Yo2QLuIGTjgCr+rOBLMSMdsnvXPlOctGSCwPJ9fWgChqmtPAsTSWaEMfmkRyMfWuf1LxXDtdLiKQxKR+7Byrf/AF61vFita2wBdSXbJGMZ9q58W9tqF0sdxACEj8xnQ42/X1oAm0XU0uNa09rbS5yZ5sbEOfLHqeMV2vjbVoNK1jSjcWUrvI4VOQMHPWuT8J317BrMeoRvDFpcD+WEC8yZ4zW9491N313TrpRE9nEpyrLnnrmgB3iHVtIbxABOHgmxt84fcIx0NbGi/ZLvSJILa78wMpwH4/KuQ8SwW+srLe237pT1j25Kn2qPw5ayW882XK5XcyduB60AakcF1awIqFmk3kBuoIB6V1ETG60+2u0iVfL+RsD7x9DXmUmtNcW8axzyxSRSyBiDkNzxx+FbWm+ILmTRLq2vEaN4wJCY3JDjuaANHW7L7VKzPbIJCxZYs7hjHQGuNg0B57hpfmt5oRvidTwfVT/hXQWd8iwC6idwZRuRSxHA6kGs+91qeOEvcOqxqSwaP734nvQBj+KNFZZY7m6kvUiuLdjJLEoZSw6ZHYV89+JVljkAK75Fz84GARXvPiTxNe3tlIYJfIKx4SIqNj88nNeUeKmmjmJnjEEsi7mXqrA/yoA8qu5HjcjPB/hIqrE7R5YHjuPWuh1e3GC7x/uz0fHWubfAY4ORQBqaVapqOp28MJKOzd+1dr8RltY9Dss27wXqnY2D8r/7Vef6ZdSWN3HcRHaVPX2r0LW9Rs/G1naW9sDHc28eCCe/qKAPMqvaJKIdRhZxlCdrfSobu0ls7qSC4QrIhwR606GNgd2CF9aAPevhM32HX9xciFMNuPQiiud8Nam09lpsNu+2QlRKT0wD0ooA8vjUbsMVIP8AEBzViMKx2klAOMnrUaMAMAHPvQflUkkZ649qAOgtoRb6VNLbq0z/AMTKPurWOr7sZ+6KLC+ljgniSV1EgwyjjcPSqwmMg2EHrgYPSgC2HBQkliOmcVXlkPlc52g9KFumhgaJSAG+8McVC33QVOeeRQAu8ngkgjp6VGsmV6n1xUZfnrT1QNySAoHWgAZwDlsnjsP50qgvkoPlA5qPKbyBub1+lWN+1GZU46AYoAfBGrMqRnEnX2qO7if7qqenIIpkCSQyGRV46jmtqOSOa2kkuGVHcY+tAHOCNkkA4BHIrY0q9Z7Ro2+YxndgnqKqS2sOGdJDnHApNAQnWrZWQbTIA4bpj3oA7/wVdxwSrPGoSWRsc88CvqH4Ni1TQtV8W3FuyzKrQ5J5ZEAZsfU4H4V4afDVtpdv5tvExgA3LKQT17H0r6Du9nhv4VaJppKxyXYijbcOPm+d8/yoA8zur1tVv31mVHa9SXzFZOvXIU+w6V6hbRyX8en61aRp+8jAkzjKn0NYuoaZBDazxxABdm+N1Xtil+GtzKGnhid5IZcbQV+VW70AdncDdMriJjt9+G+lTwsoUs2OOmf5U+WBXBntJFLx8MgP6ishtUu4ndewb+MDmgDWin52k9DkEdqr3LHzFbJHWsnT/EO7UWh8uDcc8gYOfSr93qKidQLaLDD8zQBZYrwVOTxWlZKMrt+7jp3rBh1EuyKIVXOcjHauisA7RhmCjgYFAFDX8RRyvlC6glVJ6muDuZ5ntQzTBrg55U8LXR+OJ2wVUcE9SM/hWLpdj51t+8XahzhB1b3oAqXCQvpznUWYqRkM5+8faq+j3Vlb7h9jcSXA8sMxyQPU+1atxpXnRmW5c7V4Cq3Q+tY1poht9aF1LcENbYlj3rkNgenegCbUJUt/EEFnaupto8BlQdCeenrT9VQ6joVwIyHltmPGMknrz+FVtN06WTXJtSnlSWW4kyRj5c+vHpV7w1YTWt9q63AE9pc9Qr4+bnoPSgDjbi6uYBZ3cW7ajAvjoe3NeieD9asL67mtri3WN8BdqtyM964qS3urcyI0MhUyFEGONvr+FYKTSQahi3cxEyj96vUgelAHo914XjsL24itoA8cuSA4wAfXNUoll0mdYpo40jY9WG4Een0qxF4uvr66eGWeKOWNFaHcmNx759afqWow39pHdalZsFx5Z2DG0+tAHnWuXFzFL51iGQNnEe75U5/h9awLvXbhoTFclmOdxLcE+1dH4iitra1/cyh7eRyY26kewrh9St5JJQLSQSrjjedvHuaANJtQjurDyhJuRvlMZ6gZzmuZ8U3huFaGVYiMYUqeOOmKhvUfTYwkylGdtxXOcfT61m6nqySfu2jG4naHAxj2NAGDdjdYbWY7RnIbt9K5KcKsh2jA9M12OpIjxO6qQRxgc5PrXJXibZjznNAEaqDGxzgiptNvJ7G8jntWIkU8Y7+1afg7w/eeKNat9I0xc3dw2FJ6AdyfYda7Txh4EPw1v4BrpW589W8pk9QOo+hNAC+OtJFz4UttaUKt4ComQdRnvXCxsgt/mXaD2z3ou9evboqssrGAceXnqPeoUUzSlkHy9VFAHe/BmFr/AMTxae4yZXUgdcAcmitr4A2Lt4/s9SQAR24ZJT7kECigDzO7WG0SPyTISY8tvHRvasyWYnDY5PXirV/IZrdZC3RsAelZh60AWYpcNjPB6jHSljk2D5xlu3tVZWKsCOopXdnJJPWgCUyZbJHU84NOkkIcgHIPQVFHBJIwVUPNbMHh27ecR8bsgZHQUAY5I3jA6HvUhZXYb/u4wO1ejad8NpSqSyK8qt7GtyPwHbpIoe1Eeei43NQB5NBFvdPKhdz14Xirq2t00LN9nZVY8Zr3Lw54YkhvWtI7BfMeF8M6DJAHUZ6Gqer6PaLdRWVvb/LGQxZzgqPSgDxMWdzJJ5bBgOmQOlO/s24kjUHcBgkbjjNeja74dvbbUnRyFhHzfJ6elYq6MxEhBO5RvbcemPT1oA5ePTDhSzIpQZwT1rdubC3trK3vI5ImZxlgTypHSmT6YzSL8pwV4962tD0ZpbPUHz5caJlmI9fSgD2LwSbW90W2mvb7zvtzRIIo5ASrk4ww9+K9S+K62VzdaLpNxdQQHDSosj7emAD+lfOnwoL/APCR6RYSRiQS3cZBPqHBr1n43Ca48fwDzE+zW9im4n/lludsk/WgDs7dbG50weZtmeFCryRyZH0rN8HGOK9uoYwWQndGU4AFc34WjdIHisp1KDBZlBIk+vvivQvCNjFBLKsSgnbuwB0z2oA2La0itTPLGN42E5LfzqrePbXEbM1orMAS2CRxWrIht7aUnlmbPzentWLczhFLYxgZBNAHPwS2Ed4sr6aEIcfOrHOTXQ3IsnUN9nYA/wB1u9Zd7bJdwbxIgdT8xA6nNa1nHEbZAzAuvfFAEcMMIxhGQ4wDu5Fb1qMy8N8qjv2rJQKHKkfdBPI4rWssllYLkEjn1oA57xbZx3MuxnCDcOc03TrSNI8+YrOBxgdqb41uDaP5j8IXAJ9DXM6/4pbT7e3a1ZRu+WSULu+n0oA6aWDM6oA231C8Gqs2nCcySW6SGQALlR271zMPiLUbiQOdQYKqnIi4GPcVP/buqTwiBbyZ9x3bl7+uaALsoktboEwPEkfAVOi575rQ0pAPOuTuZAVHK4xiuZfV9Qn1NoY52bBxsbGG963rjVbyxsLoI0cvAPHcnt9BQBC1yrQ3ExfaGyNpTjBqg1hZShTLbI7bN/AwB7VFceI5LbTYUmtlk3YLYxnNalj4gsJlmaeExoqgL8vAP1oAx106C51KBLZPKnCE5xjP/wBatGKyMH2iz3MIpVygkXGW781ejnt1lguo5lKDILCtiG6S5KlWUqPu7uKAPGPEejXNrB5TgxQmbCED7p9fpXG6vaXMHnW9zKnyHBMY6GvffFdhvhaWKQyunMkZ4AFeWeJtDS8neaCURnbz/tH3FAHm+paRdllaKX7QCAST0+n1rltR0m6MuGjZFX5iwOea7q7efTJTG7MQ44Y8gj2rKm1FJBNHIExtPzg80AcPcTvbQ7XUHnoT1rnbmTzJSR07e1dPr6wTQh4HBAGM+p965PvQB2Pww8YnwX4kj1EReau0o3qAetX/AIufEGbx7qlsxj8qztFZYVPXLYyf0Fef0H9KAAnNaGlPy6EHkZB96zqvaep3MTwoAb60Ae2fAyb7BqlvbOcfapAxOO46UVjfDm8z4t0mQHCPIuO3PpRQB5E8hKKvYU1VLMAoJJ7U+GIytgV1fh3RTdyKqpg/xS4+6KAOYis5pZUjVG3N0GK6HTPClxOwLAk9hXs3hXwNH+9nSLzCFGGYev8AhXa6R4OijAeKNnORwF5WgDhvCnwzhu7W1eb5iRnaFxn2r0DR/AcG7YqDIOW+XB+gNeieGtJS3i3NFsThd54rRubdTE0FkoBY/O4HzGgDnZdCtYLNF3eUo42L8zCqd9YWUbGG0ila4QAvJnv7ZrtLDS/slvum/eHnGemfeoV0UiQyBAS2c/j70Acha2tzvjniiX5flG7rt+tQa94Zt31FL2OFCsqcccbunNd+um7LZtybT2A6Y96elkLixbzVw8JBU47elAHmuoeGFurNZWWMSKMNuHDCudn8C2s14GJZVMbDEYBOccV7Vb6avlvGylxzyehzWVf6A8pAtl8pQ3JXg4oA8DTwS09y9vI5j4yMjoRU/hnwlfXU9/pksCLGYjhmONp7EYr2seE54LuaWeTzlPRdvQH1p0WmfZLi4vPLCyJFtAI4JoA8b8A+E77SfHuhm4Vdq3aZYnI49K7n4maRNcfEia9kkX7F9ijSaPOMrlv1rpLRjea5pkrmJbiGdABwNynqR71c+Idun9omUsgL24QhvqefegDntKFjp1j5NvExidcrKOQvoD7112gRNFcl5TtATCkHPbqa4KzkWKAmOQmdiAdozz0PFd7pNyrQRgRldo+ZeOfcUAXrtjJKpDNtPGM/rWaYjg5II3EgHvVyfY4GyTHOWzxTFhbJ8towB3LAEigDLniZrRgeWD8Y6gVoaJGpWQNliAQO+aY9vc4OFwvY5qzp0M0Zb5OW7A0AIMbyuTznIxWxo5YqUweDnmsaZGWYYIB69a2tHC7SxYE+xoA88+JblorxJGJCgZJOBjPX6CvHdf8AEtl9m+yhmBC4+TgE56mvV/j3C0ejbbfHmzEAdc9e2K8X1TwvKIY2MpMrRglT6kdqADQtbUXLRLNIEfjBPLfia7RddSyhRnztQEMQMMx9K810bSru01mF1h83bkbWHA963fE1pemeO2NtKXkB+YfMrZ9PSgDqdI1+2hea7aWM3HzKvp0zk1rWetW50nIZXZm3ysW65Hb2rwwTz2c72ywSEpmJvqe9TpqNzEDF5cm8qBtx2HtQB6DqeuGO4QxFZI1PybT2z3pD4jg/fqZ1yeVTHWvNtRmuIykzq2w4AQZz9Kz5LsrKGIdTxnjnHtQB7GmvxNJHFDdeSSNxjY45960rLxpBG7rcOQsbhlYYO76V4XqGq+bdRMoPIxkDk0yTVJH3IPMUKMrgGgD6Z0bxJb6jFJO7q20bmAOTjtmuW8R3KrueAkQOCQAw4PvXhser30KbraWcF1+bB4Iq7H4vlntlhuZsqgwCODQB2f22wubSS0uUR5VO4MOCD7V5p4hcWUzeWdyk5x/Srk+oxTx7orghz0GcH61ymq3UwLJKxOOh/wDr0AUbu6Ztyo3yMc7fSqNKevFJQAUtJRQA7aeOOTWxGyJpnlDHn9eBWQp55Jq3CdrAZ4PU0Ad38KX8zxRpyy9IZ1c5PTFFZHg+UxeKdLigYgzXCKSO3NFAEXhnQnnkDXJaO2yNzAZPPpX0P4J0DTbfTIPLtgQ5G0nnfjvmuU0Tw+pRIdpVFAG4DIr1/QLRLC1gjlIWKIY3Efc+lAHT6RpsckUiPCqB2AUY4AA9K2YUjtSY4olBGAzn0rLivGm2LbPi2b/lqeprRt1U7V+Z8YJJPWgCxNEbtBHC7IowMY4PvSQrNEdoUg5+81alrHlAeOOg70yZSzgjnb2zQA1JD5YjAyFPOepNTW7Kf4Tgdcmo1VSqmVsD0x0qLqx5PPQetAF9XTcR3xk7uRzT4tu2UYC5HTPSs2R+SwBzwPqaW0MvnYCHbIMFcYFAGrb7BHgEHGeahITc53BUx+NVBZSiQjcQAccdMU82oRMFi+TnHbFAE0txH5eHPbB9RWTfxNPazQtIFjc4OO4q/sVW+4MHtUgjRox8g6k4C0AeYXelDT9dsLw+Y+y4UkDPr1PrxW38TzEt/bmcZRoCBjrkMeRXQajCZWUrtVgwIOKg8c6al/Bay4y65AJGRz7UAeV6TDIN8WxWYHeG3Yxn+dejeHLWSJRO+EjIAG7+InsKydNsoEuVt5ov3qHcCx6/5NdTDPI0RSRVG3CpgY2/SgBt1AXXdEjOoHOB0rImtpRK22KXJ5IyeK6NWkaKQb+Aeg7Vn3j3Qw4lYEHINAGDJBcKWEsUmSMYIPFOshMk4B8zAGBwQK1DcXLR7VmII55OM+tIk04ZCSSeOlACeW2xidxPfIrc0RPLQBjyTwDVCKRmclzz71fgYM5HYegoA5j4qoZbSBWAAP3SegOa810zH2qIyhZZd2SzDIVR6V7P4kFtcaU8dyrYVcq56j2rgLzRUuLcwQOcMm1W24I9s0Acf4kRPt7yQhmLMMmMZC+wrtrCa3n0+HAQSIvzZGCD7fWp7fR7WytCjKjzNjkjrV0W5kC5SE7OemCaAPNNe8OW7XM80UcaNL+8YKMgnvj3qvofhiSS+3/KEQ8tjkkjgc17AdOgRCuxN543MOFHtS2+i2sMDMhYOepLZBNAHmqeFLWVCZ4Vl2EqT6nNb2m+DtKabc1lEMc42giuqTS3TjKMqn9atRWcluWaRW244AFAGGvhvTymI7C3wM4UQr/hTz4X02dFEtlatkYY+UM1stITKxB6fe4qxamLLbznAzgdKAOTvfAOjLamAWcQLcghB0rj9b+FeitaTNBZKzFecrgg+1e1wNHPFiUEnsV7VXurQvE4LdBxxyaAPjvXvhvFa3W3y5YSwO3a2Rj6V534i8M3On3DKshlA6A9a+yvFWgi4hBRQPmyB1INeFfEPT44bdmchpwSpA6j3oA8EIIJBGCKSt6bTPOLOpHJ6+lUrjSbqAncmR2PrQBnUU5lKkhgQRTaAFqwkgK7icY7etVqUcGgDqfAJEni3TXcH91Msn0waKj8Gt5erxzAnhlx+dFAH1rodjFaW5lnjEaoM5Iq48st5KDuK26/dTqGz6+/tTpmF9IIoyVtEPBA5Y+talnCsNttZDnqR17dfrQBZ0zERjypEZIzXUWmxgAqj1znINc9arujGCdueM/pW5YHygEZgT6DpQBrRtsjVTheM/WiPDIdow2ag87zZvkX5farEUeFC9weB1oAGjZnUhT65z0qdLZQpZid2PwpQQrKW5/+vQ0zByMqB2waAEaKKJCCCe5PvUiFd29htOB3qAPtTLNjHU0kl0oYiMdRnkUAWZWBydqkjruqOcrhCCcegPTiqTyswO3IAxk9zUUpBYAZ3YyG7UAWZJUC7mkx9DUL3caqRvcgc4A4quUG5jgjB/OmFVO7fnkdhzQATXMTnYcg9yKvamBcaXC8JDqACCPpWPLFmMkLjseavXQLeGYiGwVIwQcEdaAOcfAmTtIDgk9xXQW8Rkj37SSBjkY/EVyN0s01zsf+HkFjyeK6nTBJBYp87DsT60ATkMsPI+cn17VUlZdu1+/IHfFWJmLkgsCahmUBACcGgCnMqMAy5DA5644ot41LMcNjtmpZI942tj8BipFwgUL2PcUALvHOF+XoP/rVfiZtufmx0xVBwu4nJGDzg9a0LFjtJyCC2MetAGf4nITTCpBBAyQT37CudspStrbkJvfqcfwjrzWn48vGg06bYMnAKj/P0rzW11K9220TTARSZPldC3H60Ad7qD2pIcSKzHnap5H4VHYXtu1wiLHMM/eLDFYWkwSPeBp0wFOQwGCcevtWvDbos8k4JLZyQT+lAHVL5bRq/lnj723rj1qrPMAgZZVVAcHPrUa3scaGRm4YcgViX1408m5EOF4KkYzQB0kF27rxjgfnVqS7YxIqnr1571zdvI/lcMYt3Yc1Z+2SwqEbMm4cYFAGxAsZHzqGbH0JpgssKWjZuvT1/Gq9vcKwUNw44PtV9Z1IAUYCjt3oAiiuGjYoy7OPqKJ7nzVA3EvjAx6VZiCyIckEAd6bJbhQ7D5cUAc9qSs0R8wBVHUkZr5/+LSq2rRxKB5mCW9x2Ne9ai0jShArDaemeorzPxT4al1bV5LkoSgIQ884oA8HudLeMhoB8mclu2als7EXTYnyxHygenvXsieFo2tgrRjyVGBtXk/U96ybvw6AFEKiNV55HzZ96APJtY8MtBP86ZBGeeK4m/s3tZSGHy9q+gjbi5Y6ddBDcciN+mfauD8VeG3txJCYzvHRsZx9DQB5dRVzULJ7STawODVOgDofDMqq0eRyrjJH1oqt4Y3SanHAMESHHPrRQB9z6fbxxoPlc/MMr1rXEcYUMFGR0HTimy23mhmQNvJ+bb3qWFtuwNkcYORQAkakHgdMk+59KtRbndQinJP41DGA0xRQTubgVrW1qIdrNlnYYPPH/wCqgC1ZxiLOM7zjk1MZQc5HOfoarglc7Qce3AFMlnSNdx5PT60AWncjBfqOufSonuPmJiQMBznpWe1wWkwdwDDuOlORv3mAAOOtAFvJYYOD245FIGHJB+b+dQcAHBJXPXFS7huYHoenHJ9qAFcMAWycnGcCnEZRvm+X29KiLZBAJx1qUnIwSMe3pQBCScPjIJ9uSKhdcDcWAIHT3p7su0hUJweDUcq/IOCMCgCKVWZSACc1etiToE6kcoT/ADqod2W2hiAevpVzS/msryHBJwTjvmgDnxAGmEgBIHPStW3cRQBCfkXpVZSFDcYI6e9W44XMW7blc9Sf50AOyjYVHGBzzxTJPKLYWdcnqKZLHiTGDjOf/rVUCnBG1uvp0oAsny88TxqpH3TSSRE42yxbT0O/rWbLH8+BnHbtUYTa25iVP8IJoA0pMEEtIpAA4HNW7Nwi8vkAEnHasRTHv7Bm4HetSzVTCPlI6nPbNAGX41RJdMLuzbcHJNcHo9lJcanbr3Rc5IwPb869B8Wxs2jPGykq/HHasXSbXykif5Q+0Ak/SgCzHG0JZgAd4ORnJpwjAXZt3bsZNXRFG38O3acD/EVNgeYML0+UNnigDOeJROAV3YPfsaidFDu5BJ7j1rReEuwYk47j1pklpuYdNp9BQBHgOiDhcHPI9alJUkKwGexxUgjULtVMnOM+lSBFAGEPXGc5z+NAELIqxuR0IzToZpIgAAxB9amwMEMwO05AWnCMbSDwfc0AWbWRTCdpJbHTpV4P+6IAzjg1hbTCpk5yMdBnitO0nhLABjgryW9e9AFW9tk8hw3DH7rYyRXMmxkjdo5cHPzbux9hXXXhySobII6etVo4lk3I4zz8p7g+lAHNvpdvtYvJsVRwu3JNZDaZDd3jeYSIAR8qj0rtLy12KSQFUjlvWuf1NggdLUkZwGb/AA9qAPKPF2ntHeTLaptl3E7x1HsKguUTUdMMbQ/vogPNB5J46/jXX67Cglmm8s7SvBB5A9a4V7t9PuWnjDFc4cN/Ep9aAPN/FmlmTzD5fyjjAHSuAuLGaA4dCM8j3FfQFzpA1GcNH+8tXIYleOvauW8V6KIIjII8FCR8w6D0oA878LxtFq1nMyYCSqSaK0Z5PIjjVQA7OoHHvRQB96sgVAMtkjp2plxBE2zKkyDo2cZ9qKKALVjbCB2dj83of4R6VeLnbhsYx0oooAhmkKHAHyhcADnFZwdpGZm6LiiigB6EgjGCATnJqaNxv7g560UUASA5xg4P86eATIXLdfWiigAdyuc4Jz+dCHKjbxjpxjFFFACkEkjIwRnmjycMzMxPv60UUAMMbbyO3WrGlMwuZY+xToTRRQBWtrdRK7upxnGD0zVwOPvgED+6aKKAElYZAAXcegqpJLIhJVFBFFFAEDXc3RkRmPqtQyXDyP8AMiAjj7vaiigBVK5yYQQOvGK0IQq2qbAVJ446iiigAuI4Ly3a1uNzA4IZux9q5w2zW0vlP05x2/KiigCaFCwUKBtzg81ZIC4LEA9RjniiigAGM5XrjmiQZU5BIA6CiigBqrk888Z2ikkk2nGfm4OKKKAGtcASELnI59vpSC4yOGGDyCT1oooAepKpnPJ46VHGdrDOShzj0oooAlN2okbzNvop9asRMoXepJB5waKKAFu4zdQlHJKHjPpXM3VnLG8iuWVdvBPQ0UUAc3qVsSCYyzY7V59rFrNNcvbxIWkc4/H3oooA6DwzYpbaadMkUGXJdXPY9xWL4u00/Z5JpQAI13P7/wD66KKAPBZD5ur7eiq+QPYc0UUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A left selective pulmonary arteriogram shows abnormally dilated and tortuous segmental and subsegmental pulmonary arteries without early venous drainage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_20_42306=[""].join("\n");
var outline_f41_20_42306=null;
var title_f41_20_42307="Mometasone (nasal): Pediatric drug information";
var content_f41_20_42307=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mometasone (nasal): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?37/23/38261?source=see_link\">",
"    see \"Mometasone (nasal): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/4/7236?source=see_link\">",
"    see \"Mometasone (nasal): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8775137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nasonex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8775138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nasonex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10503094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Intranasal",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10503126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/23/38261?source=see_link\">",
"      see \"Mometasone (nasal): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Allergic rhinitis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 2-11 years: 1 spray (50 mcg) in each nostril once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years, Adolescents, and Adults: 2 sprays (100 mcg) in each nostril once daily; when used for the prevention of allergic rhinitis, treatment should begin 2-4 weeks prior to pollen season",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Nasal polyps:",
"     </b>",
"     Adolescents and Adults &ge;18 years: 2 sprays (100 mcg) in each nostril twice daily; 2 sprays (100 mcg) in each nostril once daily may be effective in some patients",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8775337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, intranasal, as furoate [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nasonex&reg;: 50 mcg/spray (17 g) [contains benzalkonium chloride; delivers 120 sprays]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8775140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10503127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake well prior to each use; clear nasal passages by blowing nose prior to use; occlude one nostril while administering to the other. Nasal spray must be primed before first use (10 actuations or until a fine spray appears) or after &gt;1 week of nonuse (2 actuations or until a fine spray appears); discard unit after 120 metered sprays are used. Spray should be administered once or twice daily, at a regular interval. Do not spray into eyes or directly onto nasal septum. After removing nasal spray from container, avoid prolonged exposure of product to direct light; brief exposure to light (with normal use) is acceptable.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10503122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10503104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of seasonal and perennial allergic rhinitis (FDA approved in ages &ge;2 years and adults); prevention of seasonal allergic rhinitis (FDA approved in ages &ge;12 years and adults); treatment of nasal polyps (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8775196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, dyspepsia, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, bronchitis, nasal irritation, rhinitis, sinusitis, upper respiratory tract infection, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome, viral infection (nasal inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, angioedema, growth suppression, nasal burning, nasal candidiasis, nasal septal perforation, nasal ulcers, oral candidiasis (nasal inhalation), smell disturbance (rare), taste disturbance (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10503105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mometasone or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10503107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid  using higher than recommended dosages; suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercorticism (Cushing's syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth). Use mometasone with extreme caution in patients with respiratory tuberculosis, untreated bacterial, fungal, systemic viral or parasitic infections, or ocular herpes simplex. Localized",
"     <i>",
"      Candida",
"     </i>",
"     infections of the nose and pharynx have been reported rarely; interruption of therapy may be necessary while antifungal therapy is employed. Corticosteroids impair wound healing; avoid use in patients with recent nasal ulcers, nasal surgery, or nasal trauma; allow healing to occur before use. Use of nasal mometasone in place of systemic corticosteroids may unmask allergies (eg, eczema, rhinitis) that were previously controlled by the systemic corticosteroids. Rare cases of immediate hypersensitivity reactions, nasal septum perforation, increased IOP, glaucoma, or cataracts may occur with intranasal corticosteroids.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10503106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     HPA suppression or hypercorticism (Cushing's syndrome) may occur with use of higher than recommended doses or at typical doses in susceptible patients. Acute adrenal insufficiency may occur with abrupt withdrawal after long-term use, with stress, or when converting from systemic to topical corticosteroid therapy; withdrawal or discontinuation of corticosteroids should be done carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery). Immunosuppression may occur; patients may be more susceptible to infections; avoid exposure to chickenpox and measles. Epistaxis may occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8775199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8775200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8775186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8775187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal studies following topical and SubQ administration. Hypoadrenalism may occur in infants born to women receiving corticosteroids during pregnancy. Monitor these infants closely after birth. A decrease in fetal growth has not been observed with inhaled corticosteroid use during pregnancy. Inhaled corticosteroids are recommended for the treatment of allergic rhinitis during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10503128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor growth in pediatric patients. Check mucous membranes for signs of fungal infection.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10503123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10503124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical effects are due to direct local effect, rather than systemic absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Improvement in allergic rhinitis symptoms may be seen within 11 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: Within 1-2 weeks after starting therapy",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10503125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Undetectable in plasma",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10503129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/4/7236?source=see_link\">",
"      see \"Mometasone (nasal): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Full response to this medication may not be seen for 2-5 weeks. Use regularly. Do not stop treatment, even if feeling better. Notify physician if condition being treated persists or worsens; do not decrease dose or discontinue without physician approval. Avoid exposure to chickenpox or measles; if exposed, seek medical advice without delay. Report sore mouth or mouth lesions, persistent headache, or nosebleeds to physician; carefully read and follow the patient instructions for use leaflet that accompanies the product.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16021 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-312020EB49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_20_42307=[""].join("\n");
var outline_f41_20_42307=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775137\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775138\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503094\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503126\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775337\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775140\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503127\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503122\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503104\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775196\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503105\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503107\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503106\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775199\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775200\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775186\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775187\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503128\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503123\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503124\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503125\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503129\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16021\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16021|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/23/38261?source=related_link\">",
"      Mometasone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/4/7236?source=related_link\">",
"      Mometasone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/11/34998?source=related_link\">",
"      Mometasone (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/30/7654?source=related_link\">",
"      Mometasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/6/28773?source=related_link\">",
"      Mometasone (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/46/43748?source=related_link\">",
"      Mometasone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/61/13268?source=related_link\">",
"      Mometasone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/8/13444?source=related_link\">",
"      Mometasone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_20_42308="Epidemiology and control of visceral leishmaniasis";
var content_f41_20_42308=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and control of visceral leishmaniasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/20/42308/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/20/42308/contributors\">",
"     Caryn Bern, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/20/42308/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/20/42308/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/20/42308/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/20/42308/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/20/42308/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leishmaniasis consists of a complex of vector-borne diseases caused by more than 20 species of the protozoan genus Leishmania and is transmitted by sand fly vectors (",
"    <a class=\"graphic graphic_table graphicRef58861 \" href=\"mobipreview.htm?13/56/14221\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Clinical manifestations range from cutaneous ulcers to systemic multiorgan disease. Visceral leishmaniasis (VL) is caused primarily by the two related species: Leishmania donovani and L. infantum (synonym L. chagasi).",
"   </p>",
"   <p>",
"    An estimated 500,000 new VL cases and 60,000 deaths from VL occur each year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/3\">",
"     3",
"    </a>",
"    ]. Among tropical diseases, leishmaniasis ranks second in mortality and fourth in loss of disability-adjusted life years (DALYs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/4\">",
"     4",
"    </a>",
"    ]. Leishmaniasis is considered one of the \"most neglected diseases\" given its strong association with poverty and the limited resources invested in new tools for diagnosis, treatment, and control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to epidemiology and control are discussed here. Issues related to clinical manifestations, diagnosis and treatment are discussed separately (see related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology and ecology of visceral leishmaniasis in a particular region are determined by characteristics of the parasite species, sand fly species, and mammalian reservoir host(s).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Species",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     L. donovani",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral leishmaniasis (VL) due to L. donovani occurs in South Asia (India, Bangladesh, and Nepal) and East Africa (Sudan, Ethiopia, Kenya, Somalia). Clinical disease due to L. donovani can affect individuals of all ages, although in regions with sustained endemic transmission the incidence may fall with age because of a high rate of acquired immunity in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/1,7\">",
"     1,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Indian subcontinent, transmission of L. donovani infection is considered anthroponotic; humans are the only proven reservoir host [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. In East Africa, transmission of L. donovani includes both anthroponotic and zoonotic components. In Sudan, both sylvatic rodents and domestic dogs may act as infection reservoirs, but large human VL outbreaks in villages and refugee settings are thought to reflect predominantly anthroponotic transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/9-14\">",
"     9-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     L. infantum",
"    </span>",
"    &nbsp;&mdash;&nbsp;VL due to L. infantum (synonym L. chagasi) occurs in the Mediterranean, the Middle East, Afghanistan, Iran, Pakistan, and Brazil. In addition, sporadic cases have been reported in Central Asia, China, Mexico, and Central and Latin America outside of Brazil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children &lt;10 years and immunosuppressed adults have a higher risk of clinical disease due to L. infantum than immunocompetent adults. The predominance of pediatric L. infantum cases may be related to several factors including an immature innate immune response, lack of prior exposure and acquired immunity, and higher rates of malnutrition among children than adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lower incidence of L. infantum among adults in endemic areas may be due to prior exposure resulting in cell-mediated immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/7,16\">",
"     7,16",
"    </a>",
"    ]. Immunocompetent adults without previous exposure to VL are more likely to develop clinical disease due to L. infantum than adult residents of endemic areas.",
"   </p>",
"   <p>",
"    Transmission of L. infantum infection is considered zoonotic; the major reservoir is the domestic dog (",
"    <a class=\"graphic graphic_figure graphicRef71680 \" href=\"mobipreview.htm?23/21/23895\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/1,8,17\">",
"     1,8,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;VL sand fly vectors include more than 10 species of the genus Phlebotomus (in the Old World) and Lutzomiya longipalpis (in the New World) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The female sand fly is hematophagous; both sexes take sugar meals from plant sources. Important sand fly characteristics for planning control strategies include breeding sites, peak feeding times, population seasonality, preferred blood meal sources, aggregation, and resting behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/2,18\">",
"     2,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leishmaniasis can also be transmitted via intravenous drug use, blood transfusion, organ transplantation, congenital infection, and laboratory accidents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/19-24\">",
"     19-24",
"    </a>",
"    ]. These modes of transmission are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control of VL is based on two major approaches: vector control to decrease sand fly bites among humans, and management of infected humans and animals to decrease the infection reservoir.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Vector control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vector control modalities include indoor residual insecticide spraying (IRS), insecticide-treated nets (ITNs), and other applications of insecticides or repellents to decrease sand fly biting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To reduce sand fly biting inside human dwellings, indoor residual insecticide spraying (IRS) every six months may be an effective intervention although it is costly due to the infrastructure, equipment, and training required. Appropriate supervision is required to ensure the appropriate use of materials and to prevent diversion for agricultural applications. IRS conducted for malaria eradication in the Indian subcontinent during the 1950s and 1960s nearly eliminated VL, though a major resurgence occurred within a decade following the end of the program [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/5/16473?source=see_link&amp;anchor=H8#H8\">",
"       \"Epidemiology, prevention, and control of malaria in endemic areas\", section on 'Indoor residual spraying'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Insecticide-treated bed nets can be highly effective in regions such as South Asia where the peak period of vector activity is late in the evening [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. Long-lasting insecticide treated nets may be effective although the durability of their efficacy under field conditions in areas where VL is endemic has not been evaluated. Limitations include the importance of regular use, and that those at highest risk for VL are the least likely to obtain the materials successfully.",
"     </li>",
"     <li>",
"      Treated dog collars are a promising tool for vector control in areas of zoonotic VL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of insect repellent and insecticide treated clothing is advisable for travelers but in general is not a practical routine intervention for residents of endemic areas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/1/43031?source=see_link\">",
"     \"Prevention of arthropod and insect bites: Repellents and other measures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Reservoir hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid diagnosis and effective treatment of anthroponotic VL helps decrease the human reservoir of infection. Patients with PKDL are an especially important reservoir of infection for a number of reasons; PKDL can persist for years, PKDL treatment requires a prolonged course of therapy, and such patients are less likely to seek care than those with kala-azar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Programs focusing on reduction of canine reservoirs to decrease zoonotic VL transmission have not proved highly effective. This may be due to inadequate diagnostic sensitivity to identify infectious dogs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delay between diagnosis and culling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42308/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visceral leishmaniasis (VL) is caused primarily by the two related species: Leishmania donovani and L. infantum (synonym L. chagasi). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VL due to L. infantum (synonym L. chagasi) occurs in the Mediterranean, the Middle East, Afghanistan, Iran, Pakistan, and Brazil. In addition, sporadic cases have been reported in Central Asia, China, Mexico, and Central and Latin America outside of Brazil. In general, clinical disease due to L. infantum is more likely to occur in children &lt;10 years and immunosuppressed adults. L. infantum transmission is zoonotic; the major reservoir for L. infantum infection is the domestic dog. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'L. infantum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VL due to L. donovani occurs in South Asia (India, Bangladesh, and Nepal) and the Horn of Africa (Sudan, Ethiopia, Kenya, and Somalia). Clinical disease due to L. donovani affects all ages, including otherwise healthy adults. In the Indian subcontinent, L. donovani transmission is anthroponotic; humans are the only proven reservoir host. In East Africa, both anthroponotic and zoonotic L. donovani transmission occur. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'L. donovani'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VL sand fly vectors include more than 90 species of the genus Phlebotomus (in the Old World) and Lutzomiya longipalpis (in the New World). VL can also be transmitted via intravenous drug use, blood transfusion, organ transplantation, congenital infection, and laboratory accidents; these modes of transmission are rare. &nbsp;(See",
"      <a class=\"local\" href=\"#H6\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Control of VL is based on two major approaches: vector control to decrease sand fly bites among humans, and management of infected humans and animals to decrease the infection reservoir. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Control'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Jeronimo SMB, de Queiroz Sousa A, Pearson RD. Leishmaniasis. In: Tropical infectious diseases: principles, pathogens and practice, Guerrant RL, Walker DH, Weller PF (Eds), Churchill Livingstone Elsevier, Edinburgh, Scotland 2006. p.1095.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/2\">",
"      World Health Organization. Control of the Leishmaniases: Report of the WHO Expert Committee Meeting, Geneva. March 22-26, 2010. WHO Technical Report Series 2010; 949:1.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. The Global Burden of Disease: 2004 update. Geneva, Switzerland: World Health Organization, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/4\">",
"      Mathers CD, Ezzati M, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl Trop Dis 2007; 1:e114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/5\">",
"      Yamey G, Torreele E. The world's most neglected diseases. BMJ 2002; 325:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/6\">",
"      Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol 2006; 22:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/7\">",
"      Bern C, Amann J, Haque R, et al. Loss of leishmanin skin test antigen sensitivity and potency in a longitudinal study of visceral leishmaniasis in Bangladesh. Am J Trop Med Hyg 2006; 75:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/8\">",
"      Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2008; 2:e313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/9\">",
"      Elnaiem DA, Hassan HK, Ward RD. Phlebotomine sandflies in a focus of visceral leishmaniasis in a border area of eastern Sudan. Ann Trop Med Parasitol 1997; 91:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/10\">",
"      Bucheton B, Kheir MM, El-Safi SH, et al. The interplay between environmental and host factors during an outbreak of visceral leishmaniasis in eastern Sudan. Microbes Infect 2002; 4:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/11\">",
"      Alvar J, Bashaye S, Argaw D, et al. Kala-azar outbreak in Libo Kemkem, Ethiopia: epidemiologic and parasitologic assessment. Am J Trop Med Hyg 2007; 77:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/12\">",
"      Seaman J, Mercer AJ, Sondorp E. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994. Int J Epidemiol 1996; 25:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/13\">",
"      Elnaiem DA, Hassan MM, Maingon R, et al. The Egyptian mongoose, Herpestes ichneumon, is a possible reservoir host of visceral leishmaniasis in eastern Sudan. Parasitology 2001; 122:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/14\">",
"      Dereure J, El-Safi SH, Bucheton B, et al. Visceral leishmaniasis in eastern Sudan: parasite identification in humans and dogs; host-parasite relationships. Microbes Infect 2003; 5:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/15\">",
"      Dye C, Williams BG. Malnutrition, age and the risk of parasitic disease: visceral leishmaniasis revisited. Proc Biol Sci 1993; 254:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/16\">",
"      Seaman J, Ashford RW, Schorscher J, Dereure J. Visceral leishmaniasis in southern Sudan: status of healthy villagers in epidemic conditions. Ann Trop Med Parasitol 1992; 86:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/17\">",
"      Courtenay O, Quinnell RJ, Garcez LM, Dye C. Low infectiousness of a wildlife host of Leishmania infantum: the crab-eating fox is not important for transmission. Parasitology 2002; 125:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/18\">",
"      Alexander B, Maroli M. Control of phlebotomine sandflies. Med Vet Entomol 2003; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/19\">",
"      Dey A, Singh S. Transfusion transmitted leishmaniasis: a case report and review of literature. Indian J Med Microbiol 2006; 24:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/20\">",
"      Antinori S, Cascio A, Parravicini C, et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 2008; 8:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/21\">",
"      Herwaldt BL, Juranek DD. Laboratory-acquired malaria, leishmaniasis, trypanosomiasis, and toxoplasmosis. Am J Trop Med Hyg 1993; 48:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/22\">",
"      Meinecke CK, Schottelius J, Oskam L, Fleischer B. Congenital transmission of visceral leishmaniasis (Kala Azar) from an asymptomatic mother to her child. Pediatrics 1999; 104:e65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/23\">",
"      Alvar J, Jim&eacute;nez M. Could infected drug-users be potential Leishmania infantum reservoirs? AIDS 1994; 8:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/24\">",
"      Cruz I, Morales MA, Noguer I, et al. Leishmania in discarded syringes from intravenous drug users. Lancet 2002; 359:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/25\">",
"      Bora D. Epidemiology of visceral leishmaniasis in India. Natl Med J India 1999; 12:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/26\">",
"      Sen Gupta PC. Return of kala-azar. J Indian Med Assoc 1975; 65:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/27\">",
"      Reyburn H, Ashford R, Mohsen M, et al. A randomized controlled trial of insecticide-treated bednets and chaddars or top sheets, and residual spraying of interior rooms for the prevention of cutaneous leishmaniasis in Kabul, Afghanistan. Trans R Soc Trop Med Hyg 2000; 94:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/28\">",
"      Courtenay O, Gillingwater K, Gomes PA, et al. Deltamethrin-impregnated bednets reduce human landing rates of sandfly vector Lutzomyia longipalpis in Amazon households. Med Vet Entomol 2007; 21:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/29\">",
"      Gavgani AS, Hodjati MH, Mohite H, Davies CR. Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trial. Lancet 2002; 360:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/30\">",
"      Addy M, Nandy A. Ten years of kala-azar in west Bengal, Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull World Health Organ 1992; 70:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/31\">",
"      Napier LE, Das Gupta CR. An epidemiological investigation of kala-azar in a rural area in Bengal. Indian J Med Res 1931; 19:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42308/abstract/32\">",
"      Courtenay O, Quinnell RJ, Garcez LM, et al. Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J Infect Dis 2002; 186:1314.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5690 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-125.69.132.100-B0D0D57A02-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_20_42308=[""].join("\n");
var outline_f41_20_42308=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Species",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - L. donovani",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - L. infantum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Vector control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Reservoir hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5690\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5690|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/21/23895\" title=\"figure 1\">",
"      Leishmania life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5690|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/56/14221\" title=\"table 1\">",
"      Visceral leishmaniasis species",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/5/16473?source=related_link\">",
"      Epidemiology, prevention, and control of malaria in endemic areas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/1/43031?source=related_link\">",
"      Prevention of arthropod and insect bites: Repellents and other measures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_20_42309="Synthetic conjugated estrogens B: Patient drug information";
var content_f41_20_42309=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Synthetic conjugated estrogens B: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/37/19031?source=see_link\">",
"     see \"Synthetic conjugated estrogens B: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2973872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Enjuvia&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700311",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Estrogens, when used in women after stopping periods (menopause), may raise the chance of uterine cancer. Progestins may lower this chance. A warning sign for cancer of the uterus is vaginal bleeding. Report any vaginal bleeding to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take estrogens if you are pregnant. If you get pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700259",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take estrogens to stop heart disease or dementia. Using estrogens may raise your chances of having a heart attack, a stroke, breast cancer, or a blood clot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691649",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or lower the signs of stopping periods (menopause).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702065",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to estrogens, conjugated, B (synthetic), or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, breast cancer, liver disease, recent heart attack, recent stroke, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have surgery and need bed rest.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697661",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There may be a higher chance of endometrial or breast cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high calcium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697245",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had high triglyceride levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have porphyria, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort, dong quai, black cohosh, saw palmetto, red clover, or ginseng with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking. People older than 35 years of age and/or smoking more than 15 cigarettes per day have more chance for heart disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in how contact lenses feel in the eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11729 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_20_42309=[""].join("\n");
var outline_f41_20_42309=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973872\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027380\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027382\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027381\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027386\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027387\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027389\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027384\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027385\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027390\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027391\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/37/19031?source=related_link\">",
"      Synthetic conjugated estrogens B: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_20_42310="Dopamine: Drug information";
var content_f41_20_42310=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dopamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/24/32131?source=see_link\">",
"    see \"Dopamine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/54/13157?source=see_link\">",
"    see \"Dopamine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F162703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenergic Agonist Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F162660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hemodynamic support:",
"     </b>",
"     I.V. infusion (administration requires the use of an infusion pump): 1-5 mcg/kg/minute up to 20 mcg/kg/minute; titrate to desired response (maximum: 50 mcg/kg/minute; however, doses &gt;20 mcg/kg/minute may not have a beneficial effect on blood pressure and increase the risk of tachyarrhythmias); infusion may be increased by 1-4 mcg/kg/minute at 10- to 30-minute intervals until optimal response is obtained",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If dosages &gt;20-30 mcg/kg/minute are needed, a more direct-acting vasopressor may be more beneficial (ie, epinephrine, norepinephrine).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Hemodynamic effects of dopamine are dose dependent (however, this is relative and there is overlap of clinical effects between dosing ranges):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Low-dose: 1-5 mcg/kg/minute, increased renal blood flow and urine output",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermediate-dose: 5-15 mcg/kg/minute, increased renal blood flow, heart rate, cardiac contractility, and cardiac output",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     High-dose: &gt;15 mcg/kg/minute, alpha-adrenergic effects begin to predominate, vasoconstriction, increased blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F162681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/54/13157?source=see_link\">",
"      see \"Dopamine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemodynamic support: I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 1-20 mcg/kg/minute, maximum: 50 mcg/kg/minute continuous infusion, titrate to desired response.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F162661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F162636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W, as hydrochloride: 0.8 mg/mL (250 mL, 500 mL); 1.6 mg/mL (250 mL, 500 mL); 3.2 mg/mL (250 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 40 mg/mL (5 mL, 10 mL); 80 mg/mL (5 mL); 160 mg/mL (5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F162622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F162640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer into large vein to prevent the possibility of extravasation (central line administration); monitor continuously for free flow; use infusion device to control rate of flow; administration into an umbilical arterial catheter is not recommended; when discontinuing the infusion, gradually decrease the dose of dopamine (sudden discontinuation may cause hypotension).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Extravasation management:",
"     </b>",
"     Due to short half-life, withdrawal of drug is often only necessary treatment. Use phentolamine as antidote. Mix 5 mg of phentolamine with 9 mL of NS; inject a small amount of this dilution into extravasated area. Blanching should reverse immediately. Monitor site. If blanching should recur, additional injections of phentolamine may be needed.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14471801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     400 mg in 250 mL (concentration: 1600",
"     <b>",
"      mcg",
"     </b>",
"     /mL)",
"     <b>",
"      or",
"     </b>",
"     800 mg in 250 mL (concentration: 3200",
"     <b>",
"      mcg",
"     </b>",
"     /mL)  of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1600",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"     <b>",
"      or",
"     </b>",
"     3200",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F162709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, mannitol 20%, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with sodium bicarbonate 5%, and alkaline solutions or iron salts.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alcohol (ethyl), alprostadil, amifostine, amiodarone, anidulafungin, argatroban, atracurium, aztreonam, bivalirudin, caffeine citrate, caspofungin, ceftazidime, ciprofloxacin, cisatracurium, cladribine, clonidine, daptomycin, dexmedetomidine, diltiazem, dobutamine, dobutamine with lidocaine, dobutamine with nitroglycerin, dobutamine with nitroprusside, docetaxel, doripenem, doxorubicin liposome, enalaprilat, epinephrine, esmolol, etoposide phosphate, famotidine, fenoldopam, fentanyl, fluconazole, foscarnet, gemcitabine, granisetron, haloperidol, heparin, hetastarch in lactated electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, inamrinone, labetalol, levofloxacin, lidocaine, lidocaine with nitroglycerin, lidocaine with nitroprusside, linezolid, lorazepam, meperidine, methylprednisolone sodium succinate, micafungin, midazolam, milrinone, morphine, mycophenolate, nicardipine, nitroglycerin, nitroglycerin with nitroprusside, nitroprusside, norepinephrine, ondansetron, oxaliplatin, pancuronium, pemetrexed, piperacillin/tazobactam, potassium chloride, propofol, ranitidine, remifentanil, sargramostim, streptokinase, tacrolimus, telavancin, terbutaline, theophylline, thiotepa, tigecycline, tirofiban, vancomycin, vasopressin, vecuronium, verapamil, vitamin B complex with C, warfarin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, amphotericin B cholesteryl sulfate complex, indomethacin, insulin (regular), thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Aldesleukin, alteplase, cefepime, cyclosporine, drotecogin alfa, furosemide, metronidazole, nesiritide, pantoprazole, tenecteplase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate, doxapram, heparin, midazolam, norepinephrine, ranitidine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F162639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct in the treatment of shock (eg, MI, open heart surgery, renal failure, cardiac decompensation) which persists after adequate fluid volume replacement",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F162699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic bradycardia or heart block unresponsive to atropine or pacing",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F162712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       DOPamine may be confused with DOBUTamine, Dopram&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F162701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Most frequent:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Anginal pain, ectopic beats, hypotension, palpitation, tachycardia, vasoconstriction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea and vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infrequent:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Aberrant conduction, atrial fibrillation, bradycardia, gangrene (high dose), hypertension, ventricular arrhythmia, widened QRS complex",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Piloerection, serum glucose increased (usually not above normal limits)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Extravasation of dopamine can cause tissue necrosis and sloughing of surrounding tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Dilated pupils, intraocular pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Azotemia, polyuria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F162643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sulfites (commercial preparation contains sodium bisulfite); pheochromocytoma; ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F162626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmias: May cause increases in arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tachycardia: May cause increases in heart rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tissue necrosis: Avoid infiltration - may cause severe tissue necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease, cardiac arrhythmias and/or occlusive vascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarct (post): Use with caution in patients post-MI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Shock: The use of dopamine in patients with shock (majority of patients had septic shock) demonstrated a higher incidence of adverse events (eg, tachyarrhythmias) (De Backer, 2010). Higher 28-day mortality was also seen in patients with septic shock with the use of dopamine as compared to norepinephrine (De Backer, 2012; Vasu, 2012); the use of norepinephrine may be preferred as the first-line agent in patients with shock. Current guidelines recommend the use of either dopamine or norepinephrine in the management of septic shock (Dellinger, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monoamine oxidase inhibitors (MAO-I): Use with extreme caution in patients taking MAO inhibitors; prolong hypertension may result from concurrent use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium metabisulfite: Product may contain sodium metabisulfite.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Assure adequate circulatory volume to minimize need for vasoconstrictors. Avoid hypertension; monitor blood pressure closely and adjust infusion rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation: Avoid extravasation; infuse into a large vein if possible. Avoid infusion into leg veins. Watch I.V. site closely.",
"     <b>",
"      [U.S. Boxed Warning]: If extravasation occurs, infiltrate the area with diluted phentolamine (5-10 mg in 10-15 mL of saline) with a fine hypodermic needle. Phentolamine should be administered as soon as possible after extravasation is noted.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of COMT",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F162630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the adverse/toxic effect of DOPamine. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of dopamine.  Use of hyaluronidase for other purposes in patients receiving dopamine may be considered as clinically indicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the arrhythmogenic effect of DOPamine. Management: Avoid use of dopamine in patients receiving halogenated hydrocarbon anesthetics.  If concomitant treatment cannot be avoided, monitor for arrhythmia.  Dopamine induced ventricular arrhythmia may be reversible with propranolol based on animal data.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: DOPamine may enhance the hypotensive effect of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F162632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13314046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. It is not known if dopamine crosses the placenta.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F162665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (DOPamine HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/mL (5 mL): $1.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/mL (5 mL): $3.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg/mL (5 mL): $7.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (DOPamine in D5W Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.8 mg/mL 5% (250 mL): $13.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.6 mg/mL 5% (250 mL): $15.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.2 mg/mL 5% (250 mL): $21.77",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F162634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, ECG, heart rate, CVP, RAP, MAP; serum glucose, renal function; urine output; if pulmonary artery catheter is in place, monitor Cl, PCWP, SVR, and PVR",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F162646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      A Si Ke Ding (CL);",
"     </li>",
"     <li>",
"      Catabon (JP);",
"     </li>",
"     <li>",
"      Cetadop (ID);",
"     </li>",
"     <li>",
"      Cordodopa Forte (PT);",
"     </li>",
"     <li>",
"      Docard (IL);",
"     </li>",
"     <li>",
"      Dokard (PH);",
"     </li>",
"     <li>",
"      Dopacris (BR);",
"     </li>",
"     <li>",
"      Dopamax (PH);",
"     </li>",
"     <li>",
"      Dopamex (TH);",
"     </li>",
"     <li>",
"      Dopamin (BG, CH, NO);",
"     </li>",
"     <li>",
"      Dopamin AWD (HN);",
"     </li>",
"     <li>",
"      Dopamin Giulini (HU, LU);",
"     </li>",
"     <li>",
"      Dopamin Guilini (AT, DE, ID);",
"     </li>",
"     <li>",
"      Dopamin Natterman (BG);",
"     </li>",
"     <li>",
"      Dopamina (ES);",
"     </li>",
"     <li>",
"      Dopamine (FR, NL);",
"     </li>",
"     <li>",
"      Dopamine Injection (AU);",
"     </li>",
"     <li>",
"      Dopamine Pierre Fabre (LU);",
"     </li>",
"     <li>",
"      Dopaminum (PL);",
"     </li>",
"     <li>",
"      Dopar (TW);",
"     </li>",
"     <li>",
"      Dopavate (TW);",
"     </li>",
"     <li>",
"      Dopina (PE);",
"     </li>",
"     <li>",
"      Dopinga (IN);",
"     </li>",
"     <li>",
"      Dopmin (CZ, DK, EE, FI, MY, TR);",
"     </li>",
"     <li>",
"      Dopmin E (RU);",
"     </li>",
"     <li>",
"      Drynalken (MX);",
"     </li>",
"     <li>",
"      Dynatra (BE, LU);",
"     </li>",
"     <li>",
"      Dynos (ZA);",
"     </li>",
"     <li>",
"      Emodopan (PE);",
"     </li>",
"     <li>",
"      Giludop (DK, SE);",
"     </li>",
"     <li>",
"      Glomin (ID);",
"     </li>",
"     <li>",
"      Inopin (TH);",
"     </li>",
"     <li>",
"      Inotropin (AR);",
"     </li>",
"     <li>",
"      Inovan (JP);",
"     </li>",
"     <li>",
"      Intropin (GB, IE, UY, ZA);",
"     </li>",
"     <li>",
"      Intropin IV (MY);",
"     </li>",
"     <li>",
"      Medopa (PT);",
"     </li>",
"     <li>",
"      Myocard (PH);",
"     </li>",
"     <li>",
"      Myocard-DX (PH);",
"     </li>",
"     <li>",
"      Myofast (CO);",
"     </li>",
"     <li>",
"      Pre Dopa (JP);",
"     </li>",
"     <li>",
"      Proinfark (ID);",
"     </li>",
"     <li>",
"      Revivan (IT);",
"     </li>",
"     <li>",
"      Tropin (KP, PK, SG);",
"     </li>",
"     <li>",
"      Udopa (ID);",
"     </li>",
"     <li>",
"      Uramin (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F162625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates both adrenergic and dopaminergic receptors, lower doses are mainly dopaminergic stimulating and produce renal and mesenteric vasodilation, higher doses also are both dopaminergic and beta",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic stimulating and produce cardiac stimulation and renal vasodilation; large doses stimulate alpha-adrenergic receptors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F162642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Dopamine has exhibited nonlinear kinetics in children; with dose changes, may not achieve steady-state for ~1 hour rather than 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Adults: 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Adults: &lt;10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Renal, hepatic, plasma; 75% to inactive metabolites by monoamine oxidase and 25% to norepinephrine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as metabolites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Neonates: Varies and appears to be age related; clearance is more prolonged with combined hepatic and renal dysfunction",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bellomo R, Chapman M, Finfer S, et al, &ldquo;Low-dose Dopamine in Patients With Early Renal Dysfunction: A Placebo-Controlled Randomised Trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000, 356(9248):2139-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/11191541/pubmed\" id=\"11191541\" target=\"_blank\">",
"        11191541",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brierley J, Carcillo JA, Choong K, et al, &ldquo;Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2009, 37(2):666-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/19325359/pubmed\" id=\"19325359\" target=\"_blank\">",
"        19325359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chan TY, &ldquo;Low-Dose Dopamine in Severe Right Heart Failure and Chronic Obstructive Pulmonary Disease,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(5):493-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/7655133/pubmed\" id=\"7655133\" target=\"_blank\">",
"        7655133",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Backer D, Aldecoa C, Njimi H, et al, &ldquo;Dopamine versus Norepinephrine in the Treatment of Septic Shock: A Meta-Analysis,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2012, 40(3):725-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/22036860/pubmed\" id=\"22036860\" target=\"_blank\">",
"        22036860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Backer D, Biston P, Devriendt J, et al, &ldquo;Comparison of Dopamine and Norepinephrine in the Treatment of Shock,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 362(9):779-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/20200382/pubmed\" id=\"20200382\" target=\"_blank\">",
"        20200382",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(1):296-327; published erratum appears in",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(4):1394-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/18158437/pubmed\" id=\"18158437\" target=\"_blank\">",
"        18158437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hollenberg SM, Ahrens TS, Annane D, et al, &ldquo;Practice Parameters for Hemodynamic Support of Sepsis in Adult Patients: 2004 Update,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2004, 32(9):1928-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/15343024/pubmed\" id=\"15343024\" target=\"_blank\">",
"        15343024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011.  Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson RL Jr, &ldquo;Low-Dose Dopamine and Oxygen Transport by the Lung,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1998, 98(2):97-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/9679713/pubmed\" id=\"9679713\" target=\"_blank\">",
"        9679713",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kellum JA and Decker J, &ldquo;Use of Dopamine in Acute Renal Failure: A Meta-Analysis,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2001, 29(8):1526-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/11505120/pubmed\" id=\"11505120\" target=\"_blank\">",
"        11505120",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin C, Papazian L, Perrin G, et al, &ldquo;Norepinephrine or Dopamine for the Treatment of Hyperdynamic Septic Shock?&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1993, 103(6):1826-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/8404107/pubmed\" id=\"8404107\" target=\"_blank\">",
"        8404107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patel GP, Grahe JS, Sperry M, et al, &ldquo;Efficacy and Safety of Dopamine versus Norepinephrine in the Management of Septic Shock,&rdquo;",
"      <i>",
"       Shock",
"      </i>",
"      , 2010, 33(4):375-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/19851126/pubmed\" id=\"19851126\" target=\"_blank\">",
"        19851126",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Practice Parameters for Hemodynamic Support of Sepsis in Adult Patients in Sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1999, 27(3):639-60. Available at file://www.sccm.org/pdf/Hemodynamic%20Support.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/10199548/pubmed\" id=\"10199548\" target=\"_blank\">",
"        10199548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sakr Y, Reinhart K, Vincent JL, et al, &ldquo;Does Dopamine Administration in Shock Influence Outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2006, 34(3):589-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/16505643/pubmed\" id=\"16505643\" target=\"_blank\">",
"        16505643",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van de Borne P, Oren R, and Somers VK, &ldquo;Dopamine Depresses Minute Ventilation in Patients With Heart Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1998, 98(2):126-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/9679718/pubmed\" id=\"9679718\" target=\"_blank\">",
"        9679718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vasu TS, Cavallazzi R, Hirani A, et al, &ldquo;Norepinephrine or Dopamine for Septic Shock: Systematic Review of Randomized Clinical Trials,&rdquo;",
"      <i>",
"       J Intensive Care Med",
"      </i>",
"      , 2012, 27(3):172-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42310/abstract-text/21436167/pubmed\" id=\"21436167\" target=\"_blank\">",
"        21436167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9384 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_20_42310=[""].join("\n");
var outline_f41_20_42310=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708685\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162703\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162660\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162681\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162661\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162636\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162622\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162640\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471801\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471802\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162709\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162639\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162699\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162712\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162701\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162643\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162626\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299227\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162630\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162632\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314046\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162665\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323119\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162634\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162646\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162625\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162642\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9384\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9384|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/24/32131?source=related_link\">",
"      Dopamine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/54/13157?source=related_link\">",
"      Dopamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_20_42311="Churg Strauss PA";
var content_f41_20_42311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71677%7EPULM%2F59884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71677%7EPULM%2F59884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior chest radiograph of a patient with eosinophilic granulomatosis with polyangiitis (Churg-Strauss).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) lateral chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 237px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral chest radiograph of a patient with&nbsp;eosinophilic granulomatosis with polyangiitis (Churg-Strauss) demonstrating prominent consolidative opacities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal lateral chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_20_42311=[""].join("\n");
var outline_f41_20_42311=null;
var title_f41_20_42312="Lovastatin: Drug information";
var content_f41_20_42312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lovastatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/61/6101?source=see_link\">",
"    see \"Lovastatin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/47/42743?source=see_link\">",
"    see \"Lovastatin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F13842374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      HMG-CoA Reductase Inhibitors and Risk of Increased Blood Glucose Concentrations and Diabetes",
"     </span>",
"     <span class=\"collapsible-date\">",
"      January 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has notified healthcare professionals of updates to the product monographs of HMG-CoA reductase inhibitors (aka, &ldquo;statins&rdquo;) marketed in Canada regarding the risk of increased blood glucose concentrations and a small increased risk of diabetes mellitus following administration of these agents. The risk appears to be greatest in patients already at risk for diabetes (eg, patients with increased blood glucose concentration, hypertriglyceridemia, obesity, hypertension).  However, Health Canada continues to acknowledge that the benefits of statin therapy far outweigh the risk of dysglycemia. It is recommended that clinicians carefully monitor the use of statins in patients at high risk of developing diabetes mellitus.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/16949a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Altoprev&reg;;",
"     </li>",
"     <li>",
"      Mevacor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F190413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Lovastatin&reg;;",
"     </li>",
"     <li>",
"      CO Lovastatin;",
"     </li>",
"     <li>",
"      Dom-Lovastatin;",
"     </li>",
"     <li>",
"      Gen-Lovastatin;",
"     </li>",
"     <li>",
"      Mevacor&reg;;",
"     </li>",
"     <li>",
"      Mylan-Lovastatin;",
"     </li>",
"     <li>",
"      Novo-Lovastatin;",
"     </li>",
"     <li>",
"      Nu-Lovastatin;",
"     </li>",
"     <li>",
"      PHL-Lovastatin;",
"     </li>",
"     <li>",
"      PMS-Lovastatin;",
"     </li>",
"     <li>",
"      PRO-Lovastatin;",
"     </li>",
"     <li>",
"      RAN&trade;-Lovastatin;",
"     </li>",
"     <li>",
"      ratio-Lovastatin;",
"     </li>",
"     <li>",
"      Riva-Lovastatin;",
"     </li>",
"     <li>",
"      Sandoz-Lovastatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F190451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, HMG-CoA Reductase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F190417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dyslipidemia and primary prevention of CAD:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: Initial: 20 mg once daily with evening meal, then adjust at 4-week intervals; maximum dose: 80 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: Initial: 20, 40, or 60 mg once daily at bedtime, then adjust at 4-week intervals; maximum dose: 60 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and patient response. For patients requiring smaller reductions in cholesterol, the use of the extended release tablet is not recommended; consider use of immediate release formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for lovastatin with concomitant medications:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Amiodarone:",
"     </i>",
"     Maximum recommended lovastatin dose (extended release and immediate release): 40 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Danazol, diltiazem, dronedarone, or verapamil:",
"     </i>",
"     Initial lovastatin (immediate release) dose: 10 mg daily; Maximum recommended lovastatin (extended release and immediate release) dose: 20 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Lomitapide:",
"     </i>",
"     Consider lovastatin dose reduction (per lomitapide manufacturer).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F190431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/47/42743?source=see_link\">",
"      see \"Lovastatin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heterozygous familial hypercholesterolemia:",
"     </b>",
"     Oral (immediate release tablet): Adolescents 10-17 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      LDL reduction &lt;20%:",
"     </i>",
"     Initial: 10 mg daily with evening meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      LDL reduction &ge;20%:",
"     </i>",
"     Initial: 20 mg daily with evening meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual range:",
"     </b>",
"     10-40 mg once daily with evening meal, then adjust dose at 4-week intervals; maximum dose per manufacturer: 40 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for lovastatin with concomitant medications (amiodarone, danazol, diltiazem, dronedarone, lomitapide, or verapamil):",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F190418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate release: Refer to adult dosing; Extended release: Initial: 20 mg once daily at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F190419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use with caution and carefully consider doses &gt;20 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15035959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg, 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mevacor&reg;: 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Altoprev&reg;: 20 mg, 40 mg, 60 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F190368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F190389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer immediate release tablet with the evening meal. Administer extended release tablet at bedtime; do not crush or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F190388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adjunct to dietary therapy to decrease elevated serum total and LDL-cholesterol concentrations in primary hypercholesterolemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Primary prevention of coronary artery disease (patients without symptomatic disease with average to moderately elevated total and LDL-cholesterol and below average HDL-cholesterol); slow progression of coronary atherosclerosis in patients with coronary heart disease and reduce the risk of myocardial infarction, unstable angina, and coronary revascularization procedures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adjunct to dietary therapy in adolescent patients (10-17 years of age, females &gt;1 year postmenarche) with heterozygous familial hypercholesterolemia having LDL &gt;189 mg/dL,",
"     <b>",
"      or",
"     </b>",
"     LDL &gt;160 mg/dL with positive family history of premature cardiovascular disease (CVD),",
"     <b>",
"      or",
"     </b>",
"     LDL &gt;160 mg/dL with the presence of at least two other CVD risk factors",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F190459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lovastatin may be confused with atorvaSTATin, Leustatin&reg;, Livostin&reg;, Lotensin&reg;, nystatin, pitavastatin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mevacor&reg; may be confused with Benicar&reg;, Lipitor&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lovacol [Chile and Finland] may be confused with Levatol brand name for penbutolol [U.S.]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lovastin [Malaysia, Poland, and Singapore] may be confused with Livostin brand name for levocabastine [multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mevacor [U.S., Canada, and multiple international markets} may be confused with Mivacron brand name for mivacurium [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F190449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages as reported with immediate release tablets; similar adverse reactions seen with extended release tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Neuromuscular &amp; skeletal: CPK increased (&gt;2x normal) (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2% to 3%), dizziness (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Flatulence (4% to 5%), constipation (2% to 4%), abdominal pain (2% to 3%), diarrhea (2% to 3%), nausea (2% to 3%), dyspepsia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (2% to 3%), weakness (1% to 2%), muscle cramps (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acid regurgitation, alopecia, amnesia (reversible), arthralgia, blood glucose increased, chest pain, cognitive impairment (reversible), confusion (reversible), dermatomyositis, diabetes mellitus (new onset), eye irritation, glycosylated hemoglobin (Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ) increased, insomnia, leg pain, memory disturbance (reversible), memory impairment (reversible), paresthesia, pruritus, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additional class-related events or case reports (not necessarily reported with lovastatin therapy): Alkaline phosphatase increased, alteration in taste, anaphylaxis, angioedema, anorexia, anxiety, arthritis, cataracts, chills, cholestatic jaundice, cirrhosis, depression, dryness of skin/mucous membranes, dyspnea, eosinophilia, erectile dysfunction, erythema multiforme, ESR increased, facial paresis, fatty liver, fever, flushing, fulminant hepatic necrosis, GGT increased, gynecomastia, hemolytic anemia, hepatic failure (fatal and nonfatal), hepatitis, hepatoma, hyperbilirubinemia, hypersensitivity reaction, immune-mediated necrotizing myopathy (IMNM), impaired extraocular muscle movement, impotence, interstitial lung disease, leukopenia, libido decreased, malaise, myopathy, nail changes, nodules, ophthalmoplegia, pancreatitis, peripheral nerve palsy, peripheral neuropathy, photosensitivity, polymyalgia rheumatica, positive ANA, psychic disturbance, purpura, renal failure (secondary to rhabdomyolysis), rhabdomyolysis, skin discoloration, Stevens-Johnson syndrome, systemic lupus erythematosus-like syndrome, thrombocytopenia, thyroid dysfunction, toxic epidermal necrolysis, transaminases increased, tremor, urticaria, vasculitis, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F190392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lovastatin or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; concomitant use of strong CYP3A4 inhibitors (eg, clarithromycin, erythromycin, itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole, protease inhibitors [including boceprevir and telaprevir], telithromycin); pregnancy; breast-feeding",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Concomitant use of cyclosporine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F190372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes mellitus: Increases in Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however,  the benefits of statin therapy far outweigh the risk of dysglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Postmarketing reports of fatal and nonfatal hepatic failure are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy.  If an alternate etiology is not identified, do not restart lovastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated; routine periodic monitoring of liver enzymes is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune-mediated necrotizing myopathy (IMNM): IMNM, an autoimmune-mediated myopathy, has been reported (rarely) with HMG-CoA reductase inhibitor therapy.  IMNM presents as proximal muscle weakness with elevated CPK levels, which persists despite discontinuation of HMG-CoA reductase inhibitor therapy; additionally, muscle biopsy may show necrotizing myopathy with limited inflammation.  Immunosuppressive therapy (eg, corticosteroids, azathioprine) may be used for treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy/rhabdomyolysis: Patients receiving HMG-CoA reductase inhibitors have developed rhabdomyolysis with acute renal failure and/or myopathy; patients should be monitored closely. This risk is dose-related and is increased with concurrent use of other lipid-lowering medications (eg, fibric acid derivatives, or niacin at doses &ge;1 g/day) or during concurrent use with potent CYP3A4 inhibitors. The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures). However, based upon current evidence, HMG-CoA reductase inhibitor therapy should be continued in the perioperative period unless risk outweighs cardioprotective benefit. Use caution in patients with renal impairment, inadequately treated hypothyroidism, and those taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment and/or ethanol use: Use with caution in patients who consume large amounts of ethanol or have a history of liver disease. Use is contraindicated in patients with active liver disease or unexplained transaminase elevations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; risk of myopathy is increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Concomitant use of lovastatin with some drugs may require cautious use, may not be recommended, may require dosage adjustments, or may be contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients with advanced age, these patients are predisposed to myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F190446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F190377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Dose of HMG-CoA reductase inhibitor may need to be reduced (limit simvastatin adult maximum dose to 20 mg/day, limit lovastatin adult maximum dose to 40 mg/day).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Concurrent use of simvastatin with danazol is contraindicated.  Initiate lovastatin at an adult maximum dose of 10 mg/day, and do not exceed 20 mg/day, when danazol is given concomitantly.  Fluvastatin, pravastatin and rosuvastatin may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: May increase the serum concentration of Lovastatin. Lovastatin may increase the serum concentration of Diltiazem. Management: Initiate lovastatin at a maximum adult dose of 10 mg/day, and do not exceed 20 mg/day, in patients receiving diltiazem. Monitor closely for signs of HMG-CoA reductase inhibitor toxicity (e.g., myositis, rhabdomyolysis).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of Lovastatin. Management: Limit lovastatin to a maximum of 20 mg/day (in adults).  Increase monitoring for signs of lovastatin toxicity (e.g., myopathy, rhabdomyolysis).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Lovastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): May increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased. Management: Dose adjustment of the HMG-CoA reductase inhibitor may be warranted. No interaction is expected with rosuvastatin, pravastatin, or pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use of HMG-CoA reductase inhibitors (statins) with fusidic acid if possible.  If treatment with fusidic acid is necessary, consider temporarily stopping the statin.  With any concurrent use monitor patients closely for statin toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Lovastatin. Gemfibrozil may increase the serum concentration of Lovastatin. More specifically, gemfibrozil may increase the serum concentrations of lovastatin acid (active form of parent drug).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider avoiding concurrent use of GFJ (especially larger amounts) with lovastatin, simvastatin, or atorvastatin.  Consider using a lower statin dose or a statin that is less likely to interact when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: May increase the serum concentration of Lovastatin. Management: Consider reducing lovastatin doses during concomitant treatment with lomitapide, and monitor for signs and symptoms of muscle toxicity.  Specific dosing recommendations are not presently available.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Lovastatin. Management: Avoid lovastatin during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider using a lower starting dose and lower maintenance/maximum doses of atorvastatin, simvastatin, or lovastatin when used together with quinine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: May enhance the myopathic (rhabdomyolysis) effect of Lovastatin. Ranolazine may increase the serum concentration of Lovastatin. Ranolazine may also enhance the distribution of lovastatin to specific cells/tissues/organs where P-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: May decrease the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: May increase the serum concentration of Lovastatin. Management: Avoid using doses of lovastatin greater than 40 mg/day with ticagrelor.  This specific recommendation is found in the U.S. prescribing information but not in the Canadian product monograph.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of Lovastatin. Management: Initiate lovastatin at a maximum adult dose of 10 mg/day, and do not exceed 20 mg/day, in patients receiving verapamil. Monitor closely for signs of HMG-CoA reductase inhibitor toxicity (e.g., myositis, rhabdomyolysis).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F190407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Excessive ethanol consumption may have harmful hepatic effects. Management: Avoid excessive ethanol consumption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food decreases the bioavailability of lovastatin extended release tablets and increases the bioavailability of lovastatin immediate release tablets. Lovastatin serum concentrations may be increased if taken with grapefruit juice. Management: Avoid concurrent intake of large quantities (&gt;1 quart/day) of grapefruit juice. Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease lovastatin levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F190380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F190395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholesterol biosynthesis may be important in fetal development. Contraindicated in pregnancy. Administer to women of childbearing potential only when conception is highly unlikely and patients have been informed of potential hazards.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F190423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F190396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before initiation of therapy, patients should be placed on a standard cholesterol-lowering diet for 6 weeks and the diet should be continued during drug therapy. Avoid intake of large quantities of grapefruit juice (&ge;1 quart/day); may increase toxicity. Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice. Immediate release tablet should be taken with the evening meal.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F190394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Altoprev Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $496.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $496.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (30): $496.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lovastatin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (60): $80.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (60): $142.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (60): $256.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mevacor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (60): $188.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (60): $340.12",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F190382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline CPK (recheck CPK in any patient with symptoms suggestive of myopathy; discontinue therapy if markedly elevated); baseline liver function tests (LFTs) and repeat when clinically indicated thereafter. Patients with elevated transaminase levels should have a second (confirmatory) test and frequent monitoring until values normalize; discontinue if increase in ALT/AST is persistently &gt;3 times ULN (NCEP, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Lipid panel (total cholesterol, HDL, LDL, triglycerides):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      ATP III recommendations (NCEP, 2002):",
"     </i>",
"     Baseline; 6-8 weeks after initiation of drug therapy; if dose increased, then at 6-8 weeks until final dose determined. Once treatment goal achieved, follow up intervals may be reduced to every 4-6 months. Lipid panel should be assessed at least annually, and preferably at each clinic visit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Manufacturer recommendation:",
"     </i>",
"     Analyze lipid panel at intervals of 4 weeks or more.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F190385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     NCEP classification of pediatric patients with familial history of hypercholesterolemia or premature CVD: Acceptable total cholesterol: &lt;170 mg/dL, LDL: &lt;110 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F190397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Asacor (TW);",
"     </li>",
"     <li>",
"      Cholvastin (ID);",
"     </li>",
"     <li>",
"      Dilucid (MX);",
"     </li>",
"     <li>",
"      Ellanco (HK, MY);",
"     </li>",
"     <li>",
"      Elstatin (SG);",
"     </li>",
"     <li>",
"      Favolip (IN);",
"     </li>",
"     <li>",
"      Gengxian (CL);",
"     </li>",
"     <li>",
"      Hipovastin (AR);",
"     </li>",
"     <li>",
"      Holetar (EE);",
"     </li>",
"     <li>",
"      Justin (ID);",
"     </li>",
"     <li>",
"      Liperol (MX);",
"     </li>",
"     <li>",
"      Lostatin (PE, SG);",
"     </li>",
"     <li>",
"      Lostin (PE);",
"     </li>",
"     <li>",
"      Lovacel (KP);",
"     </li>",
"     <li>",
"      Lovachol (ZA);",
"     </li>",
"     <li>",
"      Lovacol (FI);",
"     </li>",
"     <li>",
"      Lovalord (KP);",
"     </li>",
"     <li>",
"      Lovastad (DK);",
"     </li>",
"     <li>",
"      Lovastan (CO);",
"     </li>",
"     <li>",
"      Lovasterol (CO);",
"     </li>",
"     <li>",
"      Lovastin (KP, SG);",
"     </li>",
"     <li>",
"      Medisorbin (GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Medostatin (AE, BG, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SG, SY, YE);",
"     </li>",
"     <li>",
"      Mevacor (AT, BB, BM, BR, BS, BZ, CN, CZ, DK, FI, GR, GY, HK, JM, MX, NL, PK, PL, PR, SR, TT);",
"     </li>",
"     <li>",
"      Meverstin (KP);",
"     </li>",
"     <li>",
"      Mevinacor (DE);",
"     </li>",
"     <li>",
"      Rovacor (IN);",
"     </li>",
"     <li>",
"      Sancos (TW);",
"     </li>",
"     <li>",
"      Sidevar (MX);",
"     </li>",
"     <li>",
"      Xue Qing (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F190371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lovastatin acts by competitively inhibiting 3-hydroxyl-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F190391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: LDL-cholesterol reductions: 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 30%; increased with extended release tablets when taken in the fasting state",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; extensive first-pass effect; hydrolyzed to &beta;-hydroxyacid (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Increased with extended release tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1.1-1.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Immediate release: 2-4 hours; extended release: 12-14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~80% to 85%); urine (10%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berglund L, Brunzell JD, Goldberg AC, et al, &ldquo;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2012, 97(9):2969-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/22962670/pubmed\" id=\"22962670\" target=\"_blank\">",
"        22962670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Castro C and Gourley M, \"Diagnosis and Treatment of Inflammatory Myopathy: Issues and Management,\"",
"      <i>",
"       Ther Adv Musculoskelet Dis",
"      </i>",
"      , 2012, 4(2):111-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/22870499/pubmed\" id=\"22870499\" target=\"_blank\">",
"        22870499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Denus S and Spinler SA, &ldquo;Early Statin Therapy for Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(11):1749-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/12398573/pubmed\" id=\"12398573\" target=\"_blank\">",
"        12398573",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/11368702/pubmed\" id=\"11368702\" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fernandez AB, Karas RH, Alsheikh-Ali AA, et al, &ldquo;Statins and Interstitial Lung Disease: A Systematic Review of the Literature and of Food and Drug Administration Adverse Event Reports,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 134(4):824-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/18689579/pubmed\" id=\"18689579\" target=\"_blank\">",
"        18689579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fonarow GC, French WJ, Parsons LS, et al, &ldquo;Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction: Data From the National Registry of Myocardial Infarction 3,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2001, 103(1):38-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/11136683/pubmed\" id=\"11136683\" target=\"_blank\">",
"        11136683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grundy SM, Cleeman JI, Merz CN, &ldquo;Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines,&rdquo;",
"      <i>",
"       Arterioscler Thromb Vasc Biol",
"      </i>",
"      , 2004, 24(8):E149-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/15297292/pubmed\" id=\"15297292\" target=\"_blank\">",
"        15297292",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heeschen C, Hamm CW, Laufs U, et al, &ldquo;Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 105(12):1446-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/11914253/pubmed\" id=\"11914253\" target=\"_blank\">",
"        11914253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren MJ, Smith DG, Hunninghake DB, et al, &ldquo;The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients. A Comparison of Atorvastatin, Simvastatin, Lovastatin, and Fluvastatin,&rdquo;",
"      <i>",
"       Pharmacoeconomics",
"      </i>",
"      , 1998, 14(1):59-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/10182195/pubmed\" id=\"10182195\" target=\"_blank\">",
"        10182195",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaRosa JC, Grundy SM, Waters DD, et al, &ldquo;Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(14):1425-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/15755765/pubmed\" id=\"15755765\" target=\"_blank\">",
"        15755765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LeManach Y, Godet G, Coriat P, et al, &ldquo;The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 104(6):1326-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/17513620/pubmed\" id=\"17513620\" target=\"_blank\">",
"        17513620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McPherson R, Frohlich J, Fodor G, et al, &ldquo;Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(11):913-27; published erratum appears in",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(12):1077.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/16971976/pubmed\" id=\"16971976\" target=\"_blank\">",
"        16971976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial. Heart Protection Study Collaborative Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9326):7-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/12114036/pubmed\" id=\"12114036\" target=\"_blank\">",
"        12114036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;National Cholesterol Education Program (NCEP): Highlights of the Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 89(3):495-501.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/1741227/pubmed\" id=\"1741227\" target=\"_blank\">",
"        1741227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al, &ldquo;ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2002, 33(9):2337-41. Available at file://stroke.ahajournals.org/cgi/content/short/33/9/2337",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/12215610/pubmed\" id=\"12215610\" target=\"_blank\">",
"        12215610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pearson TA, Mensah GA, Alexander RW, et al, &ldquo;Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(3):499-511.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/12551878/pubmed\" id=\"12551878\" target=\"_blank\">",
"        12551878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips BG, Yim JM, Brown EJ Jr, et al, &ldquo;Pharmacologic Profile of Survivors of Acute Myocardial Infarction at United States Academic Hospitals,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1996, 131(5):872-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/8615304/pubmed\" id=\"8615304\" target=\"_blank\">",
"        8615304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poldermans D, Bax JJ, Kertai MD, et al, &ldquo;Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular Surgery,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(14):1848-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/12695283/pubmed\" id=\"12695283\" target=\"_blank\">",
"        12695283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ridker PM, Danielson E, Fonseca FAH, et al, &ldquo;Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(21):2195-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/18997196/pubmed\" id=\"18997196\" target=\"_blank\">",
"        18997196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sever PS, Dahlof B, Poulter NR, et al, &ldquo;Prevention of Coronary and Stroke Events With Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9364):1149-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/12686036/pubmed\" id=\"12686036\" target=\"_blank\">",
"        12686036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shepherd J, Cobbe SM, Ford I, et al, &ldquo;Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia. West of Scotland Coronary Prevention Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(20):1301-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/7566020/pubmed\" id=\"7566020\" target=\"_blank\">",
"        7566020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sun JX, Niecestro R, Phillips G, et al, &ldquo;Comparative Pharmacokinetics of Lovastatin Extended-Release Tablets and Lovastatin Immediate-Release Tablets in Humans,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2002, 42(2):198-204.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/20/42312/abstract-text/11831543/pubmed\" id=\"11831543\" target=\"_blank\">",
"        11831543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9575 Version 55.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_20_42312=[""].join("\n");
var outline_f41_20_42312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13842374\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190412\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190413\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190451\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190417\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190431\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190418\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190419\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15035959\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190384\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190368\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190389\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190388\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190459\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190449\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190392\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190372\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190446\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190377\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190407\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190380\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190395\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190423\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190396\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190394\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190382\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190385\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190397\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190371\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190391\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9575\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9575|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/61/6101?source=related_link\">",
"      Lovastatin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/47/42743?source=related_link\">",
"      Lovastatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_20_42313="Colonic ischemia";
var content_f41_20_42313=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Colonic ischemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/20/42313/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/20/42313/contributors\">",
"     Peter Grubel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/20/42313/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/20/42313/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/20/42313/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/20/42313/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/20/42313/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/20/42313/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesenteric ischemia is caused by a reduction in intestinal blood flow, which most commonly arises from occlusion, vasospasm,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoperfusion of the mesenteric vasculature. The clinical consequences can be catastrophic, including sepsis, bowel infarction, and death, making rapid diagnosis and treatment imperative.",
"   </p>",
"   <p>",
"    Although uncommon in the general population, ischemic colitis is the most frequent form of mesenteric ischemia, affecting mostly the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of patients (85 percent) develop non-gangrenous ischemia, which is usually transient and resolves without sequelae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/2\">",
"     2",
"    </a>",
"    ]. Only a minority of these patients develop long-term complications, which include persistent segmental colitis and the development of a stricture. On the other hand, approximately 15 percent of patients with colonic ischemia develop gangrene, the consequences of which are life-threatening.",
"   </p>",
"   <p>",
"    Colonic ischemia has been described in a number of clinical settings (",
"    <a class=\"graphic graphic_table graphicRef61647 \" href=\"mobipreview.htm?0/21/350\">",
"     table 1",
"    </a>",
"    ), although it often develops insidiously and no specific cause can be identified. The diagnosis and treatment of patients can be challenging since it often occurs in patients who are debilitated and have multiple medical problems.",
"   </p>",
"   <p>",
"    This topic review will focus on the pathogenesis, clinical manifestations, diagnosis, and treatment of colonic ischemia. Acute and chronic mesenteric ischemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44377?source=see_link\">",
"     \"Acute mesenteric ischemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33206?source=see_link\">",
"     \"Chronic mesenteric ischemia\"",
"    </a>",
"    .) A guideline on this topic has also been issued by the American Gastroenterological Association (AGA) (",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BLOOD SUPPLY OF THE COLON",
"    </span>",
"    &nbsp;&mdash;&nbsp;The colon has a specific vascular arrangement except for rare individual anatomic variations (",
"    <a class=\"graphic graphic_figure graphicRef64156 \" href=\"mobipreview.htm?13/22/13670\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/4\">",
"     4",
"    </a>",
"    ]. The superior mesenteric artery (SMA) and inferior mesenteric artery (IMA) both supply blood to the colon. The SMA arises from the aorta, about 1 cm below the celiac axis at the level of L1 or L2. It supplies the entire small intestine except for the superior part of the duodenum. The SMA has four main branches: the inferior pancreaticoduodenal, middle colic, right colic, and the ileocolic arteries. As a general rule, the ileocolic artery supplies the terminal ileum, cecum, appendix, and proximal ascending colon while a portion of the ascending colon and hepatic flexure receive blood from the right colic artery. The middle colic artery supplies the proximal transverse colon.",
"   </p>",
"   <p>",
"    The IMA arises from the aorta approximately 3 cm proximal to the aortic bifurcation at about L3. It branches into the left colic artery (supplying blood to the distal transverse colon and splenic flexure) sigmoid arteries (supplying blood the sigmoid and descending colon) and the superior rectal artery (supplying blood to the proximal rectum). The distal rectum is supplied from the internal iliac artery by branches from the internal pudendal arteries and middle rectal arteries.",
"   </p>",
"   <p>",
"    An abundant collateral blood supply exists between the SMA and IMA, and the IMA and internal iliac arteries. The arcades of the SMA and IMA interconnect at the base and border of the mesentery. The connection at the base of the mesentery is called the arc of Riolan, whereas the connection along the mesenteric border is known as the marginal artery of Drummond. Collateral flow between the IMA and iliac arteries occurs via the superior and",
"    <span class=\"nowrap\">",
"     middle/inferior",
"    </span>",
"    rectal vessels. Ischemic damage to the rectum is rare since the rectum has a dual blood supply from the IMA and iliac arteries. Despite the presence of collaterals, the colon vasculature has two weak points. Narrow terminal branches of the SMA supply the splenic flexure, and narrow terminal branches of the IMA supply the rectosigmoid junction. These two watershed areas are most vulnerable to ischemia during systemic hypotension.",
"   </p>",
"   <p>",
"    The mesenteric veins parallel their corresponding arteries. The SMV drains the small intestine, cecum, ascending, and transverse colon via the jejunal, ileal, ileocolic, right colic, and middle colic veins. The IMV drains the descending colon through the left colic, the sigmoid through the sigmoid vein, and the rectum through the superior rectal vein. The IMV fuses with the splenic vein, which then joins the SMV to form the portal vein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonic ischemia is usually the result of a sudden and usually temporary reduction in blood flow that is insufficient to meet the metabolic demands of discrete regions of the colon. Blood flow can be compromised by changes in the systemic circulation or by anatomic or functional changes in the local mesenteric vasculature. A variety of causes have been implicated ranging from drugs, heterogeneous diseases, to long-distance running (",
"    <a class=\"graphic graphic_table graphicRef61647 \" href=\"mobipreview.htm?0/21/350\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/5\">",
"     5",
"    </a>",
"    ]. In the majority of patients with colonic ischemia, a specific occluding lesion of a major artery to the colon cannot be identified on angiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonocclusive colonic ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonocclusive colonic ischemia most commonly affects the \"watershed\" areas of the colon that have limited collateralization, such as the splenic flexure and rectosigmoid junction (",
"    <a class=\"graphic graphic_figure graphicRef65067 \" href=\"mobipreview.htm?1/20/1358\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. A study of more than 1000 patients with ischemic colitis demonstrated that the left colon was involved in approximately 75 percent of patients, with about one-quarter of lesions affecting the splenic flexure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/8\">",
"     8",
"    </a>",
"    ]. The rectum was involved in only 5 percent of patients, which can be explained because of collateralization of the inferior mesenteric artery with the systemic circulation through the hemorrhoidal vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Aortoiliac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonic ischemia following aortoiliac reconstructive surgery occurs in approximately 1 to 7 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Many such patients develop transmural infarction requiring colonic resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/11\">",
"     11",
"    </a>",
"    ]. Passage of bloody stools, unexplained failure to improve, fever, leukocytosis, or thrombocytopenia should raise suspicion for the diagnosis following aortoiliac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several factors contribute to the development of bowel ischemia in these patients. Ischemia almost always affects the distal left colon due to loss of collaterals, embolic events, traction of the vessels with surgical instruments, hematoma within the mesocolon, and hypotension. In one report, independent risk factors for the development of intestinal ischemia following aortoiliac surgery were older age, renal disease, prior colectomy (because of collateral interruption), emergency surgery, less experience of the surgeon, aortobifemoral bypass, longer cross-clamping time, and ligation of both iliac arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/14\">",
"     14",
"    </a>",
"    ]. Although a number of techniques have been described to try to reduce the risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/15-18\">",
"     15-18",
"    </a>",
"    ], none is universally effective.",
"   </p>",
"   <p>",
"    A less invasive therapy for abdominal aortic aneurysm repair is endovascular treatment with stent-grafts. However, intestinal ischemia of the left colon related to this procedure has been reported in few case reports, mostly due to mesenteric arterial occlusion during deployment of the graft, peripheral embolization, and graft thrombosis or migration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. In one report, the incidence for colonic ischemia was higher after repair of ruptured aneurysm (9 percent) and open elective repair (2 percent) compared with after endovascular aneurysm repair (0.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cardiopulmonary bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonic ischemia after cardiopulmonary bypass occurs in less than 0.2 percent of patients but is a lethal complication with a mortality rate of up to 85 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Risk factors include older age, end-stage renal disease, valve operation, emergent bypass surgery, and severe postoperative low cardiac output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In addition to the low flow state of bypass perfusion, the procedure exposes the patient's blood to foreign surfaces, which may lead to hypercoagulability, microemboli, alterations in cells and proteins, release of vasoactive substances, and activation of the complement cascade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/27\">",
"     27",
"    </a>",
"    ]. Long bypass times, use of inotropic agents, and an intraaortic balloon pump are associated with increased severity of colonic ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cardiac embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent to which cardiac sources of embolism contribute to the development of ischemic colitis has not been well-defined. A case-control study involving 60 patients with segmental colonic ischemia suggested that a potential cardiac source of embolism was present in up to one-third of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/29\">",
"     29",
"    </a>",
"    ]. The authors recommended that evaluation of patients with ischemic colitis should include a routine electrocardiogram, Holter monitoring, and transthoracic echocardiography. However, whether the cardiac findings were the cause of colonic ischemia remains unsettled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic colitis was described in 14 of 100 patients who underwent a colonoscopy within a mean of 15 days after a myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/30\">",
"     30",
"    </a>",
"    ]. The indications for colonoscopy were overt or occult bleeding in most patients. One report suggested that ischemic colitis developing in the setting of myocardial infarction was associated with more complications and a worse in-hospital prognosis compared with other causes of ischemic colitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesenteric infarction in the setting of hemodialysis is typically nonocclusive and is due to underlying atherosclerosis, diabetes, and hemodialysis-induced hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20986?source=see_link\">",
"     \"Gastrointestinal disease in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mesenteric vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesenteric vein thrombosis rarely involves the colon; when present, damage almost always involves the distal small intestine, which is also drained by the inferior mesenteric vein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phlebosclerotic colitis is a rare form of ischemic colitis that results from venous obstruction caused by fibrotic sclerosis and calcification of the walls of the mesenteric veins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/38\">",
"     38",
"    </a>",
"    ]. It usually involves the right colon. Linear calcifications in the region of the right colon can be seen on plain abdominal films while CT scan may reveal colonic wall thickening associated with mesenteric venous calcifications. Symptoms usually resolve spontaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several drugs have been implicated in the development of colonic ischemia (",
"    <a class=\"graphic graphic_table graphicRef61647 \" href=\"mobipreview.htm?0/21/350\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Exercise and intestinal ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extreme exercise (as occurs in marathon running or triathlon competition) has been associated with intestinal ischemia. The ischemia is probably triggered by shunting of blood flow away from the splanchnic circulation accompanied by dehydration, hyperthermia, and electrolyte abnormalities including hyponatremia and hypokalemia. Ischemic colitis in long-distance runners presents with pain in the lower abdomen, diarrhea, and mild bleeding. Treatment with rehydration and correction of metabolic abnormalities is usually sufficient since most victims are young athletes with intact cardiovascular function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16824?source=see_link\">",
"     \"Gastrointestinal disorders in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Acquired and hereditary thrombotic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree to which acquired or hereditary hypercoagulable states contribute to the pathogenesis of colonic ischemia is not well understood. One report compared the prevalence of a variety of hypercoagulable states among 36 patients with colonic ischemia, 18 patients with diverticulitis, and 52 healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/40\">",
"     40",
"    </a>",
"    ]. The prevalence of antiphospholipid antibodies was significantly higher among patients with colonic ischemia compared to the patients with diverticulitis and controls (19.4 versus 0 and 1.9 percent, respectively). Factor V Leiden mutations were also found more frequently in patients with colonic ischemia (22.2 versus 0 and 3.8 percent, respectively). One or several prothrombotic abnormalities were present in 26 patients (72 percent).",
"   </p>",
"   <p>",
"    The high prevalence of thrombophilic abnormalities in this study must be reconciled with the observations that patients generally present with colonic ischemia in later life (mean age 65) and that recurrence of colonic ischemia is uncommon. This suggests that other factors must be involved in precipitating the ischemic event (a \"two hit\" hypothesis). It also is possible that specific types of thrombophilic disorders may predispose to particular forms of colonic ischemia such as chronic ischemic colitis and stricture formation.",
"   </p>",
"   <p>",
"    Another study focused on 19 patients with nonocclusive colonic ischemia who were younger than 55 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/41\">",
"     41",
"    </a>",
"    ]. Compared to a group of 52 matched healthy controls, patients with colonic ischemia were significantly more likely to have polymorphisms in factor V Leiden and plasminogen activator inhibitor that may predispose to thrombophilia.",
"   </p>",
"   <p>",
"    It is unclear which if any patients with colonic ischemia should undergo evaluation for hypercoagulability based upon the limited data that are currently available. Younger patients and those with recurrent colonic ischemia may be reasonable candidates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mechanisms of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the cause, a number of events take place that contribute to the development of ischemic injury. The splanchnic circulation receives between 10 to 35 percent of cardiac output, depending upon whether it is in the fed or fasting state. Although the capillary density within the intestinal vasculature is high compared to other vascular circuits, intestinal oxygen extraction is relatively low, thereby permitting sufficient oxygen to be delivered to the liver via the portal vein. However, tissue oxygen extraction by the intestine increases during periods of decreased blood flow. As a result, intestinal blood flow must be reduced by at least 50 percent from the normal fasting level before oxygen delivery to the intestine becomes compromised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/42\">",
"     42",
"    </a>",
"    ]. The colon is relatively vulnerable to hypoperfusion since it receives less blood flow compared to the rest of the gastrointestinal tract. In addition, the microvasculature plexus of the colon is less developed and is embedded in a relatively thick wall as compared to the small bowel.",
"   </p>",
"   <p>",
"    Another contributing factor to ischemic injury is vasospasm. The splanchnic vessels respond vigorously to vasoactive substances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/4\">",
"     4",
"    </a>",
"    ], an adaptation that helps redirect blood from the gut to the brain during periods of systemic hypotension. Thus, hypotension from dehydration, cardiac failure, sepsis, or hemorrhage may lead to colonic ischemia by comprising flow volume and triggering reflex mesenteric vasoconstriction. Drugs such as anti-hypertensive agents, diuretics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , and cocaine can promote colonic ischemia by a similar mechanism. In experimental conditions, ischemic injury does not occur until perfusion pressure is reduced to approximately 30 mmHg or the mean mesenteric arterial pressure is reduced to 45 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The injury to the colon following an ischemic event is due to hypoxia and to reperfusion injury. The hypoxic component causes detectable injury in the superficial part of the mucosa within one hour. Prolonged severe ischemia causes necrosis of the villous layer, which can lead to transmural infarction within 8 to 16 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/44\">",
"     44",
"    </a>",
"    ]. The reperfusion component of intestinal injury is mainly seen following partial ischemia. It is initiated by an increased release of oxygen free radicals, other toxic byproducts of ischemic injury, and neutrophil activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/45\">",
"     45",
"    </a>",
"    ]. Reperfusion injury can lead to multisystem organ failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of colonic ischemia vary depending upon the clinical setting and the extent and duration of the ischemia. Patients with acute colonic ischemia usually present with rapid onset of mild abdominal pain and tenderness over the affected bowel, most often involving the left side. Mild to moderate amounts of rectal bleeding or bloody diarrhea usually develops within 24 hours of the onset of abdominal pain. Several features distinguish colonic ischemia from acute mesenteric ischemia involving the small bowel (",
"    <a class=\"graphic graphic_table graphicRef62738 \" href=\"mobipreview.htm?25/9/25755\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/7\">",
"     7",
"    </a>",
"    ]. In particular, the pain that accompanies colonic ischemia usually is not as severe, is felt laterally rather than periumbilically, and often is associated with hematochezia.",
"   </p>",
"   <p>",
"    As a general rule, three progressive clinical stages have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperactive phase: Soon after occlusion or hypoperfusion, severe pain dominates with frequent passage of bloody, loose stools. Blood loss is usually mild without the need for transfusion. More than 80 percent of all patients with colonic ischemia show only mucosal and submucosal injury, symptoms resolved with conservative measures, and no long-term sequelae.",
"     </li>",
"     <li>",
"      Paralytic phase: The pain usually diminishes, becomes more continuous, and diffuses. The abdomen becomes more tender and distended without bowel sounds.",
"     </li>",
"     <li>",
"      Shock phase: Massive fluid, protein, and electrolytes start to leak through a damaged, gangrenous mucosa. Severe dehydration with shock and metabolic acidosis may develop, requiring rapid surgical intervention. Fortunately, this most severe form affects only 10 to 20 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is usually established based upon the clinical setting, physical examination, and radiological",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endoscopic studies. It may be harder to make the diagnosis in patients who are unconscious, such as those in an intensive care unit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/48\">",
"     48",
"    </a>",
"    ]. One study suggested that suspicion for colonic ischemia could be heightened in patients with lower abdominal pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding who had the following risk factors: older than 60, hemodialysis, hypertension, hypoalbuminemia, diabetes mellitus, constipation-inducing medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/49\">",
"     49",
"    </a>",
"    ]. The presence of four or more risk factors was 100 percent predictive of ischemic colitis.",
"   </p>",
"   <p>",
"    Invasive studies such as angiography or laparoscopy are rarely needed but may be valuable when the diagnosis is unclear or as a means to follow patients after surgery for ischemia. Magnetic resonance angiography and Duplex sonography are more recently introduced vascular studies to assess patients with suspected proximal arterial mesenteric vessel or mesenteric venous disease, but are hardly ever required in the evaluation of suspected colonic ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis includes infectious colitis, inflammatory bowel disease, diverticulitis, radiation enteritis, solitary rectal ulcer syndrome, and colon carcinoma. Stool cultures for Salmonella, Shigella, Campylobacter, Yersinia, E-coli O157:H7, and ova and parasites to exclude parasites should be considered except in patients who developed symptoms more than 72 hours after hospitalization in whom stool cultures are likely to be of low yield [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Clostridium difficile infection should be excluded in hospitalized patients exposed to antibiotics. This infection produces marked thickening of the colon on CT scan as well as very high total white blood counts which resemble the findings of ischemic colitis. However, bloody stools are quite rare in C difficile infection.",
"   </p>",
"   <p>",
"    Infection with Klebsiella oxytoca has been associated with right&ndash;sided hemorrhagic colitis that can mimic ischemic colitis. This rare infection occurs in patients exposed to antibiotics, particularly penicillin derivatives. The organism produces a cytotoxin that is thought to be involved in the pathogenesis of colitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Diagnosis is established by culture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific laboratory markers for ischemia, although an increased serum lactate, LDH, CPK, or amylase may indicate advanced tissue damage. White blood count above 20,000 &micro;L and metabolic acidosis in a patient with signs and symptoms of acute colitis are highly suggestive of intestinal ischemia with infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Plain abdominal x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;A plain abdominal x-ray is frequently non-specific. Distension or pneumatosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81253 \" href=\"mobipreview.htm?20/21/20830\">",
"     image 1",
"    </a>",
"    ) are typically seen only in advanced ischemia. In one series of 23 cases, specific signs such as thumbprinting (indicating submucosal edema) and hemorrhage could be identified in only 30 percent of patients with mesenteric infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/54\">",
"     54",
"    </a>",
"    ]. However, when present, radiographic findings suggesting ischemia may portend a worse prognosis as illustrated in one study in which patients with a normal abdominal x-ray appeared to have a lower mortality compared to those with abnormal findings (29 versus 78 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) of the abdomen with intravenous contrast is usually the first diagnostic test obtained in patients presenting with features of colonic ischemia. CT findings are generally nonspecific and scans may initially be normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/17,56,57\">",
"     17,56,57",
"    </a>",
"    ]. The typical finding of thickening of the bowel wall in a segmental pattern (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86279 \" href=\"mobipreview.htm?20/41/21142\">",
"     image 2",
"    </a>",
"    ) is not specific for ischemia and can be seen in infectious colitis such as from Clostridium difficile or Crohn's colitis. Pneumatosis and gas in the mesenteric veins may be seen in the more advanced stages but are not diagnostic of ischemia.",
"   </p>",
"   <p>",
"    Hepatic portal venous gas (HPVG) is a rare radiographic finding that has been associated with extended bowel necrosis and fatal outcome. In a patient with additional clinical and radiographic evidence of necrotic bowel, HPVG predicts a high risk of mortality (&gt;50 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/58\">",
"     58",
"    </a>",
"    ]. However, HPVG can also be detected by CT in more benign situations (eg, after surgical or endoscopic manipulation). Urgent exploratory laparotomy is mandatory only in a patient in whom intestinal ischemia or infarction is suspected on the basis of both radiologic and clinical findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) and MR angiography have not been shown to be useful in patients with acute colonic ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/59\">",
"     59",
"    </a>",
"    ]. This relates in large part to the unlikely possibility that thrombosis or embolus to a major vessel will be found in colonic ischemia. CT scanning also appears to provide better spatial resolution of colonic inflammatory changes and edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Colonoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopy or sigmoidoscopy is often required to establish the diagnosis of ischemic colitis. They are usually performed without bowel preparation (to avoid reducing blood flow from dehydrating cathartics), and with minimization of air insufflation (to avoid distention and perforation). Colonoscopy is preferable to contrast enemas since it is more sensitive in detecting mucosal lesions, permits biopsies to be obtained, and does not interfere with subsequent angiography.",
"   </p>",
"   <p>",
"    Colonoscopic findings in the acute setting frequently include pale mucosa with petechial bleeding. Bluish hemorrhagic nodules may be seen representing submucosal bleeding; these are the equivalent to \"thumbprints\" detected on radiological studies. More severe disease is marked by cyanotic mucosa and hemorrhagic ulcerations (",
"    <a class=\"graphic graphic_picture graphicRef59803 \" href=\"mobipreview.htm?5/12/5316\">",
"     picture 1",
"    </a>",
"    ). Occasional patients have pseudomembranous colitis with yellowish round plaques or confluent membranes not related to C. difficile infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/60\">",
"     60",
"    </a>",
"    ]. Segmental distribution, abrupt transition between injured and non-injured mucosa, rectal sparing, and rapid resolution on serial endoscopy or CT scan favor ischemia rather than inflammatory bowel disease. A single linear ulcer running along the longitudinal axis of the colon (the \"single-stripe sign\") may also favor an ischemic cause of colitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biopsies taken from affected areas may show non-specific changes such as hemorrhage, crypt destruction, capillary thrombosis, granulation tissue with crypt abscesses, and pseudopolyps, which may mimic Crohn's disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. In the chronic phase of ischemic colitis, mucosal atrophy and areas of granulation tissue may be found. Biopsy of a post-ischemic stricture is marked by extensive transmural fibrosis and mucosal atrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Barium enema",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema is not recommended as a diagnostic test since it has been replaced by CT scan and colonoscopy. Introduction of barium into the colonic lumen also precludes subsequent colonoscopy because the barium may adhere to the mucosa for days and obscure the mucosal abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Arteriography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiography is rarely helpful in colonic ischemia because thromboembolic disease of large arteries is hardly ever the cause. In most cases, colonic blood flow has already returned to normal by the time of symptom onset, and therefore angiography will be normal. In addition, ischemic colon vessels are mostly involved at the arteriolar level, whereas mesenteric vessels and arcades are patent.",
"   </p>",
"   <p>",
"    However, angiography may be indicated if the clinical examination and other studies cannot exclude small bowel ischemia due to acute proximal mesenteric thrombus or embolus. Angiography may also be somewhat more sensitive than CT in the diagnosis of mesenteric infarction. In one study, for example, 14 of 16 angiography studies (87.5 percent) and 18 of 22 CT examinations (82 percent) were correct in the diagnosis of mesenteric infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angiography has its limitations; it is not always readily available and patients with ischemic colitis frequently suffer from chronic diseases, such as cardiac and renal failure, making contrast injection (60 to 100 mL) potentially more dangerous. Furthermore, patients are frequently markedly dehydrated and acidotic, which requires time-consuming correction before angiography can be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopy can be an important diagnostic tool, particularly in the elderly patient with comorbid diseases who may tolerate laparotomy poorly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/65\">",
"     65",
"    </a>",
"    ]. It may also be useful for a \"second look\" to assess the viability of remaining bowel and integrity of the anastomosis after surgery for ischemic bowel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laparoscopy can be completed using local anesthesia with light intravenous sedation. A limitation of laparoscopy is that it permits visualization of only the serosal surface of the gut, which may appear normal in early or mild ischemia. In a more progressive phase, dark peritoneal fluid may be present and the ischemic bowel may demonstrate edema, patchy hemorrhages, frank gangrene, or perforation.",
"   </p>",
"   <p>",
"    A concern about laparoscopy is the effect of pneumoperitoneum on mesenteric blood flow. An animal model showed that mesenteric blood flow was reduced by more than 70 percent from baseline when the intraperitoneal pressure was more than 20 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/67\">",
"     67",
"    </a>",
"    ], as it may be during laparoscopy. In addition, a pronounced drop in femoral artery pressures was observed. It is therefore prudent that intraperitoneal pressure should not exceed 10 to 15 mmHg in a patient with suspected mesenteric ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of acute colonic ischemia depends upon its severity and the clinical setting. As a general rule, embolectomy, bypass graft, or endarterectomy is only very rarely used to treat colonic ischemia as large artery obstruction is hardly ever the cause of the ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Nonocclusive ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care is appropriate in the absence of colonic gangrene or perforation. Intravenous fluids should be given to ensure adequate colonic perfusion, and patients should be placed on bowel rest.",
"   </p>",
"   <p>",
"    Empiric broad spectrum antibiotics are recommended in moderate to severe cases. This recommendation is based mainly on old experimental studies in which antibiotics reduced the severity and extent of bowel damage when given before an ischemic event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. In addition, studies in animal models suggested a potential survival advantage with antibiotics while other studies suggested that antibiotics may theoretically protect against bacterial translocation occurring from loss of mucosal integrity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42617?source=see_link\">",
"     \"Anaerobic bacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A nasogastric tube should be inserted if an ileus is present. Any medications that can promote ischemia should be withheld promptly. Cardiac function and oxygenation should be optimized. Although local infusion of vasodilators (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/2/37923?source=see_link\">",
"     papaverine",
"    </a>",
"    ) to attenuate vasospasm has been described, its benefit is unproven in humans and data supporting its efficacy in animal models have been conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Careful monitoring for persistent fever, leukocytosis, peritoneal irritation, protracted diarrhea, and bleeding is imperative. If clinical deterioration is evident despite conservative therapy, laparotomy and segmental resection are indicated. Adequate surgical margins should be ensured and primary anastomosis should be avoided in patients with severe colitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Colonic infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonic infarction develops as a consequence of severe hypoperfusion leading to transmural necrosis of the bowel wall, which can progress to sepsis, peritonitis, free intraabdominal air, or extensive gangrene. Such patients require urgent surgical intervention. As a general rule, the bowel should not be cleansed in preparation for surgery, because bowel preparations can precipitate perforation or toxic dilatation of the colon. Antegrade intraoperative colonic irrigation has been attempted in this setting but is nevertheless associated with significant intraoperative mortality, anastomotic leaks, and wound infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Right-sided colonic ischemia and necrosis can be treated with right hemicolectomy and primary anastomosis. Resection with terminal ileostomy and creation of a colonic mucocutaneous fistula may be required if perforation is associated with peritonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/77\">",
"     77",
"    </a>",
"    ]. Patients with left-sided colonic involvement may require a proximal stoma and distal mucous fistula or Hartmann's procedure. Ostomy closure should be delayed for four to six months, although some patients never proceed to reversal because of comorbid conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/78\">",
"     78",
"    </a>",
"    ]. The rare patient with a fulminating type of colonic ischemia involving most of the colon and rectum may require colectomy with terminal ileostomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/79\">",
"     79",
"    </a>",
"    ]. Many surgeons advocate a \"second look\" operation within 12 to 24 hours to document bowel viability depending upon the findings during the first operation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/77\">",
"     77",
"    </a>",
"    ]. Despite surgical intervention, mortality following large bowel infarction is as high as 50 to 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Aortoiliac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition of postoperative ischemic colitis is important since prompt intervention may be required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/82\">",
"     82",
"    </a>",
"    ]. Some vascular surgeons recommend serial sigmoidoscopic examinations in patients in whom the bowel was considered to be at risk following surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/83\">",
"     83",
"    </a>",
"    ]. A limitation of this approach is the need to insufflate a potentially necrotic bowel segment and the poor sensitivity of endoscopic examination for transmural necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/83\">",
"     83",
"    </a>",
"    ]. Furthermore, no study has demonstrated that this approach is associated with improved survival; unrecognized colonic necrosis is almost universally fatal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/11,12,83\">",
"     11,12,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative for patients with suspected ischemic colitis following aortoiliac surgery is diagnostic laparotomy. Primary anastomosis is contraindicated in those who require bowel resection because it may result in leakage and contamination of the aortic graft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/84\">",
"     84",
"    </a>",
"    ]. Mortality in patients who require resection is as high as 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Mesenteric vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with mesenteric vein thrombosis have an underlying thrombophilic condition. Thus, treatment should include evaluation for hypercoagulability and may include anticoagulant therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44377?source=see_link\">",
"     \"Acute mesenteric ischemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    .) Recanalization of the thrombosed vein has been described following long-term anticoagulant therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/3,85\">",
"     3,85",
"    </a>",
"    ]. Guidelines published by the American Gastroenterological Association suggests that patients who have had an episode of acute mesenteric vein thrombosis and do not have a contraindication to anticoagulation should be anticoagulated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for three to six months or for life if there is a hypercoagulable state or cardiac source [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/3\">",
"     3",
"    </a>",
"    ]. The AGA guideline for intestinal ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/3\">",
"     3",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    . Thrombectomy and thrombolysis have been described in the acute setting, but experience is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/86-89\">",
"     86-89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Cardiopulmonary bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt surgical intervention can be life-saving in patients who develop bowel infarction following cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Evaluation for hypercoagulability",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the degree to which acquired or hereditary hypercoagulable states contribute to the pathogenesis of colonic ischemia is not well-understood. Until further data are available, evaluation for hypercoagulability may be reasonable in younger patients and those with recurrent colonic ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients with ischemic colitis depends upon the disease severity, distribution, and comorbidities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with nonocclusive ischemia improve within one or two days, and have complete clinical and radiological resolution within one to two weeks. More severe ischemia causes ulceration and inflammation, which may develop into segmental ulcerating colitis or strictures. These lesions may be asymptomatic, but they should be followed to document healing or the development of persistent colitis or stricture. As a general rule, non-gangrenous colonic ischemia is associated with a low mortality (approximately 6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/90\">",
"       90",
"      </a>",
"      ], in contrast to gangrenous ischemia, which is associated with a mortality as high as 50 to 75 percent with surgical resection and is almost always fatal if treated conservatively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/91,92\">",
"       91,92",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a retrospective study of 313 patients with biopsy proven ischemic colitis, patients with left colon ischemic colitis were less likely to require surgery and had a shorter length of stay than any other pattern of ischemic colitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/93\">",
"       93",
"      </a>",
"      ]. In another retrospective study of 273 patients with ischemic colitis, patients with isolated right colon ischemic colitis had a worse outcome with a fivefold higher rate of surgery and a twofold higher mortality than those with ischemia involving other colon regions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Comorbidities also influence outcome. In one small case-control study, patients with ischemic colitis occurring in the setting of an acute myocardial infarction (MI) had more severe complications than patients with ischemic colitis without MI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/31\">",
"       31",
"      </a>",
"      ]. In the retrospective study cited above, hyperthyroidism, stroke, and chronic obstructive pulmonary disease were significant predictors of mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recurrence is unlikely if predisposing conditions can be prevented. Although used for other forms of vascular disease, antiplatelet agents have not been well studied in this setting, and are generally not used. As discussed above, anticoagulant therapy is usually necessary only in patients who develop ischemia due to mesenteric venous thrombosis or cardiac embolization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     CHRONIC ISCHEMIC COLITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 20 percent of patients develop chronic colitis from irreversible ischemic injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/95\">",
"     95",
"    </a>",
"    ]. These patients can present with recurrent bacteremia, persistent sepsis, asymptomatic colonic strictures, bloody diarrhea, weight loss from protein losing enteropathy, or abdominal pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/95\">",
"     95",
"    </a>",
"    ]. The AGA technical review for intestinal ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/96\">",
"     96",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Recurrent episodes of bacteremia or sepsis in patients with unhealed areas of segmental colitis are indications for segmental colon resection. Patients who are misdiagnosed as having inflammatory bowel disease will respond poorly to immunosuppressive therapy and have an increased risk of perforation on steroids.",
"   </p>",
"   <p>",
"    Ischemic strictures that produce no symptoms should be observed. Some strictures will return to normal within 12 to 24 months without specific therapy. Segmental resection is usually adequate if symptoms of obstruction develop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/97\">",
"     97",
"    </a>",
"    ]. Endoscopic dilatation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/98\">",
"     98",
"    </a>",
"    ] or stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/20/42313/abstract/99\">",
"     99",
"    </a>",
"    ] may be alternatives, albeit unproven ones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/3/10290?source=see_link\">",
"       \"Patient information: Ischemic bowel disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ischemic colitis is the most frequent form of mesenteric ischemia, affecting mostly the elderly. The majority of patients (85 percent) develop non-gangrenous ischemia, which is usually transient and resolves without sequelae. Only a minority of these patients develop long-term complications, which include persistent segmental colitis and the development of a stricture. On the other hand, approximately 15 percent of patients with colonic ischemia develop gangrene, the consequences of which are life-threatening. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Colonic ischemia has been described in a number of clinical settings (",
"      <a class=\"graphic graphic_table graphicRef61647 \" href=\"mobipreview.htm?0/21/350\">",
"       table 1",
"      </a>",
"      ), although it often develops insidiously and no specific cause can be identified. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of colonic ischemia vary depending upon the clinical setting and the extent and duration of the ischemia. Patients with acute colonic ischemia usually present with rapid onset of mild abdominal pain and tenderness over the affected bowel, most often involving the left side. Mild to moderate amounts of rectal bleeding or bloody diarrhea usually develops within 24 hours of the onset of abdominal pain. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is usually established based upon the clinical setting, physical examination, and radiological",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      endoscopic studies. Invasive studies such as angiography or laparoscopy are rarely needed but may be valuable when the diagnosis is unclear or as a means to follow patients after surgery for ischemia. Magnetic resonance angiography and Duplex sonography can assess patients with suspected proximal arterial mesenteric vessel or mesenteric venous disease, but are hardly ever required in the evaluation of suspected colonic ischemia. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes infectious colitis, inflammatory bowel disease, diverticulitis, radiation enteritis, solitary rectal ulcer syndrome, and colon carcinoma. Stool cultures for Salmonella, Shigella, Campylobacter, Yersinia, E-coli O157:H7, and assay for stool toxins of Clostridium difficile should be considered in the appropriate clinical situation. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of acute colonic ischemia depends upon its severity and the clinical setting. As a general rule, embolectomy, bypass graft, or endarterectomy are only very rarely used to treat colonic ischemia as large artery obstruction is hardly ever the cause of the ischemia.",
"      <br/>",
"      <br/>",
"      Supportive care is appropriate in the absence of colonic gangrene or perforation. Intravenous fluids should be given to ensure adequate colonic perfusion, and patients should be placed on bowel rest. Empiric broad spectrum antibiotics are recommended in moderate to severe cases. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42617?source=see_link\">",
"       \"Anaerobic bacterial infections\"",
"      </a>",
"      .) A nasogastric tube should be inserted if an ileus is present. Any medications that can promote ischemia should be withheld promptly. Cardiac function and oxygenation should be optimized. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis of patients with nonocclusive ischemic colitis depends upon the disease severity, distribution, and comorbidities. Most patients improve within one or two days, and have complete clinical and radiological resolution within one to two weeks. More severe ischemia causes ulceration and inflammation, which may develop into segmental ulcerating colitis or strictures. These lesions may be asymptomatic, but they should be followed to document healing or the development of persistent colitis or stricture. Patients with underlying comorbidities and those with right-sided ischemic colitis have a worse prognosis. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrence is unlikely if predisposing conditions can be prevented. The degree to which acquired or hereditary hypercoagulable states contribute to the pathogenesis of colonic ischemia is not well-understood. Until further data are available, evaluation for hypercoagulability may be reasonable in younger patients and those with recurrent colonic ischemia. However, the benefit of identifying and treating a hypercoagulable disorder in such patients is unproven. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/1\">",
"      Higgins PD, Davis KJ, Laine L. Systematic review: the epidemiology of ischaemic colitis. Aliment Pharmacol Ther 2004; 19:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/2\">",
"      Greenwald DA, Brandt LJ. Colonic ischemia. J Clin Gastroenterol 1998; 27:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/3\">",
"      American Gastroenterological Association Medical Position Statement: guidelines on intestinal ischemia. Gastroenterology 2000; 118:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/4\">",
"      Rosenblum JD, Boyle CM, Schwartz LB. The mesenteric circulation. Anatomy and physiology. Surg Clin North Am 1997; 77:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/5\">",
"      Longstreth GF, Yao JF. Diseases and drugs that increase risk of acute large bowel ischemia. Clin Gastroenterol Hepatol 2010; 8:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/6\">",
"      Gandhi SK, Hanson MM, Vernava AM, et al. Ischemic colitis. Dis Colon Rectum 1996; 39:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/7\">",
"      Greenwald DA, Brandt LJ, Reinus JF. Ischemic bowel disease in the elderly. Gastroenterol Clin North Am 2001; 30:445.",
"     </a>",
"    </li>",
"    <li>",
"     Reeders, JW, Tytgat, GN, Rosenbusch, G, et al. Ischaemic colitis. Martinus Nijhoff, The Hague 1984. p.17.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/9\">",
"      Hagihara PF, Ernst CB, Griffen WO Jr. Incidence of ischemic colitis following abdominal aortic reconstruction. Surg Gynecol Obstet 1979; 149:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/10\">",
"      Brewster DC, Franklin DP, Cambria RP, et al. Intestinal ischemia complicating abdominal aortic surgery. Surgery 1991; 109:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/11\">",
"      Longo WE, Lee TC, Barnett MG, et al. Ischemic colitis complicating abdominal aortic aneurysm surgery in the U.S. veteran. J Surg Res 1996; 60:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/12\">",
"      Van Damme H, Creemers E, Limet R. Ischaemic colitis following aortoiliac surgery. Acta Chir Belg 2000; 100:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/13\">",
"      Brandt CP, Piotrowski JJ, Alexander JJ. Flexible sigmoidoscopy. A reliable determinant of colonic ischemia following ruptured abdominal aortic aneurysm. Surg Endosc 1997; 11:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/14\">",
"      Bj&ouml;rck M, Tro&euml;ng T, Bergqvist D. Risk factors for intestinal ischaemia after aortoiliac surgery: a combined cohort and case-control study of 2824 operations. Eur J Vasc Endovasc Surg 1997; 13:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/15\">",
"      Redaelli CA, Schilling MK, Carrel TP. Intraoperative assessment of intestinal viability by laser Doppler flowmetry for surgery of ruptured abdominal aortic aneurysms. World J Surg 1998; 22:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/16\">",
"      Bergman RT, Gloviczki P, Welch TJ, et al. The role of intravenous fluorescein in the detection of colon ischemia during aortic reconstruction. Ann Vasc Surg 1992; 6:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/17\">",
"      Alpern MB, Glazer GM, Francis IR. Ischemic or infarcted bowel: CT findings. Radiology 1988; 166:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/18\">",
"      Bj&ouml;rck M, Lindberg F, Broman G, Bergqvist D. pHi monitoring of the sigmoid colon after aortoiliac surgery. A five-year prospective study. Eur J Vasc Endovasc Surg 2000; 20:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/19\">",
"      Jaeger HJ, Mathias KD, Gissler HM, et al. Rectum and sigmoid colon necrosis due to cholesterol embolization after implantation of an aortic stent-graft. J Vasc Interv Radiol 1999; 10:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/20\">",
"      Madhavan P, McDonnell CO, Dowd MO, et al. Suprarenal mycotic aneurysm exclusion using a stent with a partial autologous covering. J Endovasc Ther 2000; 7:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/21\">",
"      Geraghty PJ, Sanchez LA, Rubin BG, et al. Overt ischemic colitis after endovascular repair of aortoiliac aneurysms. J Vasc Surg 2004; 40:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/22\">",
"      Perry RJ, Martin MJ, Eckert MJ, et al. Colonic ischemia complicating open vs endovascular abdominal aortic aneurysm repair. J Vasc Surg 2008; 48:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/23\">",
"      Tsiotos GG, Mullany CJ, Zietlow S, van Heerden JA. Abdominal complications following cardiac surgery. Am J Surg 1994; 167:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/24\">",
"      Simi�� O, Strathausen S, Hess W, Ostermeyer J. Incidence and prognosis of abdominal complications after cardiopulmonary bypass. Cardiovasc Surg 1999; 7:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/25\">",
"      Fitzgerald T, Kim D, Karakozis S, et al. Visceral ischemia after cardiopulmonary bypass. Am Surg 2000; 66:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/26\">",
"      Allen KB, Salam AA, Lumsden AB. Acute mesenteric ischemia after cardiopulmonary bypass. J Vasc Surg 1992; 16:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/27\">",
"      Downing SW, Edmunds LH Jr. Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 1992; 54:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/28\">",
"      Zacharias A, Schwann TA, Parenteau GL, et al. Predictors of gastrointestinal complications in cardiac surgery. Tex Heart Inst J 2000; 27:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/29\">",
"      Hourmand-Ollivier I, Bouin M, Saloux E, et al. Cardiac sources of embolism should be routinely screened in ischemic colitis. Am J Gastroenterol 2003; 98:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/30\">",
"      Cappell MS. Safety and efficacy of colonoscopy after myocardial infarction: an analysis of 100 study patients and 100 control patients at two tertiary cardiac referral hospitals. Gastrointest Endosc 2004; 60:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/31\">",
"      Cappell MS, Mahajan D, Kurupath V. Characterization of ischemic colitis associated with myocardial infarction: an analysis of 23 patients. Am J Med 2006; 119:527.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/32\">",
"      Bender JS, Ratner LE, Magnuson TH, Zenilman ME. Acute abdomen in the hemodialysis patient population. Surgery 1995; 117:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/33\">",
"      Flobert C, Cellier C, Berger A, et al. Right colonic involvement is associated with severe forms of ischemic colitis and occurs frequently in patients with chronic renal failure requiring hemodialysis. Am J Gastroenterol 2000; 95:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/34\">",
"      Han SY, Kwon YJ, Shin JH, et al. Nonocclusive mesenteric ischemia in a patient on maintenance hemodialysis. Korean J Intern Med 2000; 15:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/35\">",
"      Hung KH, Lee CT, Lam KK, et al. Ischemic bowel disease in chronic dialysis patients. Changgeng Yi Xue Za Zhi 1999; 22:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/36\">",
"      John AS, Tuerff SD, Kerstein MD. Nonocclusive mesenteric infarction in hemodialysis patients. J Am Coll Surg 2000; 190:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/37\">",
"      Clavien PA, D&uuml;rig M, Harder F. Venous mesenteric infarction: a particular entity. Br J Surg 1988; 75:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/38\">",
"      Jan YT, Yang FS. Phlebosclerotic colitis. J Am Coll Surg 2008; 207:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/39\">",
"      Moses FM. Exercise-associated intestinal ischemia. Curr Sports Med Rep 2005; 4:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/40\">",
"      Koutroubakis IE, Sfiridaki A, Theodoropoulou A, Kouroumalis EA. Role of acquired and hereditary thrombotic risk factors in colon ischemia of ambulatory patients. Gastroenterology 2001; 121:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/41\">",
"      Theodoropoulou A, Sfiridaki A, Oustamanolakis P, et al. Genetic risk factors in young patients with ischemic colitis. Clin Gastroenterol Hepatol 2008; 6:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/42\">",
"      Bulkley GB, Kvietys PR, Parks DA, et al. Relationship of blood flow and oxygen consumption to ischemic injury in the canine small intestine. Gastroenterology 1985; 89:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/43\">",
"      Haglund U, Bergqvist D. Intestinal ischemia -- the basics. Langenbecks Arch Surg 1999; 384:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/44\">",
"      Haglund U, Bulkley GB, Granger DN. On the pathophysiology of intestinal ischemic injury. Clinical review. Acta Chir Scand 1987; 153:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/45\">",
"      Granger DN, Rutili G, McCord JM. Superoxide radicals in feline intestinal ischemia. Gastroenterology 1981; 81:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/46\">",
"      Boley SJ, Brandt LJ, Veith FJ. Ischemic disorders of the intestines. Curr Probl Surg 1978; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/47\">",
"      Hunter GC, Guernsey JM. Mesenteric ischemia. Med Clin North Am 1988; 72:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/48\">",
"      Dorudi S, Lamont PM. Intestinal ischaemia in the unconscious intensive care unit patient. Ann R Coll Surg Engl 1992; 74:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/49\">",
"      Park CJ, Jang MK, Shin WG, et al. Can we predict the development of ischemic colitis among patients with lower abdominal pain? Dis Colon Rectum 2007; 50:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/50\">",
"      Savola KL, Baron EJ, Tompkins LS, Passaro DJ. Fecal leukocyte stain has diagnostic value for outpatients but not inpatients. J Clin Microbiol 2001; 39:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/51\">",
"      Rohner P, Pittet D, Pepey B, et al. Etiological agents of infectious diarrhea: implications for requests for microbial culture. J Clin Microbiol 1997; 35:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/52\">",
"      Beaugerie L, Metz M, Barbut F, et al. Klebsiella oxytoca as an agent of antibiotic-associated hemorrhagic colitis. Clin Gastroenterol Hepatol 2003; 1:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/53\">",
"      H&ouml;genauer C, Langner C, Beubler E, et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med 2006; 355:2418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/54\">",
"      Smerud MJ, Johnson CD, Stephens DH. Diagnosis of bowel infarction: a comparison of plain films and CT scans in 23 cases. AJR Am J Roentgenol 1990; 154:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/55\">",
"      Ritz JP, Runkel N, Berger G, Buhr HJ. [Prognostic factors in mesenteric infarct]. Zentralbl Chir 1997; 122:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/56\">",
"      Balthazar EJ, Yen BC, Gordon RB. Ischemic colitis: CT evaluation of 54 cases. Radiology 1999; 211:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/57\">",
"      Taourel PG, Deneuville M, Pradel JA, et al. Acute mesenteric ischemia: diagnosis with contrast-enhanced CT. Radiology 1996; 199:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/58\">",
"      Nelson AL, Millington TM, Sahani D, et al. Hepatic portal venous gas: the ABCs of management. Arch Surg 2009; 144:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/59\">",
"      Gore RM, Yaghmai V, Thakrar KH, et al. Imaging in intestinal ischemic disorders. Radiol Clin North Am 2008; 46:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/60\">",
"      Dignan CR, Greenson JK. Can ischemic colitis be differentiated from C difficile colitis in biopsy specimens? Am J Surg Pathol 1997; 21:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/61\">",
"      Zuckerman GR, Prakash C, Merriman RB, et al. The colon single-stripe sign and its relationship to ischemic colitis. Am J Gastroenterol 2003; 98:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/62\">",
"      Mitsudo S, Brandt LJ. Pathology of intestinal ischemia. Surg Clin North Am 1992; 72:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/63\">",
"      Price AB. Ischaemic colitis. Curr Top Pathol 1990; 81:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/64\">",
"      Klein HM, Lensing R, Klosterhalfen B, et al. Diagnostic imaging of mesenteric infarction. Radiology 1995; 197:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/65\">",
"      Zamir G, Reissman P. Diagnostic laparoscopy in mesenteric ischemia. Surg Endosc 1998; 12:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/66\">",
"      Slutzki S, Halpern Z, Negri M, et al. The laparoscopic second look for ischemic bowel disease. Surg Endosc 1996; 10:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/67\">",
"      Kleinhaus S, Sammartano R, Boley SJ. Effects of laparoscopy on mesenteric blood flow. Arch Surg 1978; 113:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/68\">",
"      Sarnoff SJ, Fine J. The Effect of Chemotherapy on the Ileum Subjected to Vascular Injury. Ann Surg 1945; 121:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/69\">",
"      PATH EJ, McCLURE JN Jr. Intestinal obstruction; the protective action of sulfasuxidine and sulfathalidine to the ileum following vascular damage. Ann Surg 1950; 131:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/70\">",
"      COHN I Jr, FLOYD CE, DRESDEN CF, BORNSIDE GH. Strangulation obstruction in germfree animals. Ann Surg 1962; 156:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/71\">",
"      Plonka AJ, Schentag JJ, Messinger S, et al. Effects of enteral and intravenous antimicrobial treatment on survival following intestinal ischemia in rats. J Surg Res 1989; 46:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/72\">",
"      Bennion RS, Wilson SE, Williams RA. Early portal anaerobic bacteremia in mesenteric ischemia. Arch Surg 1984; 119:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/73\">",
"      Redan JA, Rush BF Jr, Lysz TW, et al. Organ distribution of gut-derived bacteria caused by bowel manipulation or ischemia. Am J Surg 1990; 159:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/74\">",
"      Williams RA, Wilson SE. Effect of intra-arterial vasodilators on blood flow in ischemic dog colon. Arch Surg 1980; 115:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/75\">",
"      Bulkley GB, Womack WA, Downey JM, et al. Collateral blood flow in segmental intestinal ischemia: effects of vasoactive agents. Surgery 1986; 100:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/76\">",
"      Koruth NM, Krukowski ZH, Youngson GG, et al. Intra-operative colonic irrigation in the management of left-sided large bowel emergencies. Br J Surg 1985; 72:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/77\">",
"      Hanisch E, Schmandra TC, Encke A. Surgical strategies -- anastomosis or stoma, a second look -- when and why? Langenbecks Arch Surg 1999; 384:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/78\">",
"      Mosdell DM, Doberneck RC. Morbidity and mortality of ostomy closure. Am J Surg 1991; 162:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/79\">",
"      Welch GH, Shearer MG, Imrie CW, et al. Total colonic ischemia. Dis Colon Rectum 1986; 29:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/80\">",
"      Guivarc'h M, Roullet-Audy JC, Mosnier H, Boch&eacute; O. [Ischemic colitis. A surgical series of 88 cases]. J Chir (Paris) 1997; 134:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/81\">",
"      Longo WE, Ward D, Vernava AM 3rd, Kaminski DL. Outcome of patients with total colonic ischemia. Dis Colon Rectum 1997; 40:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/82\">",
"      Huddy SP, Joyce WP, Pepper JR. Gastrointestinal complications in 4473 patients who underwent cardiopulmonary bypass surgery. Br J Surg 1991; 78:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/83\">",
"      Houe T, Thorb&ouml;ll JE, Sigild U, et al. Can colonoscopy diagnose transmural ischaemic colitis after abdominal aortic surgery? An evidence-based approach. Eur J Vasc Endovasc Surg 2000; 19:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/84\">",
"      Betzler M. [Surgical technical guidelines in intestinal ischemia]. Chirurg 1998; 69:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/85\">",
"      Condat B, Pessione F, Helene Denninger M, et al. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/86\">",
"      Hassan HA, Raufman JP. Mesenteric venous thrombosis. South Med J 1999; 92:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/87\">",
"      Ryu R, Lin TC, Kumpe D, et al. Percutaneous mesenteric venous thrombectomy and thrombolysis: successful treatment followed by liver transplantation. Liver Transpl Surg 1998; 4:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/88\">",
"      Eldrup-Jorgensen J, Hawkins RE, Bredenberg CE. Abdominal vascular catastrophes. Surg Clin North Am 1997; 77:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/89\">",
"      Rhee RY, Gloviczki P. Mesenteric venous thrombosis. Surg Clin North Am 1997; 77:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/90\">",
"      Longo WE, Ballantyne GH, Gusberg RJ. Ischemic colitis: patterns and prognosis. Dis Colon Rectum 1992; 35:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/91\">",
"      Fitzgerald, SF, Kaminski, DL. Ischemic colitis. Semin Colon Rectal Surg 1993; 4:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/92\">",
"      Parish KL, Chapman WC, Williams LF Jr. Ischemic colitis. An ever-changing spectrum? Am Surg 1991; 57:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/93\">",
"      Brandt LJ, Feuerstadt P, Blaszka MC. Anatomic patterns, patient characteristics, and clinical outcomes in ischemic colitis: a study of 313 cases supported by histology. Am J Gastroenterol 2010; 105:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/94\">",
"      Sotiriadis J, Brandt LJ, Behin DS, Southern WN. Ischemic colitis has a worse prognosis when isolated to the right side of the colon. Am J Gastroenterol 2007; 102:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/95\">",
"      Cappell MS. Intestinal (mesenteric) vasculopathy. II. Ischemic colitis and chronic mesenteric ischemia. Gastroenterol Clin North Am 1998; 27:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/96\">",
"      Brandt LJ, Boley SJ. AGA technical review on intestinal ischemia. American Gastrointestinal Association. Gastroenterology 2000; 118:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/97\">",
"      Simi M, Pietroletti R, Navarra L, Leardi S. Bowel stricture due to ischemic colitis: report of three cases requiring surgery. Hepatogastroenterology 1995; 42:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/98\">",
"      Oz MC, Forde KA. Endoscopic alternatives in the management of colonic strictures. Surgery 1990; 108:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/20/42313/abstract/99\">",
"      Profili S, Bifulco V, Meloni GB, et al. [A case of ischemic stenosis of the colon-sigmoid treated with self-expandable uncoated metallic prosthesis]. Radiol Med 1996; 91:665.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2564 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-259ED97FEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_20_42313=[""].join("\n");
var outline_f41_20_42313=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BLOOD SUPPLY OF THE COLON",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonocclusive colonic ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Aortoiliac surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cardiopulmonary bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cardiac embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mesenteric vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Exercise and intestinal ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Acquired and hereditary thrombotic conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mechanisms of injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Plain abdominal x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Barium enema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Arteriography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Nonocclusive ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Colonic infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Aortoiliac surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Mesenteric vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Cardiopulmonary bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Evaluation for hypercoagulability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      CHRONIC ISCHEMIC COLITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2564\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2564|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/21/20830\" title=\"diagnostic image 1\">",
"      Pneumatosis intestinalis of the colon on plain film",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/41/21142\" title=\"diagnostic image 2\">",
"      Colonic ischemia on computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2564|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/22/13670\" title=\"figure 1\">",
"      Arterial circulation to the large bowel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/20/1358\" title=\"figure 2\">",
"      Distribution of colon ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2564|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/12/5316\" title=\"picture 1\">",
"      Ischemic colitis on colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2564|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/21/350\" title=\"table 1\">",
"      Etiology of colonic ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/9/25755\" title=\"table 2\">",
"      Clinical features of acute colonic and small bowel ischemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44377?source=related_link\">",
"      Acute mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42617?source=related_link\">",
"      Anaerobic bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33206?source=related_link\">",
"      Chronic mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20986?source=related_link\">",
"      Gastrointestinal disease in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16824?source=related_link\">",
"      Gastrointestinal disorders in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/3/10290?source=related_link\">",
"      Patient information: Ischemic bowel disease (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_20_42314="Esophageal tumor staging EUS";
var content_f41_20_42314=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72915%7EGAST%2F63620%7EGAST%2F72321%7EGAST%2F77939%7EGAST%2F75810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72915%7EGAST%2F63620%7EGAST%2F72321%7EGAST%2F77939%7EGAST%2F75810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Esophageal tumor staging with endoscopic ultrasound (EUS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 399px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A: Superficial esophageal carcinoma (T1 tumor) extending into the submucosa (third hyperechoic layer), but not into the muscularis propria (fourth layer). Panel B: Esophageal tumor going into the muscularis propria (fourth hypoechoic layer) but not through, defining a T2 lesion by EUS criteria. Panel C: Carcinoma of the esophagus extending through the esophageal wall and invading the adventitia (fifth layer) (T3 tumor). Panel D: EUS image of an esophageal tumor going through the esophageal wall and extending into the pleural space, defining the tumor as a T4 lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Enrique Vazquez-Sequeiros, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    T1 esophageal cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 428px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound image showing stage T1 esophageal cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John R Saltzman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    T2 esophageal cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 463px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound image showing stage T2 esophageal cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John R Saltzman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    T3 esophageal cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound image showing stage T3 esophageal cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John R Saltzman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    T4 esophageal cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound image showing stage T4 esophageal cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John R Saltzman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_20_42314=[""].join("\n");
var outline_f41_20_42314=null;
var title_f41_20_42315="Chemical peels";
var content_f41_20_42315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of chemical peels",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Depth",
"       </td>",
"       <td class=\"subtitle1\">",
"        Agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Very superficial",
"       </td>",
"       <td>",
"        Glycolic acid, 30-50 percent applied for 1-2 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jessner (resorcinol, salicylic acid, lactic acid, ethanol) solution applied in 1-3 coats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low concentration resorcinol, 20-30 percent applied for 5-10 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TCA (trichloroacetic acid) 10 percent applied in 1 coat",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Superficial",
"       </td>",
"       <td>",
"        Glycolic acid, 50-70 percent, applied for 2-5 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyruvic acid, 40-50 percent applied for 3-5 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jessner solution applied in 4-10 coats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resorcinol, 40-50 percent applied for 30-60 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TCA, 10-30 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Medium",
"       </td>",
"       <td>",
"        Glycolic acid 70 percent applied for 3-15 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyruvic acid 60 percent applied for 3-5 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TCA, 35-50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Augmented TCA (carbon dioxide and TCA 35 percent; Jessner solution and TCA 35 percent; glycolic acid 70 percent and TCA 35 percent)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Deep",
"       </td>",
"       <td>",
"        Phenol 88 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baker-Gordon phenol formula (88 percent phenol, distilled water, septisol, croton oil)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: Fabbrocini G, De Padova MP, Tosti A. Chemical peels: what's new and what isn't new but still works well. Facial Plast Surg 2009; 25:329.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_20_42315=[""].join("\n");
var outline_f41_20_42315=null;
var title_f41_20_42316="Identify and assess OSA";
var content_f41_20_42316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Identification and assessment of obstructive sleep apnea (OSA): American Society of Anesthesiologists example",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical signs and symptoms suggesting the possibility of OSA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        1. Predisposing physical characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        a. Body mass index 35 kg/m",
"        <sup>",
"         2",
"        </sup>",
"        (95th percentile for age and gender)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        b. Neck circumference 17 inches (men) or 16 inches (women)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        c. Craniofacial abnormalities affecting the airway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        d. Anatomical nasal obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        e. Tonsil nearly touching or touching in the midline",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_single\">",
"        2. History of apparent airway obstruction during sleep (two or more of the following are present: if patient lives alone or sleep is not observed by another person, then only one of the following needs to be present)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        a. Snoring (loud enough to be heard through closed door)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        b. Frequent snoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        c. Observed pauses in breathing during sleep",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        d. Awakens from sleep with choking sensation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        e. Frequent arousals from sleep",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        f. (Intermittent vocalization during sleep)*",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_single\">",
"        3. Somnolence (one or more of the following is present)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        a. Frequent somnolence or fatigue despite adequate \"sleep\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        b. Falls asleep easily in a non stimulating environment (eg, watching TV, reading, riding in or driving a car) despite adequate \"sleep\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        c. (Parent or teacher comments that child appears sleepy during the day, is easily distracted, is overly aggressive, or has difficulty concentrating)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        d. (Child often difficult to arouse at usual awakening time)*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    If a patient has signs or symptoms in&nbsp;two or more of the above categories, there is a significant probability that he or she has obstructive sleep apnea (OSA). The severity of OSA may be determined by sleep study. If a sleep study is not available, such patients should be treated as though they have moderate sleep apnea unless one or more of the signs or symptoms above is severely abnormal (eg, markedly increased body mass index or neck circumference, respiratory pauses that are frightening to the observer, patient regularly falls asleep within minutes after being left unstimulated), in which case they should be treated as though they have severe apnea.",
"    <div class=\"footnotes\">",
"     * Item in parentheses refers to pediatric patients.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Obstructive Sleep Apnea. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Obstructive Sleep Apnea. Anesthesiology 2006; 104:1081. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_20_42316=[""].join("\n");
var outline_f41_20_42316=null;
var title_f41_20_42317="Postsecondary transition skills";
var content_f41_20_42317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Skills required for transition to postsecondary educational setting",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        The ability to establish social interaction with peers, neighbors, and other community members",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        The ability to develop skills and competencies that permit independence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        The ability to advocate for oneself:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Understand personal learning weaknesses and strengths",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Understand legal rights under Section 504 and the Americans with Disabilities Act",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The ability to participate in community, social, and recreational activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        The ability to demonstrate skills required to be productive members of society",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Independent problem-solving skills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Independent organization, time-management, and study skills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Personal recognition of the postsecondary program accommodations and supports necessary for personal success:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Part-time schedule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Increased time to complete postsecondary program",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ability to repeat classes without penalty",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Waiver of foreign language requirements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Late course withdrawal without penalty",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Priority registration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Additional time to complete courses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Course substitution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Tutoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Personal counseling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Effective use of assistive technology devices:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Electronic spell checkers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Word processors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Personal organizers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Time-management software",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Calculators",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Speech-control tape recorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Listening aids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Speech-synthesis systems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Speech-recognition systems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Data managers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The ability to recognize personal strengths and self-worth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        The ability to evaluate the various educational, work, living, recreational, and social options to achieve personal goals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Recognize personal program support requirements and evaluate postsecondary school programs realistically (comprehensive versus minimal support services)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Recognize the need for a comprehensive postsecondary learning disability (LD) program with the following characteristics:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Coordination of program by a specialist in LD and individualization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Diagnostic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Individualized educational program",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Academic and program advising",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Basic-skills remediation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Subject-area tutoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Specialized courses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Auxiliary aids and services",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Counseling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Identify programs with minimal support services at postsecondary level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Minimal requirements as mandated by Section 504 for all students with disabilities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Access to taped textbooks, tape recorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Assistance arranging testing accommodations, readers, note-takers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Provisions for arranging course substitutions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Demonstrate the ability to select activities, options, and services to meet personal needs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Provide assistance selecting course work at the high school level that will be required for college entrance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Provide learning-strategy instruction training and study-skill training",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Provide explicit career exploration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Provide Scholastic Assessment Test (SAT) and ACT assessment preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Assist students to register for the Preliminary Scholastic Assessment Test (PSAT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Encourage students to apply to take examinations with accommodations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Tape-recorded versions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Large block print on answer sheets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Extended time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Use of a private room",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_20_42317=[""].join("\n");
var outline_f41_20_42317=null;
var title_f41_20_42318="Diagnostic algorithm for DVT";
var content_f41_20_42318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnostic algorithm in patients with suspected deep vein thrombosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 435px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Wells, PS, Anderson, DR, Bormanis, J, et al, Lancet 1997; 350:1795.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_20_42318=[""].join("\n");
var outline_f41_20_42318=null;
var title_f41_20_42319="Tendon sheath";
var content_f41_20_42319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tendon anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tendon sheaths, like bursae, develop in response to motion as tendons pull and transmit power. The visceral sheath has a flat synovial lining, and the parietal layer has vesicular and granular patches. There is no basement membrane, only a fatty or collagenous connective tissue. Tendon healing is facilitated by an intact tendonsheath. Snapping or triggering of joint movement can be due to nodular enlargement of the tendon, stenosis of the sheath, or both. Tendonitis typically involves the area of the tendon that inserts into bone; peritendonitis involves the area that inserts into muscle; and tenosynovitis represents inflammation of the tendon and its enveloping sheath.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_20_42319=[""].join("\n");
var outline_f41_20_42319=null;
